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Abstract 
Development of New Strategies for Expeditious Oligosaccharide Synthesis 
 
Sophon Kaeothip 
Doctor of Philosophy 
University of Missouri - St. Louis 
Prof. Alexei V. Demchenko, Chairperson 
 
The important role that carbohydrates play in biology and medicine has been the 
major incentive for devising new methods for chemical and enzymatic glycosylation. The 
chemical approach to oligosaccharides involves multiple synthetic steps and the 
development of new strategies that allow for streamlining the synthesis of these complex 
biomolecules is a significant area of research.  
The aim of this doctoral dissertation is to develop new reagents and efficient 
methodologies for oligosaccharide synthesis.  It was found that siver(I) tetrafluoroborate 
can be used as a powerful activator of various glycosyl donors for oligosaccharide 
synthesis. This study evolved into the development of a very effective orthogonal 
strategy which allowed for the synthesis of a variety of oligosaccharide sequences with 
moderate stereoselectivity.  Further studies showed that the improvement of 
stereoselectivity of glycosylation can be achieved in two different modes.  First, we 
found that electron withdrawing protecting groups on the glycosyl acceptor can help to 
obtain excellent α-stereoselectivity.  Second, the stereoselectivity of glycosidation of 
thioglycosides in the presence of bromine depends greatly on the anomeric orientation of 
 II  
the leaving group.  The mechanistic studies of this phenomenon were conducted using 
high field NMR and the developed methodology was applied to the synthesis of a range 
of therapeutically attractive carbohydrate-amino acid conjugates.  
 
 III  
  
 
 
 
 
 
 
 
This dissertation is dedicated to my parents with 
love and respect 
 
 
 
 
 
 
 
 
 
 
 
 
 IV  
Acknowledgements 
 
I owe my sincere gratitude and appreciation to my advisor, Prof. Alexei 
Demchenko, for accepting me as a PhD student, for his inspiring guidance, and for his 
patience during my PhD dissertation at University of Missouri-Saint Louis. I wish to 
thank my graduate committee members; Prof. James S. Chickos, Prof. Rudolph E. K. 
Winter, and Prof. Michael R. Nichols for their valuable suggestions and comments. 
  I am very grateful to Dr. Papapida Pornsuriyasak who was a post-doctoral fellow 
in our laboratory for her kindly training when I started working in this group. I also 
would like to thank Prof. Rudolph E. K. Winter and Mr. Joe Kramer for their help with 
the mass spectrometry, Prof. Rensheng Luo for NMR spectrometry, and Prof. Nigam P. 
Rath for X-ray crystallography. I also would like to acknowledge Prof. Michael R. 
Nichols and his co-workers for their help with the biological activity testing. I would also 
like to express my special thanks to my colleagues, previous and current Demchenko 
group members, for their supports and discussions. I would like to thank the faculty and 
staff of the department of chemistry and biochemistry of UMSL for their support and 
providing me with pleasant working atmosphere. 
I wish to express extremely grateful to my parents and members in my family for 
their love, understanding, support and looking forward to my graduation. 
Finally, I would like to thank the American Heart Association, the National 
Science Foundation, Department of Chemistry and Biochemistry UM-St. Louis and the 
UM-St. Louis Graduate School Dissertation Fellowship for financial support during my 
doctoral studies. 
 V  
Table of Contents 
 
List of abbreviations .....................................................................................................X 
Tables....................................................................................................................... XIV 
Figures...................................................................................................................... XVI 
Schemes .................................................................................................................. XVII 
 
Chapter I.  Introduction 
1.1 Introduction. Complex carbohydrates, chemical glycosylation, and conventional 
oligosaccharide synthesis......................................................................................2 
1.2  Expeditious oligosaccharide synthesis: selective and chemoselective 
 concepts.................................................................................................................5 
1.3 Selective activation ...............................................................................................8 
1.3.1 Glycosyl bromides and chlorides..............................................................8 
1.3.2 Glycosyl fluorides...................................................................................13 
1.3.3 O-Linked glycosyl donors.......................................................................15 
1.3.4 S-linked glycosyl donors.........................................................................27 
1.3.5 Miscellaneous glycosyl donors (orthoesters, Se-glycosides,  
 glycal/epoxides) ......................................................................................34 
1.4 Multistep sequences based on selective activations............................................38 
1.5  Semi-orthogonal approach ..................................................................................43 
1.6 Orthogonal activation..........................................................................................46 
1.6.1 Fluorides and thioglycosides...................................................................47 
 VI  
1.6.2 Thioglycoside and thioimidate................................................................48 
1.6.3 Thioimidate-only (SBox and STaz glycosides) ......................................49 
1.6.4 n-Pentenyl and propargyl activation .......................................................50 
1.7 Selective and orthogonal activations in modern high  
 throughput technologies......................................................................................52 
1.7.1 Intramolecular glycosylations.................................................................52 
1.7.2 One-pot synthesis....................................................................................53 
1.7.3 Polymer-supported synthesis ..................................................................60 
1.8   Conclusions and future directions......................................................................64 
1.9 References...........................................................................................................65 
 
Chapter II.    Evaluation of the applicability of Siver (I) tetrafluoroborate as a 
promoter for chemical glycosylation 
2.1 Introduction.........................................................................................................80 
2.2 Results and discussion ........................................................................................81 
2.3 Conclusions.........................................................................................................90 
2.4 Experimental .......................................................................................................90 
2.5 References.........................................................................................................101 
 
Chapter III.   Unexpected orthogonalilty of S-benzoxazolyl and S-thiazolinyl 
glycosides: Application to expeditious oligosaccharide assembly  
3.1 Introduction.......................................................................................................106 
3.2 Results and discussion ......................................................................................107 
 VII  
3.3 Conclusions.......................................................................................................117 
3.4 Experimental .....................................................................................................118 
3.5 References.........................................................................................................134 
 
Chapter IV.   On the stereoselectivity of glycosidation of thiocyanates, thioimidates 
and thioglycosides 
4.1 Introduction.......................................................................................................138 
4.2 Results and discussion ......................................................................................140 
4.3 Conclusions.......................................................................................................146 
4.4 Experimental .....................................................................................................147 
4.5 References.........................................................................................................152 
 
Chapter V.    Glycosidation of thioglycosides in the presence of bromine: 
mechanism, reactivity, and stereoselectivity 
5.1 Introduction.......................................................................................................158 
5.2 Results and discussion ......................................................................................160 
5.3 Conclusions.......................................................................................................177 
5.4 Experimental .....................................................................................................178 
5.5 References.........................................................................................................187 
 
Chapter VI.   Development of CD14-targeting therapeutics: Synthesis and 
evaluation of glucopyranoside-spacer-amino acid motifs 
6.1 Introduction.......................................................................................................189 
 VIII  
6.2 Results and discussion ......................................................................................192 
6.3 Conclusions.......................................................................................................200 
6.4 Experimental .....................................................................................................200 
6.5 References.........................................................................................................212 
 
Appendix ...................................................................................................................214 
 
 
 IX  
List of abbreviations 
Å.............................................................................................................................Angstrom 
Ac................................................................................................................................Acetyl 
Bn............................................................................................................................... Benzyl 
BSP.............................................................................................Benzenesulfinyl piperidine 
Bz ............................................................................................................................. Benzoyl 
CMP...............................................................................................Cytidine monophosphate 
COD.............................................................................................................Cyclooctadienyl 
Cp...............................................................................................................Cyclopentadienyl 
CSA.......................................................................................... (±)10-Camphorsulfonic acid 
d.................................................................................................................................Doublet 
DAST..................................................................................(Diethylamino)sulfur trifluoride 
DBU........................................................................................1,8-Diazabicycloundec-7-ene 
DCC......................................................................................N,N-dicyclohexylcarbodiimide 
DCE........................................................................................................ 1,2-Dichloroethane 
DCM ...................................................................................................... Methylene chloride 
DDQ........................................................................2,3-Dichloro-5,6-dicyanobenzoquinone 
dd.............................................................................................................Double of doublets 
DEIPS..................................................................................................Diethylisopropylsilyl 
Dimedone......................................................................5,5-dimethyl-1,3-cyclohexanedione 
DIPEA...............................................................................................Diisopropylethylamine 
DMF.............................................................................................. N,N-Dimethylformamide 
DMAP..............................................................................................Dimethylaminopyridine 
 X  
DMDO....................................................................................................Dimethyl dioxirane 
DMTST...................................Dimethyl(methylthio) sulfonium trifluoromethanesulfonate 
DTBMP.........................................................................................di(t-butyl)methylpyridine 
Et ...................................................................................................................................Ethyl 
FAB-MS...........................................................Fast atom bombardment mass spectroscopy 
Fmoc...........................................................................................Fluorenylmethoxycarbonyl 
h..................................................................................................................................hour(s) 
Hz..................................................................................................................................Hertz 
IDCP.............................................................................Iodonium(di-δ-collidine)perchlorate  
Lev........................................................................................................................Levulinoyl  
LG...................................................................................................................Leaving group 
m .............................................................................................................................Multiplet 
MBn..............................................................................................................p-Methylbenzyl 
MBz...............................................................................................................p-Methylbenzo 
Me ..............................................................................................................................Methyl 
min ............................................................................................................................. minute 
MPEG......................................................................................Methoxypolyethylene glycol 
MS.........................................................................................Molecular sieves (in schemes) 
m/z .........................................................................................................Mass to charge ratio 
NBS.......................................................................................................N-bromosuccininide 
Neu.............................................................................................................Neuraminic Acid 
NIS .......................................................................................................... N-iodosuccinimide 
NMR ........................................................................................ Nuclear magnetic resonance 
 XI  
PFBz.......................................................................................................Pentafluorobenzoyl 
Pfp............................................................................................................Pentafluorophenyl 
Ph ............................................................................................................................... Phenyl 
Phth ....................................................................................................................Phthalimido 
Piv.............................................................................................................................Pivaloyl 
ppm .............................................................................................................Parts per million 
Rf ..................................................................................................................Retention factor 
RRV................................................................................................Relative reactivity value 
s .................................................................................................................................. Singlet 
SBox.............................................................................................................S-Benzoxazolyl 
STaz.................................................................................................................S-Thiazolinyl 
t ...................................................................................................................................Triplet 
TBDMS...............................................................................t-Butyldimethylsilyl (also TBS) 
TCA...............................................................................................................Trichloroacetyl 
TESOTf..................................................................................................Triethylsilyl triflate 
TFA............................................................................................................... Trifluoroacetyl 
Tf....................................................................................Trifluoromethanesulfonyl (triflate) 
TIPS............................................................................................................Triisopropylsilyl 
TLC............................................................................................Thin layer chromatography 
TMS ................................................................................................................Trimethylsilyl 
TMSOTf.................................................Trimethylsilyl trifluoromethanesulfonate (triflate)  
Tol.................................................................................................................................Tolyl 
Tr.....................................................................................................Triphenylmethyl (trityl) 
 XII  
Troc....................................................................................2,2,2-Trichloroethyloxycarbonyl 
TTBP...............................................................................Tris(tribromoneopentyl)phosphate 
UDP.......................................................................................................Uridine diphosphate 
Z,cbz.......................................................................................................Benzyloxycarbonyl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XIII  
Tables 
Page 
Table 2.1 AgBF4 promoted glycosylations of glycosyl acceptor 2.12-2.15 ........84 
Table 2.2 Selective activation of various glycosyl donors over n-pentenyl  
acceptor 2.20 and SEt acceptor 2.22 ....................................................88 
Table 3.1 Alkylation-initiated glycosidation of benzylated thioimidates                 
3.1-3.3 ................................................................................................108 
Table 3.2 Alkylation-initiated glycosidation of benzoylated thioimidates               
3.6-3.8 ................................................................................................109 
Table 3.3 Orthogonal activations for oligosaccharide synthesis........................115 
Table 4.1 Glycosylation of various glycosyl donors 4.1 (thiocyanate), 4.2  
 (S-benzoxazolyl) and 4.9 (S-Thiazolinyl) with glycosyl acceptor  
 4.10 and 4.11......................................................................................143 
Table 4.2 The glycosylation of secondary acceptor 4.12, 4.14, 4.16, 4.18,  
4.20, and 4.22 with the STaz donor 4.9 .............................................145 
Table 5.1 Glycosidation of differently protected glucosyl bromides  
 5.1a-5.5a in the presence of Bu4NBr .................................................161 
Table 5.2 Comparative glycosidations of β-thioglycosides and their  
 corresponding α-glycosyl bromides in the presence of bromine.......163 
Table 5.3 Reactions of thioglycosides 5.12-5.14 with bromine:  
 NMR monitoring of glycosyl bromide formation and  
 anomerization.....................................................................................169 
 XIV  
Table 5.4 Glycosidation of thioglycoside 5.12a with various glycosyl           
acceptors ............................................................................................174 
Table 5.5 Attempts to anomerize unreactive α-bromide 5a into  
 its more reactive β-counterpart 5b .....................................................176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 XV  
Figures 
Page 
Figure 2.1 Structure of disaccharide 2.16-2.19 .....................................................86 
Figure 3.1 Working hypothesis for thioimidate activation..................................112 
Figure 3.2 X-ray structure of compound 3.14 and 3.15 ......................................113 
Figure 3.3 HPLC chromatograms of reaction mixture at 1h, 2h, 3h, 5h, 9h and       
16h .....................................................................................................114 
Figure 5.1 In situ NMR monitoring of the reaction of thioglycoside 5.12b with 
bromine in presence of CD3OD .........................................................168 
Figure 5.2 NMR monitoring of the conversion of thioglycoside 5.12a into  
 bromides 5a/5b at rt ...........................................................................173 
Figure 6.1 Structure of monosaccharide and disaccharide Lipid A analogues ...191 
Figure 6.2       Antagonistic activity of compound 6.10, 6.12 and 6.13.....................194 
Figure 6.3       Antagonistic activity and toxicity of compound 6.11 ........................194 
Figure 6.4 Biological activity test of compound 6.19 .........................................198 
Figure 6.5        Biological activity test of compound 6.24.........................................199  
Figure 6.6        Biological activity test of compound 6.4...........................................199 
 
 
 
 
 
 XVI  
Schemes 
Page 
Scheme 1.1 Traditional linear oligosaccharide synthesis..........................................4 
Scheme 1.2 Chemoselective activation strategy........................................................7 
Scheme 1.3 Selective activation strategy ..................................................................7 
Scheme 1.4 Selective activation of glycosyl bromide over thioglycoside ................9 
Scheme 1.5 Selective activation approach to the synthesis of a tetrasaccharide 
repeating unit of V. cholerae O139......................................................10 
Scheme 1.6 Tri(1-pyrrolidineo)phosphine oxide as the activator of glycosyl  
 bromides in selective activations .........................................................11 
Scheme 1.7 Selective activation of glycosyl chloride over glycosyl fluoride.........12 
Scheme 1.8 Selective activation of glycosyl iodide 1.21 over glycosyl acetate 
 1.22 and thioglycoside 1.24 .................................................................13 
Scheme 1.9 Selective activation utilizing glycosyl fluoride as glycosyl donor ......14 
Scheme 1.10 Selective activation utilizing glycosyl fluoride as glycosyl donor ......14 
Scheme 1.11 Selective activation of hemiacetal over glycosyl acetate (a) and 
thioglycoside (b) ..................................................................................16 
Scheme 1.12 Selective activation of glycosyl acetate 1.40 (a), carbonate 1.43 (b),  
 and ortho-alkynylbenzoate 1.46 (c) over thioglycoside acceptors ......17 
Scheme 1.13 Glycosyl trichloroacetimidates in oligosaccharide synthesis via  
 selective activation over thioglycoside 1.50 (a), n-pentenyl glycoside   
1.53 (b) and propargyl glycoside 1.56 (c)............................................19 
Scheme 1.14 Selective activation of (N-phenyl)trifluoroacetimidate 1.58 over  
 XVII  
 n-pentenyl glycoside 1.59 (a) and sequential activation of 
trichloroacetimidate 1.61 followed by the activation of  
 (N-phenyl)trifluoroacetimidate 1.62 (b)...............................................20 
Scheme 1.15 Selective activation of 6-nitro-2-benzothiazoate 1.65 over  
 thioglycoside 1.66 and glycosyl fluoride 1.15 .....................................21 
Scheme 1.16 Selective activation of glycosyl phosphite over thioglycoside (a) and 
phosphorodiamidate (b) .......................................................................23 
Scheme 1.17 Glycosyl phosphate in selective activation reported by                  
Seeberger et al......................................................................................24 
Scheme 1.18 Application of n-pentenyl glycosyl donors in selective  
 glycosylation strategy ..........................................................................25 
Scheme 1.19 Application of 3-methoxy-2-pyridyl (a), and propargyl glycosides (b) 
 in selective activations .........................................................................26 
Scheme 1.20 Utilizing sulfoxide glycoside in selective activation as a part of the 
synthesis of Lea antigen........................................................................28 
Scheme 1.21 Selective glycosidation of thiocyanate (a) and  
 1-piperidinecarbodithioate (b) over thioglycoside acceptors...............29 
Scheme 1.22 SBox glycosides in selective activation strategy .................................30 
Scheme 1.23 STaz glycosides as glycosyl donors and acceptors in selective    
activations ............................................................................................31 
Scheme 1.24 Selective of thioglycosides over glycosyl fluoride (a),  
 S-thiazolinyl (b), and n-pentenyl (c) glycosyl acceptors .....................32 
Scheme 1.25 Application of the selective activation of thioglycoside over 
 XVIII  
  propagyl in the synthesis of trisasccharide 1.129 ...............................34 
Scheme 1.26 Convergent synthesis of pentasaccharides 1.135 using selective 
 activation of selenoglycosides over thioglycosides .............................35 
Scheme 1.27 Selective activation of orthoesters in oligosaccharide synthesis .........37 
Scheme 1.28 Danishefsky’s glycal-epoxide method for oligosaccharide  
 synthesis...............................................................................................38 
Scheme 1.29 Selective activation approach to the synthesis of heparin  
 analogues..............................................................................................40 
Scheme 1.30 Selective activation utilizing three different leaving group.................41 
Scheme 1.31 Three-step SBox→ SEt → n-pent sequential selective activation.......42 
Scheme 1.32 Selective activation utilizing six different leaving groups in the  
 synthesis of 1,2-trans hexasaccharide..................................................43 
Scheme 1.33 Semi-orthoganality of thioglycoside and n-pentenyl  
 leaving groups......................................................................................44 
Scheme 1.34 Semi-orthogonality of n-pentenyl glycoside and glycosyl fluoride.....45 
Scheme 1.35 Orthogonal strategy for oligosaccharide synthesis ..............................46 
Scheme 1.36 Orthogonal activation of phenylthio glycosides and fluorides ............47 
Scheme 1.37 Orthogonality of ethyl and thiazolinyl thioglycosides.........................49 
Scheme 1.38 Thioimidate-only orthogonal strategy..................................................50 
Scheme 1.39 Orthogonality of n-pentenyl vs. O-propargyl leaving groups..............51 
Scheme 1.40 p-Methoxybenzyl mediated intramolecular aglycon delivery  
 and selective activation concepts .........................................................53 
Scheme 1.41 A generic selective activation-based oligosaccharide synthesis  
 XIX  
 in one pot..............................................................................................54 
Scheme 1.42 Convergent one-pot synthesis by selective activation .........................55 
Scheme 1.43 Typical examples of two-step one-pot oligosaccharide syntheses ......56 
Scheme 1.44 One-pot synthesis of tetrasaccharide 1.221 by the three-step  
 sequential selective activation..............................................................57 
Scheme 1.45 Ley’s synthesis via alternating chemoselective and selective         
couplings ..............................................................................................58 
Scheme 1.46 Mukaiyama’s one-pot synthesis involving the elements of  
 orthogonal activation ...........................................................................59 
Scheme 1.47 Takahashi’s synthesis using the elements of orthogonal  
 activations ............................................................................................60 
Scheme 1.48 Utilizing glycosyl sulfoxides in selective activations over  
 thioglycoside bound to the polymer support........................................61 
Scheme 1.49 Solid phase synthesis of Leb blood-group antigen analog ...................62 
Scheme 1.50 Orthogonal glycosylation reactions on solid phase for  
 synthesis of fucosyl galactose oligosaccharides ..................................63 
Scheme 2.1 Conversion of the a common STaz glycoside 2.5a into  
 a range of glycosyl donors ...................................................................82 
Scheme 2.2 Conversion of the STaz glycosides 2.5b, c into  
 thioimidates 2.3b, c and 2.4b...............................................................83 
Scheme 2.3 One-pot glycosylation: synthesis of trisacharide 2.25 .........................89 
Scheme 3.1 Activation of thioimidates: a study with SBox glycoside 3.10..........111 
Scheme 3.2 Mechanism of thioimidate activation with BnBr...............................112 
 XX  
Scheme 3.3 Selective activation utilizing six different leaving groups  
 employing SBox and STaz glycoisdes in the synthesis of  
 1,2-trans hexasaccharide....................................................................118 
Scheme 4.1 Reaction of thiocyanate 4.1 with differently protected  
 6-O-trityl glycosyl acceptors 4.2-4.4 .................................................140 
Scheme 5.1 Lemieux’s in situ anomerization concept ..........................................160 
Scheme 5.2 In situ NMR monitoring of the reaction of thioglycoside 5.13b 
  with bromine ......................................................................................166 
Scheme 5.3 Mechanistic rationale for the transformation of thioglycosides to  
bromides.............................................................................................171 
Scheme 6.1     Synthesis of monosaccharide Lipid analog 6.10-6.13........................193 
Scheme 6.2 Synthesis of monosaccharide Lipid A analog 6.19............................195 
Scheme 6.3     Synthesis of monosaccharide Lipid A analog 6.24 ............................197   
 
 
 
 
  
 
 XXI  
  
 
 
 
 
 
CHAPTER I 
 
Introduction 
 
 
 
 
 
 
 
_________________________________________________________________ 
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1.1  Introduction. Complex carbohydrates, chemical glycosylation, and 
conventional oligosaccharide synthesis 
Carbohydrates are the most abundant biomolecules on Earth, nevertheless, their 
chemistry and biology has been a “Cinderella” field. Our current knowledge about the key 
roles of these fascinating natural compounds is not yet complete. However, thanks to the 
explosive growth of the field of glycobiology in recent years, we already know that 
carbohydrates are involved in a broad range of vital biological processes, fertilization, 
anti-inflammation, immunoresponse, joint lubrication, antigenic determination, are only a 
few to mention.1-4 Carbohydrates are also responsible for many damaging processes in 
our cells - bacterial and viral infections, development and growth of tumors, metastasis, 
tissue rejection, etc.5 This area of science has stimulated major scientific efforts in the 
beginning of 21st century primarily due to the fact that many of these processes are 
directly associated with deadly diseases, such as AIDS, cancer, meningitis, septicemia, 
hepatitis, and malaria.  
The elucidation of the exact mechanisms of the disease progression would be 
significantly facilitated if we had comprehensive knowledge of the structure, 
conformation, and properties of the associated carbohydrate molecules. Although 
glycoscientists have learned to selectively cleave, isolate, purify, and characterize certain 
classes of naturally occurring glycostructures, the availability of pure natural isolates in 
sufficient quantities remains low. In order to ensure the availability of pure complex 
carbohydrates, their chemical or enzymatic synthesis is of prime importance. It is well 
appreciated that a reliable and efficient synthesis could lead to useful glycostructures for 
structural studies and determination of their biological roles. In addition, the synthetic 
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approach can provide significant quantities and natural carbohydrates or their unnatural 
mimetics that are often required for investigating their therapeutic and diagnostic 
applications. Pharmaceutical and biotechnology companies have already demonstrated an 
interest in producing complex oligosaccharides or glycoconjugates, however, examples 
including heparin and its analogs,6,7 oligosaccharide antibiotics,8,9 carbohydrate-based 
vaccines,10-14 and other therapeutic agents15-17 are still rare. Therefore, the development of 
stereoselective methods and efficient strategies for the synthesis of complex 
carbohydrates is critical to the emerging areas of glycosciences. 
The monomeric units in complex carbohydrates are connected via glycosidic 
linkages.  The glycosidic linkage is obtained by means of the glycosylation reaction, 
arguably the most important and challenging reaction in carbohydrate chemistry. A 
typical chemical glycosylation is based on the nucleophilic displacement of a leaving 
group (LG) on the glycosyl donor by a hydroxyl moiety of the glycosyl acceptor (Scheme 
1). The remaining hydroxyls of both units are temporarily masked with protecting groups. 
In spite of significant progress made in the area of glycoside synthesis, the necessity to 
form either a 1,2-cis or a 1,2-trans-glycosidic bond with complete stereoselectivity 
remains the main reason chemical O-glycosylation is ranked among the most challenging 
problems of modern synthetic chemistry. The achievement of high yields and complete 
stereocontrol is difficult due to the complexity of the glycosylation process that often 
proceeds along with a variety of side reactions. Various factors such as temperature, 
pressure, structure, conformation, solvent, promoter, steric hindrance, or leaving group 
can affect the stereoselectivity of glycosylation. Some of these factors influence the 
stereoselectivity dramatically, others only to certain extent;18,19 undoubtedly, the 
 3
neighboring substituent at C-2 is one of the major players. If the use of a base-labile 
ester-protecting groups is permitted, 1,2-trans glycosides can be prepared with the 
assistance of a neighboring participating group.20,21 These glycosylations proceed 
primarily via a bicyclic acyloxonium ion intermediate that can only accept the top face 
nucleophilic attack resulting in the stereoselective formation of a 1,2-trans glycoside. 
Many traditional glycosyl donors such as halides, thioglycosides, or O-imidates provide 
excellent stereoselectivity and high yields. However, if the use of an acyl participating 
group is impractical or impossible, the synthesis of 1,2-trans glycosides becomes 
cumbersome, which has stimulated the development of a number of alternative 
approaches.   
 
 
Scheme 1.1  Traditional linear oligosaccharide synthesis. 
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Another important factor affecting the outcome of glycosylations is the nature of 
the anomeric leaving group. As a result, a large number of glycosyl donors have been 
developed.22,23 In addition to traditionally used chlorides or bromides,24,25 more recent 
glycosyl donors such as Schmidt’s O-trichloroacetimidates,26 Mukaiyama’s fluorides,27,28 
alkyl/aryl thioglycosides pioneered by Ferrier, Nicolaou and Garegg,29,30 Fraser-Reid’s 
O-pentenyl glycosides,31,32 and Danishefsky’s glycal-epoxide system33 have become 
valuable alternatives to the classic approaches.34 
Moreover, a single-step glycosylation is not the only challenge researchers 
working on oligosaccharide synthesis face. Traditional linear approaches for the synthesis 
of oligosaccharides involve extensive protecting group manipulations between each 
glycosylation step.35 Such additional manipulations increase the number of total synthetic 
steps and decrease the efficiency of the oligosaccharide assembly as reflected in dramatic 
drop in yield. This called for revisiting existing linear strategies for oligosaccharide 
synthesis and some significant improvements have already emerged.  
 
1.2 Expeditious oligosaccharide synthesis: selective and chemoselective concepts 
More recent strategies for oligosaccharide synthesis are typically based on the 
selective activation of one leaving group over another.35,36 These expeditious approaches 
significantly shorten oligosaccharide assembly by minimizing the need for protecting 
group manipulations between glycosylation steps. Nicolaou’s selective activation,27 
Fraser-Reid’s armed-disarmed approach,37 Danishefsky’s glycal assembly,33 Ogawa’s 
orthogonal technique,38,39 Roy’s40 and Boons’41 active-latent concept, Wong’s and Ley’s 
programmable strategies,42-45 are only few to mention.  
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One of the most conceptually attractive and practically efficient procedures, 
Fraser-Reid’s armed-disarmed approach, is based on the principle of chemoselectivity. 
According to this principle, a benzylated (electronically activated, armed) glycosyl donor 
is chemoselectively activated over the acylated (electronically deactivated, disarmed) 
glycosyl acceptor bearing the same type of leaving group (Scheme 2).46,47 The 
availability of a suitable mild promoter is essential to effectively differentiate the 
reactivity levels of the armed and disarmed species. At this stage, a 1,2-cis-linked 
disaccharide is preferentially obtained due to the general use of the ether-type arming 
substituent, a non-participating group. The obtained disaccharide can then be used for 
1,2-trans glycosylation directly in the presence of a more potent promoter that can 
activate the disarmed leaving group. Initially developed for O-pentenyl glycosides,32,47 
this approach works with many other classes of stable glycosyl donors.35 The armed-
disarmed strategy thus offers an efficient tool for the synthesis of oligosaccharides with 
cis-trans glycosylation patterns. While the synthesis of cis-cis-linked derivatives is also 
possible (after additional reprotection OAc→OBn), the classic armed-disarmed strategy 
is not applicable to the synthesis of other oligosaccharide patterns, which significantly 
limited its versatility. This resulted in a number of improvement and various reactivity 
levels as well as inverse procedures that expand the scope of the armed-disarmed 
approach. 
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 Scheme 1.2  Chemoselective activation strategy. 
 
 In principle, the use of the selective activation concept offers a more flexible 
oligosaccharide sequencing because this approach does not rely on the nature of the 
protecting groups. Instead, it requires a few leaving groups (LGa, LGb, LGc, etc) that can 
be sequentially activated. Unfortunately, this relatively simple concept is limited to the 
number of available leavings groups compatible with the principle of sequential 
activation. This in part can be addressed by related semi-orthogonal and orthogonal 
strategies (vide infra).  
 
 
Scheme 1.3  Selective activation strategy. 
 
This chapter is dedicated to a thorough overview of strategies making use of the 
principle of selective activation of one leaving group of another. The accumulated 
 7
knowledge has eventually translated into more advanced semi-orthogonal and orthogonal 
strategies that are also discussed below. 
 
1.3  Selective activation  
1.3.1 Glycosyl bromides and chlorides  
The application of glycosyl bromides and chlorides as an effective glycosyl donor 
in the glycosylation reaction was first introduced by Michael followed by more versatile 
approach developed by Koenigs and Knorr.48 Being relatively unstable, glycosyl chloride 
and bromide can only be selectively activated over other, more stable leaving groups, 
such as thio, seleno and n-pentenyl glycosides. The first application of glycosyl bromide 
in selective glycosylation strategy was reported by Zen49 in the synthesis of isomaltose, 
isomaltotetraose and isomaltooctaose. Zen demonstrated that glycosyl bromide can be 
selectively activated over a thioglycoside acceptor in presence of silver carbonate 
(AgCO3). This principle is illustrated by a two-step synthesis reported by Lonn (Scheme 
1.4).50,51 Accordingly, fucosyl bromide 1.1 was selectively activated over the S-ethyl 
leaving group of glycosyl acceptor 1.2. The resulting disaccharide 1.3 is then coupled 
directly with glycosyl acceptor 1.4. This was achieved in the presence of MeOTf and led 
to the formation of trisaccharide 1.5. This example clearly illustrated the advantage of the 
selective activation strategy over the traditional approach that would imply additional 
protecting/leaving group manipulations after the first coupling step.   
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 Scheme 1.4  Selective activation of glycosyl bromide over thioglycoside. 
 
Stronger promoters for bromide activation, such as AgOTf, can be also 
successfully employed as required.52,53  For example, as reported by Oscarson et al., the 
synthesis of a tetrasaccharide of Vibro cholerae O139 began with AgOTf-promoted 
activation of bromide 1.6 over S-ethyl glycosyl acceptor 1.7 (Scheme 1.5).54 The 
resulting disaccharide 1.8 was then subjected to a two-step deprotection sequence, which 
brings the elements of a conventional strategy. The resulting diol 1.10 is then 
glycosylated with glycosyl bromide 1.11 to afford tetrasaccharide 1.12. All three 
glycosidic linkages were constructed using selective activation strategy although some 
interim protecting group manipulations were necessary.  
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 Scheme 1.5  Selective activation approach to the synthesis of a tetrasaccharide repeating 
unit of V. cholerae O139. 
 
Kovac et al. showed that glycosyl bromide and chloride can be selectively 
activated with AgOTf in presence of anomeric actetate.55 Pinto et al. described selective 
activation of glycosyl bromide donors over phenyl selenoglycoside acceptors, which was 
realized in the presence of AgOTf and γ-collidine.56 Selective activation of glycosyl 
bromide over n-pentenyl glycoside acceptor in presence of AgOTf was demonstrated in 
the synthesis of an elicitor-active analog57 and in the synthesis of 
glycophosphatidylinositol.58 Mukaiyama and Kobashi introduced tri(1-
pyrrolidino)phosphine oxide as an activator for glycosyl bromide suitable for conducting 
selective activations.59 The activation takes place via glycosyl phosphonium bromide 
 10
intermediate. Scheme 1.6 illustrates the activation of glycosyl bromide 1.13 over 
thioglycoside 1.14 and glycosyl fluoride 1.15 leading to the respective disaccharides 1.16 
and 1.17 in good yields. 
 
 
Scheme 1.6  Tri(1-pyrrolidineo)phosphine oxide as the activator of glycosyl bromides in 
selective activations. 
 
Glycosyl chlorides can be also selectively activated with AgOTf in presence of 
thioglycosides. An example of this activation was employed in the synthesis of 
dodecasaccharide described by Ito and co-worker.60,61 Selective activation of glycosyl 
chloride over glycosyl fluoride was also employed as depicted in Scheme 7.62,63 Thus, 
sialyl chloride donor 1.18 was activated over sialyl fluoride acceptor 1.19 to afford a 
2→8-linked disialoside in 49% yield.   
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 Scheme 1.7 Selective activation of glycosyl chloride over glycosyl fluoride. 
  
Glycosyl iodides were also developed as an extension of the glycosyl chlorides 
and the glycosyl bromide.64 The first glycosyl iodide was reported in 1910 by Fischer,65 
but it was mainly due to the efforts by Gervay-Hague et al. that glycosyl iodides found 
broad application in glycoside and oligosaccharide synthesis, including that via selective 
activation.66,67 The glycosidation of glycosyl iodide 1.21 with glycosyl acetate acceptor 
1.22 under neutral conditions (TBAI/DIPEA) gave disaccharide 1.23 with complete α-
stereoselectivity (Scheme 1.8). Another example of glycosyl iodide utility is selective 
activations was reported by Oscarson.68 Glycosyl iodide donor 1.21 was activated over 
thioglycoside acceptor 1.24 in the presence of triphenylphosphine oxide (Ph3PO) to 
afford the corresponding disaccharide 1.25 with complete α-stereoselectivity.  
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 Scheme 1.8  Selective activation of glycosyl iodide 1.21 over glycosyl acetate 1.22 and 
thioglycoside 1.24. 
 
1.3.2 Glycosyl fluorides 
   Glycosyl fluorides were introduced by Mukaiyama et al. as glycosyl donors that 
can be activated with fluorophilic activator SnCl2-AgClO4.69 Since then, glycosyl 
fluorides have become useful building blocks for oligosaccharide synthesis because they 
can be used both as glycosyl donors and glycosyl acceptors. It was established that the 
glycosyl fluorides are typically stable under basic as well as weakly acidic conditions 
required for protecting group manipulations. Glycosyl fluorides are also able to withstand 
typical conditions required for the activation of other anomeric halides (vide supra). 
Nicolaou and his co-workers extensively studied the application glycosyl fluorides in 
oligosaccharide and natural product synthesis.70,71 It was proven that glycosyl fluorides 
can be activated in the presence of thioglycosides with a combination of AgClO4 and 
SnCl2. An example of the total synthesis of the tumor-associated Lex family of 
glycosphingolipids is depicted in Scheme 1.9.72   
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 Scheme 1.9  Selective activation utilizing glycosyl fluoride as glycosyl donor. 
 
As depicted in Scheme 1.10, a similar concept was applied to the synthesis of a 
tetrasaccharide containing two consecutive sialic acid units, which were also connected 
by selective activation (vide supra). Thus, the activation of glycosyl donor 1.20 over 
thioglycoside acceptor 1.32 was achieved in presence of AgOTf/SnCl2 and resulted in the 
formation of tetrasaccharide 1.33.62,63  
AcO
O
OAc
AcHN
AcO
AcO
OAc CO2Me
SPh
O
CO2Me
OAc
AcHN
F
SPh
O
AcO
1.20
O
HO
OH
OPivHO
O
OPiv
O
HO
PivO
SEt
AgOTf/SnCl2
MeCN
1.32
1.33
39%
AcO
O
OAc
AcHN
AcO
AcO
OAc CO2Me
SPh
O
CO2Me
OAc
AcHN SPh
O
AcO
O
O
OH
OPivHO
O
OPiv
O
HO
PivO
SEt
 
Scheme 1.10  Selective activation utilizing glycosyl fluoride as glycosyl donor. 
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In 2002, Mukaiyama et al. reported that a catalytic amount of protic acid, such as 
TfOH, HClO4 or C4F9SO3H is also suitable for the activation of fluoride donors over 
thioglycoside acceptors.73 Danishefsky demonstrated that glycals also can tolerate 
activation of glycosyl fluorides in the presence of Sn(OTf)2.74,75 Nicolaou and co-workers 
have described a related glycosylation strategy based on two-stage activation concept, 
whereby thioglycoside is first converted into a glycosyl fluoride, which is then used as a 
glycosyl donor for coupling with a thioglycoside acceptor.71,76-80 
 
1.3.3 O-Linked glycosyl donors 
 
1.3.3.1 Hemiacetals (1-OH derivatives) 
The direct glycosidation of 1-hydroxyl sugar is undoubtedly the most direct 
method of glycosylation. Reported by Fischer in 1901, this general approach has 
undergone a few stages of modifications and conceptual adjustments, and today, the 
dehydrative approach is arguably the most commonly used in application to 
oligosaccharide synthesis. In 1976, Leroux and Perlin developed the direct dehydrative 
glycosylation using triflic anhydride in the presence of a sterically hindered base, γ-
collidine, and Bu4NBr81,82 The reaction proceeded via a stepwise activation of glycosyl 
donor 1.34 via the formation of the anomeric triflate followed by glycosyl bromide 
intermediates. Resultantly, glycosylation of glycosyl acceptor 1.35 bearing an anomeric 
acetate group afforded disaccharide 1.36 in 60% yield (Scheme 1.11a).  
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 Scheme 1.11  Selective activation of hemiacetal over glycosyl acetate (a) and 
thioglycoside (b). 
 
In last few years, Gin and co-workers have developed a sulfonium-based 
electrophile activation of hemiacetal donor with treatment of Ph2SO and Tf2O. The in situ 
formation of the highly reactive sulfonium bistriflate provided the formation of the 
activated anomeric oxosulfonium intermediate. Van der Marel et al. then utilized the 
diphenyl sulfoxide protocol for selective glycosylation of hemiacetal with 
thioglycosides.83,84 Thus, Ph2SO/Tf2O-mediated dehydrative condensation of 1-hydroxyl 
donor 1.37 with thioglycoside 1.38 afforded disaccharide 1.39 in 91%. This approach was 
then extended to the synthesis of heparin oligosaccharide (vide infra).84  
 
1.3.3.2 Acyl and carbonyl derivatives 
Advantages of the glycosyl ester donors in the carbohydrate synthesis are their 
easy preparation and relative chemical stability. The most representative anomeric 
functional group in this area is the acetyl group. In general, Lewis acids (SnCl4, FeCl3, 
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BF3.OEt2, TsOH) are used as promoters to activate glycosyl esters. To date, several 
glycosyl esters have been developed as efficient glycosyl donors, particularly for the 
synthesis of thioglycosides and glycosylation of simple alcohols. However, a number of 
applications to oligosaccharide synthesis via selective activation have also emerged. 
Below is a brief survey of relevant applications. Mukaiyama et al. utilized a 
preactivation-based glycosidation of glycosyl acetate 1.40 using iodotrimethylsilane 
followed by the addition of thioglycoside glycosyl acceptor 1.41 and phosphine oxide 
(Scheme 1.12a).85 This glycosylation provided disaccharide 1.42 in good yields and 
high α-selectivity.  
 
 
Scheme 1.12  Selective activation of glycosyl acetate 1.40 (a), carbonate 1.43 (b), and 
ortho-alkynylbenzoate 1.46 (c) over thioglycoside acceptors. 
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A example from work reported by Mukaiyama et al. involves selective activation 
of anomeric carbonate 1.43 over thioglycosyl acceptor 1.44 in the presence of 
TrB(C6F5)4).86,87 As depicted in Scheme 1.12b, the requisite disaccharide 1.45 was 
isolated in a nearly quantitative yield. Recently, Yu et al. introduced ortho-
alkynylbenzoates as efficient glycosyl donors, which can be activated with catalytic 
amount of Ph3PAuOTf.88 The utility of glycosyl donor 1.46 was demonstrated selective 
activation of thioglycoside acceptor 1.47 to afford the disaccharide 1.48 (Scheme 1.12c). 
 
1.3.3.3 O-Imidates 
Glycosyl trichloroacetimidates, that over the years have become the most 
commonly used glycosyl donors, were introduced by Schmidt and co-workers. These are 
relatively unstable derivatives, and their glycosidation can be readily promoted by the 
catalytic amount of a mild Lewis acid. The selective activation of trichloroacetimidates 
over other glycosyl donors can be straightforwardly executed with TMSOTf89 or BF3-
OEt2.90 For example, as a part of the synthesis of glycolipid of Mycobacterium 
smegmatis, TMSOTf-promoted coupling of trichloroacetimidate 1.49 and thioglycoside 
acceptor 1.50 afforded β(1→4) linked trisaccharide 1.51 in 71% yield (Scheme 1.13a).89 
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 Scheme 1.13  Glycosyl trichloroacetimidates in oligosaccharide synthesis via selective 
activation over thioglycoside 1.50 (a), n-pentenyl glycoside 1.53 (b) and propargyl 
glycoside 1.56 (c).  
 
The use of TESOTf for selective activation was also demonstrated in the 
glycosidation of glycosyl trichloroacetimidate donor with selenoglycoside acceptor, as 
described by Pinto et al.56 A number of syntheses involving the activation of 
trichloroacetimidates over O-pentenyl glycosides also emerged.91-93 For example, towards 
the synthesis of proteoglycan linkage region, trichloroacetimidate glycosyl donor 1.52 
was selectively activated over with n-pentenyl glycosyl acceptor 1.53 in the presence of 
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TESOTf. As depicted in Scheme 1.13b, disaccharide 1.54 was isolated in 89% yield.92  
Recently, Mukhopadhyay et al. showed that H2SO4-silica can be used as an activator to 
selectively activate trichloroacetimidate disaccharide donor 1.55 over propargyl glycosyl 
acceptor 1.56 leading to trisaccharide 1.57 in 91%.94  
Similar glycosyl donors, (N-phenyl)trifluroacetimidates introduced by Yu and co-
workers95 can also be selectively activated over a range of glycosyl acceptors bearing 
stable anomeric leaving groups. For example, as reported by Seeberger et al.96 activation 
of (N-phenyl)trifluoroacetimidate donor 1.58 over n-pentenyl glycosyl acceptor 1.59 was 
accomplished in the presence of TMSOTf (Scheme 1.14a). The resulting tetrasaccharide 
1.60 was isolated in 80% yield and served as a precursor towards the synthesis of the 
repeating unit of Bacillus Anthracis cell wall polysaccharide.96   
 
Scheme 1.14  Selective activation of (N-phenyl)trifluroacetimidate 58 over n-pentenyl 
glycoside 59 (a) and sequential activation of trichloroacetimidate 61 followed by the 
activation of (N-phenyl)trifluroacetimidate 62 (b).  
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Iadonisi et al. demonstrated that the reactivity of glycosyl trichlro- and (N-
phenyl)trifluoroacetimidates can be differentiated.97 It was found that a mild promoter, 
such as Yb(OTf)3, allows for selective activation of glycosyl trichloroactimidate building 
block 1.61 over glycosyl (N-phenyl)trifluoroacetimidate 1.62 (Scheme 1.14b). It should 
be noted that since both glycosyl donor and glycosyl acceptor bear the same protecting 
groups, the nature of this activation is clearly selective. The resulting disaccharide is then 
coupled with glycosyl acceptor 1.63 in a one-pot manner. This was affected by using 
additional quantities of the promoter and led to the formation of trisaccharide 1.64 in 
40% yield over 2 steps.  
Mukaiyama and co-workers reported selective activation of cyclic imidate donor, 
6-nitro-2-benzothiazoate 1.65 over thioglycoside 1.66 or glycosyl fluoride acceptor 
1.15.98 As depicted in Scheme 1.15, these HB(C6F5)4-catalyzed selective activations 
resulted in the formation of disaccharides 1.67 and 1.68, respectively, in good yields.    
 
Scheme 1.15.  Selective activation of 6-nitro-2-benzothiazoate 1.65 over thioglycoside 
1.66 and glycosyl fluoride 1.15. 
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1.3.3.4 O-P derivatives 
Several glycosyl donors possessing a phosphorus atom in the leaving group at the 
anomeric center have also been investigated. Diethyl and dibenzyl glycosyl phosphites 
independently introduced by Schmidt and Wong, respectively, have found a wide 
application in glycoside and oligosaccharide synthesis. The activation of glycosyl 
phosphite requires only catalytic of TMSOTf (usually 10-20%), which allows for 
potential application in selective activations over a broad range of leaving groups, 
similarly to that of O-imidates (vide supra). Thus, the selective activation of glycosyl 
phosphites over thioglycoside acceptors affected in the presence of TMSOTf was also 
reported.99,100 For example, Nagorny demonstrated that the coupling of sialyl phosphite 
donor 1.69 and thioglycoside acceptor 1.70 was accomplished using TMSOTf as a 
promoter. The resultant trisaccharide product was obtained as a 3.5:1 mixture of anomers, 
which was acetylated and purified to furnish trisaccharide 1.71 as a pure α-anomer.100 
Danishefsky demonstrated that the coupling of glycosyl phosphites with glycals can be 
affected in the presence of TMSOTf.101   
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 Scheme 1.16  Selective activation of glycosyl phosphite over thioglycoside (a) and 
phosphorodiamidate (b). 
 
Further expansion emerged with the development of glycosyl diphenyl 
phosphates,102 glycosyl diphenylphosphineimidates,103 and glycosyl 
phosphoroamidates.104 Towards the synthesis of ganglioside GM3, sialyl phosphite 1.72 
could be selectively activated over phosphorodiamidate acceptor 1.73 in the presence of 
TMSOTf, BF3-OEt2 or TfOH.105 As depicted in Scheme 1.16b, the disaccharide 1.74 was 
isolated in excellent yield after fine-tuning of the reaction conditions.  
In 2001, Seeberger and co-workers reinvented the use of glycosyl phosphates as 
glycosyl donors.106,107 TMSOTf, TBSOTf, or BF3.OEt2 were all proved to be suitable 
promoters for the activation of glycosyl phosphates, also in oligosaccharide synthesis via 
selective activations. For example, selective activation of glycosyl phosphate 1.75 over 
thioglycoside acceptor 1.76 in the presence of TMSOTf resulted in the formation of 
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disaccharide 1.77 in 96% yield (Scheme 1.17). Similarly, glycosyl phosphate 1.78 was 
activated over n-pentenyl glycosyl acceptor 1.79 that resulted in the formation of 
disaccharide 1.80 in 82% yield.   
 
 
Scheme 1.17  Glycosyl phosphate in selective activation reported by Seeberger et al. 
 
Along similar lines, Mukaiyama et al. glycosyl diphenylphosphinites as a 
glycosyl donors.85 It was noted that this donor can be selectively activated over 
thioglycoside and glycosyl fluoride acceptors in the presence of MeI. 
 
1.3.3.5 Transglycosylation (n-pentenyl, propargyl, hetaryl) 
The use of n-pentenyl glycoside as glycosyl donors, was introduced by Fraser-
Reid in 1988.108 The activation of the leaving group is based on an electrophilic reagent, 
most commonly in the presence of IDCP, NIS/TfOH or NIS/TESOTf. Since these are 
essentially the same activation conditions as those for the activation of more common 
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thioglycosides, the use of n-pentenyl glycosides as glycosyl donors in selective 
activations is rare. For example, it was found that n-pentenyl glycoside 1.81 could be 
selectively activated with IDCP over disarmed thioglycoside 1.82 (Scheme 1.18a).109 
This coupling needs the additional enforcement by the electronic effects as only armed n-
pentenyl glycoside could be activated over disarmed thioglycoside. Lopez et al. 
demonstrated that n-pentenyl glycosides can be selectively activated over glycosyl 
fluoride acceptors (vise infra).110 More recently, Hotha et al. paired n-pentenyl glycoside 
with propargyl glycosides for selective glycosylation.111 It was observed that n-pentenyl 
glycoside 1.84 could be activated over propargylated glycosyl acceptor 1.85 in the 
presence of NIS/TMSOTf (Scheme 1.18b). Resultantly, disaccharide 1.86 was obtained 
in 68% yield propargyl disaccharide in moderate yield.   
 
 
Scheme 18.  Application of n-pentenyl glycosyl donors in selective glycosylation 
strategy. 
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The utility of 3-methoxy-2-pyridyl glycoside as a glycosyl donor in selective 
glycosylations was described by Hanessian et al.112 As depicted in Scheme 1.19a, 3-
methoxy-2-pyridyl glycosyl donor 1.87 was selectively activated over thioglycoside 
acceptor 1.88 in the presence of Cu(OTf)2 and the resulting disaccharide 1.89 was 
obtained in 75% yield. Very recently, Hotha described that propargyl glycoside 1.90 can 
be selectively activated over n-pentenyl glycoside 1.91 in the presence of AuBr3 at 
65°C.111 As depicted in Scheme 1.19b, disaccharide 1.92 was isolated in 65 % yield.   
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Scheme 1.19  Application of 3-methoxy-2-pyridyl (a), and propargyl glycosides (b) in 
selective activations. 
 
Chenault et al. discovered that isopropenyl glycosides can be activated over n-
pentenyl glycosides in the presence of TMSOTf.113 Jensen and co-workers reported a 
glycosylation method employing methyl 2-hydroxy-3,5-dinitrobezoate glycosides 
(methyl 3,5-dinitrosalicylate, DISAL) as a glycosyl donors.114 DISAL glycosyl donor 
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was applied to the synthesis of starch-related linear hexasaccharide whereas DISAL 
donor can be activated over thioglycoside acceptor in the presence of LiClO4 and Li2CO3 
as the promoter system.115 Kim et al. discovered that 2-(benzyloxycarbonyl)benzyl 
(BCB) glycosides are perfectly stable, whereas the corresponding 2-
(hydroxycarbonyl)benzyl (HCB) counterparts can be activated in presence of Tf2O and 
DTBMP.75 This phenomenon was applied to selective activation of 2-
(hydroxycarbonyl)benzyl donor over 2-(benzyloxycarbonyl)benzyl acceptor. This 
activation, however, was performed using pre-activation conditions under which HCB 
was first treated with DTBMP (30 min), followed by the treatment with Tf2O. After that, 
BCB glycosyl acceptor was added, therefore, formally this cannot be classified as the 
selective activation.   
 
1.3.4  S-linked glycosyl donors 
 
1.3.4.1 Sulfoxides, thiocyanates, xanthates, etc. 
Glycosyl sulfoxides prepared from the corresponding thioglycosides via 
oxidation,116 can be glycosidated in the presence of trifluoromethanesulfonic 
anhydride.117 In 1994, van Boom et al. reported that TMSOTf and triethylphosphite 
(TEP) is an effective promoter system for the selective activation of phenylsulfenyl 
glycosides over phenylthioglycoside acceptors.118 The synthesis of antigens Lea, Leb and 
Lex utilizing the glycosyl sulfoxide method was reported by Kahne (Scheme 1.20).119  
Herein, Tf2O in presence of 2,6-di-tert-butyl-4-methylpyridine (DTBMP) was used as 
activator. Thus, glycosidation of sulfoxide 1.93 over thenylthio glycoside 1.94 resulted in 
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the formation of disaccharide 1.95 in 86% yield. The latter was converted into a glycosyl 
acceptor 1.96, which was subjected to another round of selective glycosylation with 
glycosyl sulfoxides 1.97. The resulting trisaccharide 1.98 was obtained in 95% yield.  
 
O
PivO
PivO
OPivPivO
S
O
Ph Tf2O, DTBMP
CH2Cl2, -78 --> -30 oC
86%
O
S
OBn
OBnBnO
O Ph
Tf2O, DTBMP
CH2Cl2, -78 - 0 oC
95%
O
BnO
OBn
OBn
1.9
1.94
1.95
1.961.97
1.98
O
HO
N3
SPh
O
O
Ph
O
PivO
PivO
OPiv
PivO
O
O
N3
SPh
O
O
Ph
O
AcO
AcO
OAcAcO
O
O
N3
SPh
OPiv
HO
4 steps
O
AcO
AcO
OAcAcO
O
O
N3
SPh
OPiv
O
 
Scheme 1.20  Utilizing sulfoxide glycoside in selective activation as a part of the 
synthesis of Lea antigen. 
 
Kochetkov and co-workers showed that glycosyl thiocyanates can be selectively 
activated over the 6-O-trityl thioglycoside acceptor.120 As depicted in Scheme 1.21a, 
thiocyanate 1.99 was selectively activated over thioglycoside 1.100 in the presence of 
triphenylmethylium perchlorate (TrClO4) as an activator. The resulting disaccharide 
1.101 was obtained in 82% yield. Fügedi et al. introduced glycosyl 1-
piperidinecarbodithioates as glycosyl donors that can be activated in the presence of 
AgOTf or TMSOTf.121 As depicted in Scheme 1.21b, selective activation of 1-
piperidinecarbodithioate donor 1.102 over thioglycosides acceptor 1.103 was affected in 
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the presence of AgOTf and resulted in the formation of disaccharide 1.104. Along similar 
lines, condensation of pentafuranosyl dithiocarbamate with 5-nitro-2-pyridyl 
thioglycoside in the presence of NIS/TfOH was described by Bogusiak and Szeja.122  
 
 
Scheme  1.21 Selective glycosidation of thiocyanate (a) and 1-piperidinecarbodithioate 
(b) over thioglycoside acceptors. 
 
1.3.4.2 Thioimidates 
The first wave of glycosyl thioimidates, compounds with a generic leaving group 
SCR1=NR2, included benzothiazolyl,123 pyridin-2-yl,124-126 pyrimidin-2-yl,124,127 
imidazolin-2-yl,124 and 1’-phenyl-1H-tetrazolyl.128 Although all of these derivatives have 
been tested as glycosyl donors and promising results have been obtained, the application 
of this class of compounds to selective activations emerged only much later. A few years 
ago, Demchenko et al. found that S-benzoxazolyl (SBox) and S-thiazolinyl (STaz) 
glycosides were sable toward many harsh reaction conditions associated with protective 
group manipulations.129,130 In addition, these thioimidates could be glycosidated under a 
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range of mild reaction conditions and provided excellent anomeric stereoselectivity – 
important traits for both glycoside synthesis and oligosacccharide assembly. The 
particular versatility of thioimidates derives from the different modes that can be used for 
their activation. Activations can take place either directly via the anomeric sulfur or 
remotely via the nitrogen.131,132 Further studies revealed that SBox and STaz glycosides 
can be selectively activated over other classes of leaving groups. For example, AgBF4 – 
promoted activation of SBox glycoside 1.105 over n-pentenyl glycoside acceptor 1.106 
resulted in the formation of disaccharide 1.107 in 86% yield (Scheme 1.22a).133 
Similarly, De Meo and Parker described that the SBox sialyl donor 1.108 can be activated 
over SEt glycosyl acceptor 1.109 in the presence of AgOTf.134 As shown in Scheme 
1.22b, the resulting disaccharide 1.110 was obtained in 89% yield.  
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Scheme 1.22  SBox glycosides in selective activation strategy. 
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STaz glycosyl donor 1.111 was glycosidated selectively over thioglycoside 
acceptor 1.112 in the presence of AgBF4.133 As depicted in Scheme 1.23a, disaccharide 
1.113 was isolated in 89% yield. SBox glycosyl donor 1.114 could be also selectively 
activated over STaz acceptor 1.115 in the presence of Bi(OTf)3 to afford disaccharide 
1.116 in 69% yield (Scheme 1.23b).132 
 
 
Scheme 1.23  STaz glycosides as glycosyl donors and acceptors in selective activations. 
 
1.3.4.3 S-Alkyl and aryl glycosides 
Alkyl and aryl thioglycosides have been widely studied as versatile building block 
for oligosaccharide synthesis due to their high chemical stability. They are also good 
intermediates to be transformed into a range of other glycosyl donors and can act as 
acceptors in glycosylation reactions, which make thioglycosides suitable for use in 
chemoselective, selective and iterative glycosylations. As shown by Ogawa et al., 
selective activation of thioglycosides over glycosyl fluorides can be executed in the 
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presence of NIS and AgOTf as a promoter system.38 In addition, other promoters 
including NIS/TfOH,135 MeOTf,60,61 and DMTST136,137 are also capable of the selective 
activation of thioglycosides over fluorides. For example, selective activation of 
thioglycoside 1.117 over fluoride acceptor 1.118 led to the formation of trisaccharide 
1.119 in 85% yield (Scheme 1.24a).137 Selective activation of thioglycoside 1.120 over S-
thiazolinyl glycosyl acceptor 1.115 could be affected in the presence of NIS in 
combination with a catalytic amount of TfOH.129 As shown in Scheme 1.24b, this 
coupling resulted in the formation of disaccharide 1.116. STaz glycosides can be also 
activated in the presence of the same activators, but this requires at least stoichiometric 
amount of TfOH.  
 
Scheme 1.24  Selective of thioglycosides over glycosyl fluoride (a), S-thiazolinyl (b), 
and n-pentenyl (c) glycosyl acceptors. 
 32
Boons reported that the glycosidation of thioglycoside 1.121 with di-O-trityl 
pentenyl glycosyl acceptor 1.122 can be achieved in the presence of MeOTf.138 As shown 
in Scheme 1.24c, trisaccharide 1.123 was obtained in 96% yield.  The regioselectivity 
observed is due to the observation reported by Kochetkov et al. that trityl ethers invert the 
reactivity of alcohols towards glycosylation.139 Boons and co-workers also developed as 
interesting concept for oligosaccharide synthesis by demonstrating that the increase of 
steric hindrance around the active site of the leaving group has a dramatic effect on the 
leaving group ability.140 Thus, it was shown that an S-ethyl glycoside can be selectively 
activated over dicyclohexylmethyl thioglycoside in the presence of NIS/TMSOTf at low 
temperature.   
In the development of 4-acetoxy-2,2-dimethylbutanoate as a novel protecting 
group for oligosaccharide synthesis, Ensley demonstrated that the activation of 
thioglycosides over 1-O-acyl glycosyl acceptor can be performed in the presence of 
NIS/AgOTf.141 It was also reported that glycals are stable under MeOTf-promoted 
activation of thioglycosides.142 Recently, it was reported that S-tolyl rhamnopyranoside 
1.124 can be selectively activated over propargyl glycosyl acceptor 1.125 in the presence 
of NIS/H2SO4-silica.94 As shown in scheme 1.25, the resulting disaccharide 1.126 
obtained in 87% yield, was converted to glycosyl acceptor 1.137. The latter was then 
subjected to glycosylation with S-tolyl glycosyl donor 1.128 under the same reaction 
conditions. This sequence resulted in the formation of trisaccharide 1.129 related to the 
cytotoxic triterpenoid saponin in 83% yield.  
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 Scheme 1.25  Application of the selective activation of thioglycoside over propagyl in 
the synthesis of trisaccharide 1.129. 
 
1.3.5 Miscellaneous glycosyl donors (orthoesters, Se-glycosides, 
glycal/epoxides) 
Anomeric phenylselenides, introduced by Pinto et al. in 1991, are very effective 
glycosyl donors.143 The phenylseleno leaving group behaves similarly to that of 
thioglycosides with respect to their stability towards protecting group manipulations and 
lability towards electrophilic reagents. Very differently though, selenoglycosides can be 
activated with AgOTf and K2CO3, which allows for their selective activation in presence 
of thioglycosides.56,143 In 2000, selenoglycosides are also more reactive towards MeOTf 
or NIS/TfOH than their thioglycoside counterparts.144,145 Thus, Ley et al. reported 
selective activation of phenylseleno glycoside 1.130 over thioglycoside acceptor 1.131 in 
application to convergent synthesis of GPI anchor of Trypanosoma brucei (Scheme 
1.26).144 This coupling was performed in the presence of MeOTf and resulted in the 
formation of trisaccharide 1.132 in 75% yield. The latter was then converted into 
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glycosyl acceptor 1.133 which was glycosylated with selenoglycoside 1.134 again in the 
presence of MeOTf. This second selective activation resulted in the formation of 
pentasaccharide 1.135 in 75% yield. Recently, Fairbanks utilized electrochemistry for 
activation selenoglycoside donors, although selective glycosylation of selenoglycoside 
over thioglycoside acceptor gave low yields.146 
 
 
Scheme 1.26  Convergent synthesis of pentasaccharides 1.135 using selective activation 
of selenoglycosides over thioglycosides. 
Yoshida et al. reported the use of telluroglycosides as glycosyl donors which can 
be activated either electrochemically147,148 or in the presence of MeOTf, NIS/t-BuOCl, or 
NBS/TMSOTf.149 The latter reaction conditions allowed for selective activation of 
telluroglycosides over thioglycoside acceptors.  
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Orthoesters have been used as useful glycosyl donors for 1,2-trans glycosylation 
for decades. Their activation is typically achieved in the presence of Lewis acid or mild 
electrophilic promoters, which permits their selective activation over a number of leaving 
groups of different classes. For example, it was demonstrated that ethylthio orthoester 
1.136 can be activated over conventional thioglycoside 1.137 using NIS/TfOH as an 
activator (Scheme 1.27a).150 The resulting disaccharide 1.138 was isolated in 75% yield.  
Lopez et al. reported a glycosylation approach in which n-pentenyl 1,2-orthoesters are 
activated over glycosyl fluoride acceptor using NIS and Yb(OTf)3 as a promoter 
system.110  Recently, Hotha et al. reported that n-pentenyl 1,2-orthoester 1.139 can be 
selectively activated over propargyl glycoside acceptor 1.85 in the presence of 
NIS/Yb(OTf)3 to afford disaccharide 1.140 in 62% yield (Scheme 1.27b).111 Along 
similar lines, propagyl 1,2-orthoester 1.141 can be selectively activated over n-pentenyl 
acceptor 1.142 in the presence with AuBr3 leading to trisaccharide 1.143 (Scheme 1.27c).  
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Scheme 1.27  Selective activation of orthoesters in oligosaccharide synthesis. 
 
Cyanoethylidene approach to 1,2-trans-glycosylation of tritylated acceptors has 
been extensively studied by Kochetkov.151 As reported by Boons, this approach allows 
for selective activation over n-pentenyl glycosyl acceptor in the presence of TrClO4.138,152 
Backinowsky also reported that 1,2-O-(1-cyanoethylidene) glycoside can be activated 
with TrClO4 in presence of thioglycoside acceptors described in synthesis of a “fully-
carbohydrate” mannodendrimer.153 
Danishefsky and his-coworkers developed a convenient method for the 
preparation of the 1,2-anhydro sugars from glycals using dimethyldioxirane (DMDO)154 
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as an effective epoxidation reagent.155  For example, 1,2-anhydro sugar 1.144 generated 
from glycal 1.145 could be activated over glycal acceptor 1.146 in the presence of ZnCl2 
in THF to afford 1,2-trans-linked disaccharide 1.147 in 81% (Scheme 1.28). The 
epoxidation-glycosylation sequence can be then reiterated to yield larger 
oligosaccharides, although similarly to other pre-activation type of couplings, this 
approach cannot be classified as the formal oligosaccharide synthesis via selective 
activations.  
 
 
Scheme 1.28  Danishefsky’s glycal-epoxide method for oligosaccharide synthesis. 
 
1.4 Multistep sequences based on selective activations 
Multistep oligosaccharide synthesis have been developed using selective 
activation strategy. In principle, the activation sequence can be continued providing 
beyond previously discussed couplings of building blocks equipped with LGa and LGb.  
The continuation requires the availability of a LGc, which would withstand activation 
conditions for the LGb. However, these elongated multi-step sequences are not yet 
routinely available (vide infra).62,63 This can be circumvented by performing additional 
modifications between glycosylations that allow repetition of the sequence involving 
repetitive LGa and LGb activations. An example applying such selective-activation 
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strategy is the synthesis of heparin-like oligosaccharides reported by van der Marel and 
co-workers (Scheme 1.29).84 The synthesis of pentasaccharide 1.157 began by utilizing 
the diphenyl sulfoxide—triflic anhydride dehydrative protocol developed by Gin156 for 
the activation of the hemiacetal donor 1.148 over thioglycoside acceptor 1.149. The 
phenylthio moiety of the resulting disaccharide 1.150 was then directly coupled with 
glycosyl acceptor 1.151 with the benzenesulfinyl piperidine (BSP)- triflic anhydride 
system.157 The resulting trisaccharide 1.152 is then converted to the corresponding 
hemiacetal derivative 1.153, which was selectively activated over thioglycoside acceptor 
1.154 in the presence of diphenyl sulfoxide-triflic anhydride. The resulting 
tetrasaccharide 1.155 isolated in 51% yield was glycosidated with glycosyl acceptor 
1.156 in the presence of the BSP/Tf2O promoter system to furnish the target 
pentasaccharide 1.157 in 53% yield. 
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 Scheme 1.29  Selective activation approach to the synthesis of heparin analogues. 
 
An example with the involvement of three different leaving groups is depicted in 
Scheme 1.30, in which trichloroacetimidoyl is used as a LGa, phenylselnyl as LGb, and S-
ethyl as LGc.158 Thus, activation of trichloroacetimidate 1.158 over selenoglycoside 
acceptor 1.159 was achieved in the presence of TMSOTf. The resulting disaccharide 
1.160 isolated in 90% was then coupled with thioglycoside acceptor 1.112 in the presence 
of AgOTf and K2CO3 leading to trisacccharide 1.161 in 81% yield. In principle the 
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thioethyl moiety can be activated further. A similar sequence using bromide as LGa, 
Selenoglycoside as LGb and thioglycosides as LGc was also reported.56   
 
 
Scheme 1.30  Selective activation utilizing three different leaving group. 
 
Another relevant example is the use of the S-benzoxazolyl (SBox) moiety as LGa, 
S-ethyl as LGb, and O-pentenyl as LGc depicted in Scheme 1.31.159,160 The SBox glycosyl 
donor 1.114 was selectively activated over the SEt acceptor 1.82 in the presence of 
AgOTf to produce disaccharide 1.162 in 99% yield. The latter disaccharide was 
glycosidated with the n-pentenyl acceptor 1.163 in the presence of MeOTf to provide 
trisaccharide 1.164 in 90% yield. Finally, the leaving n-pentenyl moiety of the 
trisaccharide donor 1.164 was then activated with NIS/TMSOTf for the coupling with 
glycosyl acceptor 1.165, resulting in the formation of tetrasaccharide 1.166 in 73% yield.  
A similar example included the following three-step activation sequence performed in a 
one-pot fashion: SBox as LGa, S-thiazolinyl (STaz) as LGb, and S-ethyl as LGc.161  
 
 41
 Scheme 1.31  Three-step SBox→ SEt → n-pent sequential selective activation. 
  
Very recently, the synthesis of a β-(1→6)-linked hexasaccharide via the five-step 
selective activation sequence was employing six different leaving groups as depicted in 
Scheme 1.32.162 The synthesis began with the selective activation of thiocyanate donor 
1.167 over STaz glycosyl acceptor 1.115 using Cu(OTf)2 as a promoter. The STaz 
leaving group of disaccharide 1.116 was then directly activated over SBox acceptor 1.168 
with benzyl bromide to give trisaccharide 1.169. The SBox moiety of 1.169 was then 
selectively activated over the fluoride acceptor 1.170 in the in presence of MeOTf. The 
resulting tetrasaccharide 1.170 was glycosidated with thioglycoside acceptor 1.137 in 
presence of AgClO4/Cp2ZrCl2 to provide pentasaccharide 1.171. Finally, the S-ethyl 
leaving group of 1.171 was selectively activated over the n-pentenyl acceptor 1.91 in the 
presence of MeOTf as a promoter to furnish the hexasaccharide 1.172 in 72% yield.162  
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Scheme 1.32  Selective activation utilizing six different leaving groups in the synthesis of 
1,2-trans hexasaccharide 1.172. 
 
1.5 Semi-orthogonal approach 
The orthogonal approach makes use of two leaving groups LGa and LGb that can 
be independently activated one over another and vice versa (vide infra). A semi-
orthogonal strategy is based on a similar principle, but it requires the additional 
enforcement by electronic effects, similarly to that of the “armed-disarmed concept”. 
Overall, this concept combines advantages of both selective and chemoselective 
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activation; its utility, however, is limited as the protecting groups also often determine the 
stereoselectivity as well.   
Thus, it was demonstrated109 that either armed or disarmed thioglycoside can be 
selectively activated over either armed or disarmed n-pentenyl glycosides in the presence 
of MeOTf. However, only armed n-pentenyl could then be activated over a disarmed 
thioglycoside acceptor using IDCP as a mild promoter. Thus, lactose S-ethyl donor 1.173 
was selectively activated over the n-pentenyl moiety of glycosyl acceptor 1.142 in the 
presence of MeOTf. The resulting trisaccharide was isolated in 98% yield as depicted in 
Scheme 1.33. The n-pentenyl moiety of the latter was then subjected to 
selective/chemoselective activation over S-ethyl acceptor 1.82 in the presence of IDCP 
leading to tetrasaccharide 148 in 92% yield.  
 
 
Scheme 1.33  Semi-orthoganality of thioglycoside and n-pentenyl leaving groups. 
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This semi-orthogonal concept was recently extended to another suitable pair of 
leaving groups, namely fluoride and n-pentenyl.110 While either armed or disarmed 
glycosyl fluorides underwent smooth glycosylation with armed/disarmed n-pentenyl 
glycoside in presence of Yb(OTf)3, only armed n-pentenyl glycosides could be activated 
over disarmed glycosyl fluorides in presence of IDCP. As depicted in Scheme 1.34, 
fluoride donor 1.176 was selectively activated over pentenyl glycosyl acceptor 1.177 in 
the presence of Yb(OTf)3. The resulting n-pentenyl disaccharide was isolated in 68% 
yield. Conversely, the activation of armed n-pentenyl glycoside 1.179 was achieved 
selectively over fluoride acceptor 1.180 to afford disaccharide 1.181. No activation of 
benzoylated n-pentenyl glycosides could be accomplished, whereas NIS/BF3-Et2O–
promoted selective activation resulted in a poor yield (25%).   
 
 
Scheme 1.34  Semi-orthogonality of n-pentenyl glycoside and glycosyl fluoride. 
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1.6  Orthogonal activation 
The combination of two chemically distinct glycosylation reactions, in which one 
of the leaving groups is activated while the other one remains intact, and vice versa, has 
led to the discovery of the orthogonal strategy for oligosaccharide synthesis.38 This 
unique, and virtually one of the most conceptually attractive techniques for expeditious 
oligosaccharide synthesis, requires the use of two orthogonal classes of glycosyl 
donors.163,164 As with the selective activation strategy, at the first step the glycosyl donor 
bearing LGa is activated over the glycosyl acceptor bearing LGb. Uniquely to the 
orthogonal strategy, however, the LGb is then activated over LGa of the new glycosyl 
acceptor (Scheme 1.35). This activation sequence can then be reiterated to give 
straightforward access to larger oligosaccharides. Ideally, the orthogonal approach allows 
for an unlimited number of reiterations of the two orthogonal leaving groups LGa and 
LGb, which is conceptually very attractive. In practice, however, the efficiency of 
glycosidation is usually inversely correlated to the size of the glycosyl donor involved.  
And since this approach presumes the elongation of glycosyl donors, the yields are 
typically decreased dramatically at the later stage of the assembly.   
 
Scheme 1.35  Orthogonal strategy for oligosaccharide synthesis. 
 
1.6.1 Fluorides and thioglycosides. 
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The classic variation of the orthogonal activation route introduced by Ogawa et 
al. involves building blocks bearing S-phenyl and fluoro leaving groups.38 Phenyl 
thioglycoside donor 1.182 can be selectively activated over glycosyl fluoride acceptor 
1.183 in the presence of NIS/AgOTf to afford the disaccharide 1.184 in 85% (Scheme 
1.36). The fluoro leaving group of disaccharide 1.184 can then be activated over 
thioglycoside acceptor 1.185 in the presence Cp2Hf2Cl2/AgOTf as a promoter system. 
The resulting trisaccharide 1.186 is obtained in 72% yield. This selective activation 
sequence can be then reiterated; to illustrate this, the trisaccharide donor 1.186 bearing S-
phenyl was activated over the fluoride acceptor 1.183 to provide tetrasaccharide 1.187 in 
66% yield.  
 
 
Scheme 1.36.  Orthogonal activation of phenylthio glycosides and fluorides. 
 
1.6.2 Thioglycoside and thioimidate 
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A combination of S-ethyl and S-thiazolinyl (STaz) leaving groups also represents 
a promising orthogonal pair. STaz glycosides can be activated selectively with AgOTf, 
whereas the ethyl thioglycoside can be activated with NIS and catalytic TfOH.129 This 
finding was applied to the synthesis of a pentasaccharide derivative 1.192, as depicted in 
Scheme 1.37.165 Thioglycoside donor 1.188 was first activated over the STaz acceptor 
1.115 in the presence of NIS/cat. TfOH. The resulting disaccharide 1.189 isolated in 98% 
yield was in turn activated over thioglycoside acceptor 1.137 with AgOTf to give 
trisaccharide 1.190 in 93% yield. The sequence was then reiterated as follows. 
Thioglycoside donor 1.190 was activated over STaz acceptor 1.115 in the presence of 
NIS/cat. TfOH. The resulting tetrasaccharide 1.191 was selectively activated over 
thioglycoside acceptor 1.137 by the addition of AgOTf to give pentasaccharide 1.192 in 
59% yield.   
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Scheme 1.37  Orthogonality of ethyl and thiazolinyl thioglycosides. 
 
1.6.3 Thioimidate-only (SBox and STaz glycosides) 
A related approach involving orthogonal activation of STaz and SBox glycosides 
has also recently emerged.133 SBox glycosides can be selectively activated with 
Cu(OTf)2165 or Bi(OTf)3132 over the STaz leaving group. As shown in Scheme 1.38, STaz 
leaving group that is typically more stable than SBox towards a majority of thiophilic 
activation conditions, can be also selectively activated over SBox in the presence of 
relatively mild alkylation reagents, benzyl bromide or methyl iodide. Thorough 
mechanistic studies showed that the selective activation is based on the different 
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activation modes reactivity of these leaving groups. Thus, it was found that preferential 
glycosidation of a certain thioimidate is not simply determined by the strength of 
activating reagents; instead, the type of activation – direct (for SBox) vs. indirect (for 
STaz) – comes to the fore and plays the key role. Thus, activation of STaz donor 1.193 
over SBox acceptor 1.168 in the presence of BnBr at 55 °C afforded disaccharide 1.194 
in 76% yield. The latter could be then activated over STaz acceptor in the presence of 
Bi(OTf)3 at 0 °C.  The resulting trisaccharide 1.195 was isolated in 62% yield.  
 
 
Scheme 1.38  Thioimidate-only orthogonal strategy. 
 
1.6.4 n-Pentenyl and propargyl activation 
Recently, Hotha et al. reported a new promising pair of leaving groups for 
orthogonal activation involving of propargyl and n-pentenyl glycosides (Scheme 
1.39a).111 According to this study, NIS/TMSOTf served as an efficient activator for 
selective activation of n-pentenyl glycoside 1.84 (Scheme 1.39a). In this case, either 
alkylated or acylated O-propagyl glycosyl acceptors 1.56 or 1.85, respectively, worked 
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equally well. As the result of this selective activation, disaccharides 1.197 and 1.86 were 
isolated in 66 and 68% yield. On the other hand, propargyl glycosyl donor 1.90 can be 
selectively activated over propargyl glycosyl acceptor 1.91 in the presence of AuBr3 to 
afford disaccharide in 65%. This activation works particularly well for benzoylated 
glycosyl acceptor 1.91 and as glycosylation of its benzylated counterpart 1.142 led to 
modest yield of the respective disaccharide 1.198. This implies a more semi-orthogonal 
like activation (vide supra) rather than purely orthogonal. 
 
 
Scheme 1.39  Orthogonality of n-pentenyl vs. O-propargyl leaving groups. 
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1.7 Selective and orthogonal activations in modern high throughput technologies 
 
1.7.1 Intramolecular glycosylations 
An intramolecular aglycone delivery (IAD) approach first introduced by Barresi 
and Hindsgaul166,167 and later by Stork and Kim168,169 is the one of the most reliable 
methods to obtain β-mannosides. Ogawa et al. then reported the use of a p-
methoxybenzyl (PMB) group at the C-2 position as the stereocontrolling tether for β-
mannosylation.170 The p-methoxybenzyl assisted IAD process was used as the key 
reaction for the construction of β-mannoside containing fragment that also involved 
selective activation concept (Scheme 40).60,61 According to this approach, thioglycoside 
donor 1.199 was linked to fluoride acceptor 1.138 via DDQ-mediated tethering. The 
resulting construct 1.200 was subjected to treatment with MeOTf and DTBMP that 
allowed for selective activation of the S-methyl group over the fluoro group to afford β-
mannoside 1.201. The free hydroxyl group in 1.201 was then acetylated, and the resulting 
fluoride donor 1.202 was glycosylated with glycosyl acceptor 1.203. The resulting 
trisaccharide 1.204 was obtained in 85% yield. In principle, the last step can also be 
considered selective activation, as O-allyl glycosides can be activated via a two-step one-
pot isomerization-glycosidation sequence. A similar approach was also investigated using 
polymer support.171 
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 Scheme 1.40  p-Methoxybenzyl mediated intramolecular aglycone delivery and selective 
activation concepts.  
 
1.7.2 One-pot synthesis 
Conceptually, one-pot strategies offer the shortest pathway to oligosaccharides, as 
the sequential glycosylation reactions are performed in a single flask (pot) and do not 
require purification of the intermediates. It is very important for a successful one-pot 
glycosylation that there is complete consumption of all building blocks and the high yield 
in each glycosylation step. In addition, the requirement for very high or preferably 
complete stereoselectivity in every glycosylation step becomes particularly important.  
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These will ensure that only the target oligosaccharide is being produced as the major 
product, thus providing high efficiency of this technique. Many variations of the one-pot 
strategy have been developed,172,173 herein we focus our discussion on the approaches 
based on selective activation of one type of a leaving group over another. The use of 
selective activation strategy for the one-pot oligosaccharide sequencing is easy to 
envisage. As illustrated in Scheme 1.41, it requires a set of suitable leaving groups (LGa, 
LGb, LGc) activators that would activate one leaving group over another: A (selectively 
activates LGa), B (selectively activates LGb), etc.  
 
 
Scheme 1.41  A generic selective activation-based oligosaccharide synthesis in one pot. 
 
The first one-pot synthesis based on the leaving group based activation concept 
was reported by Takahashi and co-workers.57 As depicted in Scheme 1.42, this synthesis 
involved the use of trichloroacetimidate donor 1.205, which was selectively activated 
over thioglycoside 1.206 with TMSOTf. The SPh moiety of the formed, but not isolated, 
tetrasaccharide was then glycosidated by adding glycosyl acceptor 1.207 in the presence 
of NIS/TfOH to provide hexasaccharide 1.208 in 50% yield over two steps. This 
approach incorporates advantages of the convergent block strategy according to which 
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pre-synthesized oligosaccharide building blocks i.e. 1.205 and 1.207 are converged 
together during the final assembly.  
 
 
Scheme 1.42  Convergent one-pot synthesis by selective activation. 
 
A number of related two-step one-pot syntheses have emerged, and the most 
representative examples are surveyed below. As depicted in Scheme 1.43a, reaction of 
bromide 1.209 and S-phenyl acceptor 1.210 was affected in the presence of silver triflate. 
The S-phenyl leaving group of the intermediate disaccharide was then glycosidated by 
adding glycosyl acceptor 1.211 and NIS.  The resulting trisaccharide 1.212 was isolated 
in 84% yield over two steps.174 In a similar fashion, a tetrasaccharide glycosyl glycerol 
which represents the core structure of a glycoglycerolipid of M. taiwanesis, based on a 
three-component one-pot strategy was synthesized as depicted in Scheme 1.43b.175 A 
trisaccharide intermediate was formed from the glycosyl phosphite 1.213, which was 
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selectively activated over selenoglycoside acceptor 1.214 in the presence of TMSOTf. 
Subsequent addition of acceptor 1.215 and NIS produced the target tetrasaccharide 1.216 
in 46% yield over-all. Seeberger and co-workers presented an efficient one-pot synthesis 
of a pentasaccharide 1.220 shown in Scheme 1.43c.176 Accordingly, disaccharide 
trichloroacetimidate 1.217 was activated with TMSOTf to react regioselectively at the C-
4 hydroxyl group of the thioglycoside 1.218. Subsequent addition of disaccharide 
acceptor 1.219, followed by the addition of NIS/TfOH to promote the thioethyl group of 
the in situ formed trisaccharide completed the sequence. The requisite pentasaccharide 
1.220 was isolated in 63% yield. 
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Scheme 1.43  Typical examples of two-step one-pot oligosaccharide syntheses. 
A representative example involving three sequential glycosylation steps is shown 
in Scheme 1.44.161 This three step activation was achieved by the stepwise activation of 
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S-benzoxazolyl (SBox) glycosyl donor 1.114 over S-ethyl glycosyl acceptor 1.82 by 
addition of AgOTf. Thioethyl moiety of the resulting disaccharide intermediate was then 
activated over the added S-thiazolinyl (STaz) acceptor 1.115 by the addition of NIS and 
catalytic TfOH. Finally, the STaz moiety of the trisaccharide intermediate was reacted 
with freshly added glycosyl acceptor 1.165 in the presence of additional quantity of 
AgOTf. As a result, the linear tetrasaccharide 1.221 was obtained in 73% yield over three 
steps.  
 
Scheme 1.44  One-pot synthesis of tetrasaccharide 1.221 by the three-step sequential 
selective activation. 
 
Utilizing longer sequences of selective activations are not yet routinely available. 
Although a number of one-pot syntheses or large oligosaccharides has emerged, all are based 
on mixed convention, typically a combination of selective and chemo or regioselective 
sequential activations. For example, Ley’s group reported the synthesis of a GPI anchor 
involving building blocks with well defined levels of reactivity (Scheme 1.45).177 Thus, 
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armed and disarmed glycosyl fluorides (1.222, 1.223), armed and disarmed selenoglycosides 
(1.224, 1.225) and thioglycoside 1.226 were all sequentially activated to provide the target 
linear pentamannoside 1.227 in 8% overall yield in four steps. Evidently the first and the third 
steps involved chemoselective activations, whereas the second and fourth steps involved 
selective activations of fluoride over SePh and SePh over SPh, respectively. 
 
 
Scheme 1.45  Ley’s synthesis via alternating chemoselective and selective couplings. 
 
Mukaiyama reported an elaborate one-pot sequence that resulted in the formation of a 
phytoalexin elicitor heptasaccharide 1.232 in 48% yield.178 As depicted in Scheme 1.46, the 
synthesis of heptasaccharide 1.232 involved a combination of sequential selective (fluoride 
1.228 over thioglycoside 1.229) and chemoselective activations (armed SEt disaccharide 
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intermediate over disarmed acceptor 1.230), as well as convergent approach (4 + 3, building 
block 1.231), all in one pot.   
 
 
Scheme 1.46  Mukaiyama’s one-pot synthesis involving the elements of orthogonal 
activation. 
 
A similar target was obtained by Takahashi in a six-step one-pot synthesis of 
heptasaccharide  using a Quest 210 manual synthesizer.179 As depicted in Scheme 1.47, this 
one-pot synthesis required the sequential addition of seven reaction components 1.233-1.239 
using four different leaving groups. Sequential activations employed herein included: 
activation of glycosyl bromide 1.233 (activated with AgOTf over S-ethyl acceptor), ethyl 
thioglycosides 1.234 and 1.235 (with MeOTf over fluoride acceptor 1.236), tetrasaccharide 
fluoride (with Cp2HfCl2/AgOTf over S-phenyl acceptor 1.237) and phenyl thioglycosides 
1.238 and hexasaccharide (with DMTST in the armed-disarmed fashion). The resulting 
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protected phytoalexin elicitor heptasaccharide 1.240 was isolated in 24% yield over six steps. 
To the best of our knowledge, this is the only selective activation-based synthesis that 
incorporates the elements of the orthogonal-like activations in one-pot (steps three and four).   
 
 
Scheme 1.47  Takahashi’s synthesis using the elements of orthogonal activations. 
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1.7.3 Polymer-supported synthesis 
Solid-phase synthesis has been developed and widely utilized in a routine 
preparation of oligopeptides and oligonucleotides, and is attracting renewed attention in 
connection with combinatorial chemistry. The use of polymer supports in oligosaccharide 
synthesis has also been attractive and several intriguing approaches have been reported.  
Most of the concepts involve glycosyl acceptor bound approach, with examples involving 
glycosyl acceptor bound strategies that allow for selective activations also known. For 
instance, Kahne et al. reported selective activation of sulfoxide donor 1.241 over the 
Merrifield resin –bound thioglycoside acceptor 1.242 in the presence of Tf2O and 
DTBMP (Scheme 1.48).180  Upon completion of the sequencing that resulted in the 
formation of trisaccharide 1.245, the thioglycoside linker is cleaved under mild 
conditions employing mercuric trifluoroacetate.  
 
 
Scheme 1.48  Utilizing glycosyl sulfoxides in selective activations over thioglycoside 
bound to the polymer support. 
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An example of a donor-bound approach utilizing selective activations on solid 
phase synthesis is the synthesis of the Leb blood group antigen reported by Seeberger and 
co-workers (Scheme 1.49).181,182 Glycal connected to Merrifield’s resin 1.246 was 
subjected to epoxidation with DMDO, followed by coupling with glycal acceptor 1.247 
in the presence of ZnCl2. Fucosyl fluoride donor 1.248 was then activated over polymer-
bound glycal disaccharide 1.249 in the presence of Sn(OTf)2 and DTBP. This steps 
incorporates the elements of a two-directional concept developed by Boons.183,184 The 
resulting tetrasaccharide glycal 1.250 was then converted into the corresponding 2-amino 
thioglycoside 1.251.  This transformation allowed the continuation of the sequence that 
resulted in glycosidation of 1.251 with glycal acceptor 1.252. The resulting 
pentasaccharide was then cleaved off of the polymer support to afford pentasaccharide 
1.253 in 20% over-all. Selective activation of the SBox bound glycosyl donor over 
solution phase thioglycoside acceptor in the presence of TMSOTf was also reported.185 
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Scheme 1.49  Solid phase synthesis of Leb blood-group antigen analog. 
 
The application of an orthogonal strategy utilizing polymer support was also 
developed by Ogawa in 1996.39 Ogawa reported a combination of chemistry on polymer 
supports and orthogonal glycosylation (thioglycosides and glycosyl fluorides) which 
resulted in the construction of oligosaccharide by minimize the number of operation. To 
illustrate this concept, a representative example reported by Kanie et al. (Scheme 1.50) is 
included.186 According to this approach, polymer-bound glycosyl donor 1.254 was 
activated selectively over fluoride acceptor 1.15 in the presence of DMTST. The resulting 
disaccharide 1.255 was activated over S-phenyl acceptor 1.256 in the presence of 
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Cp2Hf(OTf)2. Finally, S-phenyl trisaccharide 1.257 was glycosidated with octanol in the 
presence of DMTST.   
 
Scheme 1.50  Orthogonal glycosylation reactions on solid phase for synthesis of fucosyl 
galactose oligosaccharides. 
 
1.8 Conclusions and future directions 
It is critical to make complex carbohydrates more accessible to the general 
chemical, biochemical, and industrial audience to keep pace with the exploding area of 
glycobiology. This can be only achieved by the development of methods and strategies 
for efficient oligosaccharide synthesis that would be applicable for both laboratory and 
industrial preparation. A number of excellent strategies that offer a reasonably efficient 
route to oligosaccharide assembly have already emerged. Important discoveries surveyed 
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in this article have already allowed scientists to synthesize complex oligosaccharides and 
glycoconjugates for structural, biological, and medical studies.  Nevertheless, 
carbohydrates of even moderate complexity still present a considerable challenge, even to 
experts. No expeditious strategy developed to date can offer an easy and reliable access 
to all full range of compounds of interest. Some strategies offer a very efficient approach 
to certain sequences, but in general each target still requires careful selection of methods, 
conditions, and strategies. 
The development of efficient and general methods for the expeditious synthesis of 
complex carbohydrates will undoubtedly remain an important and active arena for 
scientific endeavours during the 21st century. In the coming years, glycoscientists are 
expected to have developed simple, efficient, and flexible approaches to oligosaccharide 
assembly that will complement existing methodologies and bring our ability to obtain 
complex oligosaccharides up to a significantly higher level. The recent innovations 
surveyed herein make contemporary glycoscientists well positioned to undertake further 
studies. Future developments may be expected to incorporate existing methodologies, and 
combinations thereof, while blending in new concepts and technologies.  
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2.1 Introduction 
With increasing demand for the synthesis of biologically important and 
therapeutically active oligosaccharides and glycoconjugates, efforts to expand the arsenal 
of glycosylation methods and techniques have emerged. In spite of significant recent 
advances in the areas of stereoselective glycosylation1,2 and expeditious oligosaccharide 
synthesis,3,4 the construction of complex oligosaccharides with high efficiency and 
complete stereoselectivity remains a difficult task. As a part of a program to develop new 
methods and strategies for glycochemistry, we became interested in glycosyl 
thioimidates, a class of glycosyl donors with the generic leaving group SCR1=NR2.5,6 We 
have already reported the synthesis of S-benzoxazolyl (SBox)7,8 and S-thiazolinyl 
(STaz)9,10 glycosides and evaluated their properties in stereoselective glycosylations and 
expeditious oligosaccharide syntheses. Metal salt-based promoters were shown to provide 
efficient activation of the thioimidoyl moiety for glycosylation.8,11 Among a variety of 
metal salts investigated, arguably, silver trifluoromethanesulfonate (AgOTf) was one of 
the best choices for the activation of the SBox and STaz moieties for a variety of 
synthetic applications. Beyond the scope of our own research program, AgOTf has been 
commonly employed as an activator for many other classes of glycosyl donors including 
glycosyl bromides,12-14 chlorides,15 trichloroacetimidates,16 and seleno glycosides.17 In 
spite of wide applicability and high versatility of AgOTf, there are some significant 
drawbacks that limit the usage of this promoter in synthesis. In a majority of applications, 
AgOTf requires fresh activation by repetitive co-evaporation with toluene followed by 
extended drying under vacuum directly prior to use. In addition, we noticed that the 
quality of commercial reagent may significantly vary depending on the supplier and the 
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batch. It should be noted that the use of AgOTf as an acidic additive in NIS-promoted 
glycosidation of thioglycosides does not require preactivation of AgOTf. Bearing in mind 
these drawbacks, we questioned if any other silver salts could be used to achieve an 
efficient glycosidation of a variety of glycosyl donors and would produce reproducible 
results without the requirement of the preactivation or azeotropic dehydration. Herein we 
present a report that demonstrates the use of silver tetrafluoroborate (AgBF4) as a potent 
promoter for the activation of various types of glycosyl donors. It should be noted that 
AgBF4 has already been used in glycosylations, yet these applications, including 
alcoholysis of glycosyl bromides,18,19 synthesis of C-glycosides from chlorides,20 
glycosidation of 2-deoxy thioglycosides,21 and α-stereoselective glycosidation of 1,2 
anhydro sugars,22 were scarce and scattered. In this context, Cp2ZrCl2–AgBF4 in benzene 
has proven to be a powerful promoter combination for the activation of tetra-O-benzyl-D-
mannosyl fluoride.23  
 
2.2 Results and discussion 
To generate a broad array of glycosyl donors we investigated whether thiazolinyl 
2,3,4,6-tetra-O-benzyl-1-thio-β-D glucopyranoside 2.5a10 could serve as a common 
precursor. These studies were successful and we discovered that the STaz glycoside 2.5a 
can be directly converted into the following glycosyl donors: acetate 2.1, bromide 2.2a, 
chloride 2.8, fluoride 2.9, and hemiacetal 2.10 in excellent yields (84–95%, Scheme 2.1). 
Moreover, glycosyl bromide 2.2a was then used as a precursor for the next synthetic 
steps to obtain benzoxazolyl, benzothiozolyl, and ethyl thioglycosides (2.3a, 2.4a, and 
2.6), as well as n-pentenyl glycoside 2.7—all with exclusive β stereoselectivity. The 
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hemiacetal derivative 2.10 was converted into the corresponding glycosyl 
trichloroacetimidate 2.11 as shown in Scheme 2.1.  
 
 
Scheme 2.1 Conversion of the a common STaz glycoside 2.5a into a range of glycosyl 
donors 
 
Synthesis of a range of differently protected glycosyl thioimidates has been 
similarly accessed and is depicted in Scheme 2.2. Yields given are over-all yields for two 
synthetic steps.   
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 Scheme 2.2 Conversion of the STaz glycosides 2.5b,c into thioimidates 2.3b,c and 
2.4b 
 
Having synthesized a library of glycosyl donors, we performed a number of test 
glycosylation reactions using AgBF4 as a promoter (Table 2.1). Since we wanted to 
determine whether the glycosylations could be performed without pre-activation of 
AgBF4, all reactions were performed with commercial reagent as received, without 
further conditioning.  
Glycosidation of glycosyl acetate 2.1 with glycosyl acceptor 2.13 in the presence 
of AgBF4 did not proceed (entry 3). A similar coupling in the presence of BF3–Et2O, a 
conventional promoter for the activation of glycosyl acetates,24 gave disaccharide 2.17a 
(Fig. 2.1) in 91% yield, although it required 16 h for the reaction to complete. We 
determined that the reaction time of this reaction could be significantly reduced (16 h vs 
5 h, entries 4 and 5) by adding 20–50 mol % of AgBF4. In these couplings, even higher 
yield of 2.17a (95%) and an improved stereoselectivity were detected.  
Glycosidation of glycosyl bromides 2.2 and 2.2 could be efficiently accomplished 
with AgBF4, although the coupling of per-benzoylated bromide 2.2, prepared as shown in 
Scheme 2.2, with the sterically hindered acceptor 2.14 required prolonged reaction time 
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(entries 15–16). These results were comparable with the glycosylations using traditional 
bromide activators-silver carbonate,25,26 or mercury salts.27,28  
 
Table 2.1 AgBF4 promoted glycosylations of glycosyl acceptor 2.12-2.15 
 
Entry Donor Acceptor Time Product Yield (%) α/β Ratio 
1 2.1 2.13 24 h 2.17a -a - 
2b 2.1 2.13 16 h 2.17a 91 1.4/1 
3c 2.1 2.13 5 h 2.17a 95 2.0/1 
4 2.2a 2.13 5 min 2.17a 92 2.4/1 
5 2.2b 2.13 5 min 2.17b 96 β only 
6 2.2b 2.14 24 h 2.18b 82 β only 
7 2.3a 2.13 10 min 2.17a 89 1.2/1 
8 2.3b 2.13 10 min 2.17b 91 β only 
9 2.3b 2.14 15 min 2.18b 84 β only 
10 2.3c 2.13 15 min 2.17c 91 1.6/1 
11 2.4a 2.15 5 min 2.19a 87 7.4/1 
12 2.4b 2.13 20 min 2.17b 90 β only 
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13 2.5a 2.13 5 min 2.17a 95 1.3/1 
14 2.5a 2.14 5 min 2.18a 92 1.4/1 
15 2.5b 2.13 10 min 2.17b 90 β only 
16 2.5c 2.13 20 min 2.17c 75 1.2/1 
17 2.6 2.13 24 h 2.17a -a - 
18d 2.6 2.13 24 h 2.17a 91 1.2/1 
19e 2.6 2.13 10 min 2.17a 92 1.2/1 
20 2.7 2.13 24 h 2.17a -a - 
21d 2.7 2.13 24 h 2.17a 89 1.0/1 
22e 2.7 2.13 20 min 2.17a 76 1.2/1 
23 2.8 2.13 5 min 2.17a 97 1.6/1 
24 2.8 2.12 10 min 2.16a 91 1/3.4 
25 2.9 2.13 20 h 2.17a 81 2.0/1 
26 2.9 2.15 1.5 h 2.19a 81 2.3/1 
27 2.10 2.13 24 h 2.17a -a - 
28 2.11 2.13 5 min 2.17a 80 1/1.5 
29 2.11 2.12 2 days 2.16a 65 1/5.4 
 
a No product formation was detected; all glycosylations were promoted with AgBF4 
except the following. 
b -3.0 equiv of BF3–Et2O were used. 
c -3.0 equiv of BF3–Et2O and 0.5 equiv of AgBF4 were used. 
d -2.0 equiv of NIS was used. 
e  -2.0 equiv of NIS and 0.5 equiv of AgBF4 were used. 
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 Figure 2.1 Structure of disaccharide 2.16-2.19 
 
Glycosidation of glycosyl thioimidates 2.3-2.5 was smoothly driven to completion 
in a matter of minutes (entries 7–16). All glycosylations proceeded with very high 
conversion yields, comparable or even exceeding those achieved in glycosylations 
promoted with preactivated AgOTf. For example, AgBF4-promoted couplings depicted in 
entries 14 and 16 (Table 2.1) proceeded in 92% (90% with AgOTf) and 75% (70% with 
AgOTf) yield, respectively.9 While the anchimerically assisted couplings with 
benzoylated glycosyl donors were β stereoselective, only fair α-stereoselectivity was 
achieved with 2-O-benzylated glycosyl donors. All couplings were performed in the 
neutral solvent since the stereoselectivity optimization was not a primary intention of 
these studies. 
Promoters for thioglycoside and n-pentenyl glycoside activation include thiophilic 
reagents, among which NIS/TfOH or NIS/TMSOTf are arguably the most common.29,30 
Therefore, not surprisingly, the activation of stable glycosyl donors,  thioglycoside 2.6 or 
n-pentenyl glycoside 2.7, did not take place in the presence of AgBF4. It should be noted 
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that NIS alone can also activate both S-ethyl and n-pentenyl glycosides, however, these 
transformations require prolonged reaction time (entries 18 and 21). Having decided to 
investigate whether these glycosyl donors can be activated by NIS/AgBF4 system, we 
discovered that these coupling reactions proceeded very rapidly and provided the 
corresponding disaccharide in minutes (entries 19 and 22). We then demonstrated that 
AgBF4 could be employed as a suitable promoter for glycosidation of chloride 2.8, 
fluoride 2.9, or trichloroacetimidate 2.11, whereas the hemiacetal derivative 2.10 
remained inert under these reaction conditions (entry 23-29).  
Based on the results summarized in Table 2.1, we anticipated that it might be 
possible to activate glycosyl halides, S-benzothiazolyl, SBox, or STaz glycosides over the 
SEt or n-pentenyl moieties in the presence of AgBF4. We have already reported that 
selective activation of SBox and STaz glycosides over SEt glycosyl acceptor can be 
achieved in the presence of AgOTf.7,31 Also in this case, AgBF4 was found to be capable 
of providing smooth couplings with consistently high yields (Table 2.2). We observed 
that glycosidation of glycosyl fluoride 2.9 was sluggish and the moderate to good yields 
presented in Table 2.2 are based on unreacted acceptor recovery (entries 1 and 5).  
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Table 2.2 Selective activation of various glycosyl donors over n-pentenyl acceptor 2.20 
and SEt acceptor 2.22 
 
Entry Donor Acceptor Time Product Yield (%) α/β Ratio 
1 2.3a 2.20 10 min 2.21 86 1.1/1 
2 2.4a 2.20 20 min 2.21 85 3.3/1 
3 2.5a 2.20 10 min 2.21 83 1/1.2 
4 2.9 2.20 16 h 2.21 65a 1.6/1 
5 2.2a 2.22 15 min 2.23 84 1.6/1 
6 2.3a 2.22 20 min 2.23 87 2.01 
7 2.5a 2.22 15 min 2.23 89 2.41 
8 2.8 2.22 15 min 2.23 84 2.2/1 
9 2.9 2.22 24 h 2.23 83a 2.41 
a This yield is based on the recovery acceptor. 
 
Based on the results of the selective activations, we assumed that it could be 
possible to perform the activation sequence in a highly efficient one-pot fashion. 
Presumably, any building block that can be activated with AgBF4 can be used as the 
glycosyl donor for the first activation step. We chose to investigate SBox and STaz 
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glycosides as well as glycosyl bromides as glycosyl donors. Glycosyl acceptors should 
withstand AgBF4 activation, but in turn could be readily activated by addition of NIS. 
Either S-ethyl or n-pentenyl leaving groups could be used for this purpose. An example 
shown in Scheme 2.3 makes use of the STaz leaving group in 2.5a for the first coupling 
step. At this stage the S-ethyl moiety of the glycosyl acceptor 2.24 remains inert. Upon 
the formation of the intermediate disaccharide, its SEt moiety can then be activated for 
the reaction with the newly added acceptor 2.13 by adding 2.0 equiv of NIS. As 
demonstrated above, NIS along with AgBF4 (used in excess and is remaining from the 
previous step) serves as an efficient promoter for this type of glycosylation. As a result of 
this two-step activation, trisaccharide 2.25 was isolated in 72% yield. Other leaving 
group combinations mentioned above were also found to be capable of the one-pot 
activations and provided the corresponding trisaccharides in 55–70% overall yields. 
 
 
Scheme 2.3 One-pot glycosylation: synthesis of trisacharide 2.25 
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2.3 Conclusion 
In summary, we have identified silver tetrafluoroborate as an excellent promoter 
for the activation of various glycosyl donors, prepared from the common precursor 
bearing the STaz anomeric moiety. Easy handling and no requirement for azeotropic 
dehydration prior to the application makes AgBF4 especially beneficial in comparison to 
the commonly used AgOTf. We also demonstrated that selective activation of glycosyl 
halides or thioimidates over thioglycosides or n-pentenyl glycosides could lead to simple 
one-pot syntheses via sequential selective activation of one leaving group over another. 
Therefore, we believe that AgBF4 should be considered as a powerful and convenient 
alternative for silver(I) activated glycosylations. 
 
2.4 Experiment part 
 
2.4.1 General  
Column chromatography was performed on silica gel 60 (70-230 mesh), reactions 
were monitored by TLC on Kieselgel 60 F254. The compounds were detected by 
examination under UV light and by charring with 10% sulfuric acid in methanol. 
Solvents were removed under reduced pressure at <40 °C. Dichloromethane and 1,2-
dichloroethane were distilled from CaH2 directly prior to application. Methanol was dried 
by refluxing with magnesium methoxide, distilled and stored under argon. Pyridine was 
dried by refluxing with CaH2 and then distilled and stored over molecular sieves (3Å). 
Molecular sieves (3Å), used for reactions, were crushed and activated in vacuo at 390 °C 
during 8 h in the first instance and then for 2-3 h at 390 °C directly prior to application. 
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AgBF4 (Acros) was used as received. Optical rotations were measured at ‘Jasco P-1020’ 
polarimeter. 1H-NMR spectra were recorded at 300 or 500 MHz, 13C-NMR spectra were 
recorded at 75 or 125 MHz. HRMS determinations were made with the use of JEOL 
MStation (JMS-700) Mass Spectrometer. 
 
2.4.2  Transformation of the STaz moiety into other leaving groups: synthesis of 
glycosyl donors 
 
1-O-Acetyl-2,3,4,6-tetra-O-benzyl-D-glucopyranose (2.1) 
Pd(OAc)2 (35 mg, 0.156 mmol) was added to a mixture of 2-thiazolinyl 2,3,4,6-tetra-O-
benzyl-1-thio-β-D-glucopyranoside (2.5a, 50 mg, 0.078 mmol) and activated molecular 
sieves 3Å (150 mg) in dry (ClCH2)2 (0.5 mL). The reaction mixture was stirred under 
argon for 24 h at 55 °C. Upon completion, the solid was filtered-off and the filtrate was 
concentrated under reduced pressure. The residue was purified by column 
chromatography on silica gel (ethyl acetate/ hexane gradient elution) to afford 1-O-
acetate 2.1 as a colorless syrup in 72% yield (α/β = 1.6/1). Analytical data for 2.1 were 
essentially the same as reported previously.32 
 
2-Benzoxazolyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside (2.3a) 
A mixture of 2.4a (50 mg, 0.078 mmol) and activated molecular sieves 3Å (40 mg) in dry 
CH2Cl2 (1.2 mL) was stirred under argon for 1 h. Freshly prepared solution of Br2 in dry 
CH2Cl2 (0.75 mL, 1/165, v/v) was then added dropwise over the period of 5 min at rt. 
Quantitative TLC estimates were made based on the accumulation of 2,3,4,6-tetra-O-
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benzyl-α-D-glucopyranosyl bromide 2.2a. After that, the solvent was evaporated under 
reduced pressure at rt. The residue containing crude 2.2a was then treated dissolved in 
dry acetone (0.5 mL) and the potassium salt, KSBox, (22 mg, 0.117 mmol) and 18-
crown-6 (4 mg, 0.012 mmol) were added. The reaction mixture was stirred under argon 
for 1 h at rt. After that, the mixture was diluted with CH2Cl2 (20 mL) and washed with 
water (10 mL), 1% aq. NaOH (10 mL) and water (3 x 10 mL), the organic phase was 
separated, dried, and concentrated in vacuo. The residue was purified by silica gel 
column chromatography (ethyl acetate/hexane gradient elution) to afford the title 
compound 2.3a as a white foam in 82% yield. Analytical data for 2.3a were essentially 
the same as reported previously.8   
 
2-Benzothiazolyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside (2.4a).        
Crude glycosyl bromide 2.2a (~48 mg, 0.078 mmol), obtained as described for the 
synthesis of 2.3a, was dissolved in dry acetone (0.5 mL) and potassium salt of 2-
mercaptobenzotriazole (24 mg, 0.117 mmol) and 18-crown-6 (4 mg, 0.012 mmol) were 
added. The reaction mixture was stirred under argon for 1 h at rt, then diluted with 
CH2Cl2 (20 mL) and washed with water (10 mL), 1% aq. NaOH (10 mL), and water (3 x 
10 mL). The organic phase was separated, dried, and concentrated in vacuo. The residue 
was purified by silica gel column chromatography (ethyl acetate/hexane gradient elution) 
to afford the title compound 2.4a as a white foam in 75% yield. Analytical data for 2.4a 
were essentially the same as reported previously.33 
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Ethyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside (2.6)   
A mixture of ethanethiol (17 μL, 0.225 mmol) and sodium hydride (1.0 mg, 0.025 mmol) 
was added to a solution of 2.2a (~95 mg, 0.15 mmol), prepared as described for the 
synthesis of 2.3a, in dry CH2Cl2 (1.0 mL) at 0 °C and the resulting mixture was stirred 
under argon for 1 h at rt. The reaction mixture was then diluted with CH2Cl2 (20 mL) and 
washed with water (10 mL), 20% aq. NaHCO3 (10 mL), and water (3 x 10 mL), the 
organic phase was separated, dried, and concentrated in vacuo. The residue was purified 
by silica gel column chromatography (ethyl-acetate/hexane gradient elution) to afford the 
title thioglycoside 2.6 as a white foam in 92% yield. Analytical data for 2.6 were 
essentially the same as reported previously.34  
 
2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl chloride (2.8)  
To a stirred solution of 2.5a (100 mg, 0.15 mmol) and dimethylformamide (6 μL, 0.075 
mmol) in dry CH2Cl2 (1.2 mL) under argon, thionyl chloride (34 μL, 0.45 mmol) was 
added dropwise. The reaction mixture was kept for 1 h and then concentrated under the 
reduced pressure. The residue was purified by short-path silica gel column 
chromatography (ethyl acetate/hexane gradient elution) to afford the title compound 2.8 
as a colorless syrup in 84% yield. Analytical data for 2.8 were essentially the same as 
reported previously.35 
 
2,3,4,6-Tetra-O-benzyl-D-glucopyranosyl fluoride (2.9) 
To a stirred solution of 2.5a (100 mg, 0.15 mmol) in THF (1.2 mL) diethylaminosulfur 
trifluoride (DAST, 72 μL, 0.55 mmol) was added at -30 °C under argon. The external 
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cooling was then removed and the reaction mixture was stirred for 24 h at rt. After that, 
the solution was cooled to -30 °C and methanol (0.1 mL) was added, the resulting 
mixture was warmed to rt and the volatiles were evaporated off in vacuo. The residue was 
dissolved in CH2Cl2 (20 mL) and washed successively with water (10 mL), 20% aq. 
NaHCO3 (10 mL), and water (3 x 10 mL). The organic phase was separated, dried, and 
concentrated in vacuo. The residue was purified by short-path silica gel column 
chromatography (ethyl acetate/hexane gradient elution) to afford the title fluoride 2.9 as a 
white foam in 88% yield (α/β = 1/2.8). Analytical data for 2.9 were essentially the same 
as reported previously.36,37 
 
2,3,4,6-Tetra-O-benzyl-D-glucopyranose (2.10) 
A solution of 2.5a (65 mg, 0.10 mmol) and N-bromosuccinimide (NBS) (45 mg, 0.20 
mmol) in acetone/water (1.5 mL, 9/1, v/v) was stirred for 16 h at rt. The reaction mixture 
was then diluted with CH2Cl2 (20 mL) and washed with water (10 mL), 20% aq. 
NaHCO3 (10 mL), and water (3 x 10 mL). The organic phase was separated, dried, and 
concentrated in vacuo. The residue was purified by silica gel column chromatography 
(ethyl acetate/hexane gradient elution) to afford the title hemiacetal 2.10 as a colorless 
syrup in 90% yield (α/β = 1/1). Analytical data for 2.10 were essentially the same as for 
the commercial sample. 
 
2,3,4,6-Tetra-O-benzyl-α-D-glucopyranosyl trichloroacetimidate (2.11)  
NaH (8 mg, 0.37 mmol) was added portionwise to a stirred solution of compound 2.10 
(100 mg, 0.185 mmol) and trichloroacetonitrile (85 μL, 0.84 mmol) in dry CH2Cl2 (2 
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mL). After stirring for 3 h at rt, the reaction mixture was concentrated under the reduced 
pressure. The residue was purified by column chromatography on silica gel (ethyl 
acetate/ hexane gradient elution) to afford the title compound 2.11 as a colorless syrup in 
82% yield. Analytical data for 2.11 were essentially the same as reported previously.38 
 
2.4.3 General Glycosylation Procedures: Synthesis of O-Glycosides and 
Oligosaccharides. 
 
Method A – Activation with AgBF4.  
A mixture containing the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), 
and freshly activated molecular sieves (3Å, 200 mg) in (Cl2CH2)2 (2mL) was stirred 
under argon for 1.5 h. BF3.Et2O (40 μL, 0.3 mmol) was added and the reaction mixture 
was stirred for 16 h at rt. It was then diluted with CH2Cl2, the solid was filtered-off and 
the residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed with 
20% aq. NaHCO3 (10 mL) and water (3 x 10 mL). The organic phase was separated, 
dried with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford the 
disaccharide derivative. 
 
Method B – Activation of glycosyl donor 2.1 with BF3.Et2O 
A mixture containing the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), 
and freshly activated molecular sieves (3Å, 200 mg) in (Cl2CH2)2 (2mL) was stirred 
under argon for 1.5 h. BF3.Et2O (40 μL, 0.3 mmol) was added and the reaction mixture 
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was stirred for 16 h at rt. It was then diluted with CH2Cl2, the solid was filtered-off and 
the residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed with 
20% aq. NaHCO3 (10 mL) and water (3 x 10 mL). The organic phase was separated, 
dried with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford the 
disaccharide derivative. 
 
Method C- Activation of 2.1 with BF3.Et2O/AgBF4. A mixture of the glycosyl donor (0.11 
mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular sieves (3 Å, 200 
mg) in (Cl2CH2)2 (2 mL) was stirred under argon for 1.5 h. BF3.Et2O (40 μL, 0.33 mmol) 
and AgBF4 (10 mg, 0.05 mmol) were added and the reaction mixture was stirred for 5 h 
at rt. Upon completion, it was diluted with CH2Cl2, the solid was filtered-off and the 
residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% 
aq. NaHCO3 (10 mL) and water (3 x 10 mL). The organic phase was separated, dried 
with MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford the 
disaccharide derivative. 
 
Method D - Activation of 2.6 and 2.7 with NIS. A mixture of the glycosyl donor (0.11 
mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular sieves (3 Å, 200 
mg) in (Cl2CH2)2 (2 mL) was stirred for 1.5 h under argon. NIS (50 mg, 0.22 mmol) was 
then added and the reaction mixture was stirred for 24 h at rt. Upon completion, the solid 
was filtered-off and the residue was washed with CH2Cl2. The combined filtrate (30 mL) 
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was washed with 20% aq. Na2S2O3 (10 mL) and water (3 x 10 mL). The organic phase 
was separated, dried over MgSO4, and concentrated in vacuo. The residue was purified 
by column chromatography on silica gel (ethyl acetate/ hexane gradient elution) to afford 
the disaccharide derivative. 
 
Method E - Activation of 2.7 and 2.8 with NIS/AgBF4. A mixture of the glycosyl donor 
(0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular sieves (3 Å, 
200 mg) in (Cl2CH2)2 (2 mL) was stirred for 1.5 h under argon. NIS (50 mg, 0.22 mmol) 
and AgBF4 (10 mg, 0.05 mmol) were added and the reaction mixture was stirred for 10-
20 min at rt. Upon completion, the solid was filtered-off and the residue was washed with 
CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq. Na2S2O3 (10 mL) and 
water (3 x 10 mL). The organic phase was separated, dried over MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate/ hexane gradient elution) to afford the disaccharide derivative. 
 
Pent-4-en-1-yl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside (2.7)  
The title compound was synthesized from glycosyl bromide 2.2a, obtained as described 
for the synthesis of 2.3a, and 4-penten-1-ol by Method A in 89% yield as a white foam. 
Analytical data for 2.7 were essentially the same as reported previously.39 
 
Methyl 4-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-2,3,6-tri-O-benzyl-α-D-
glucopyranoside (2.16a) 
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The title compound was obtained by Method A from 2.1 and 2.1240 in 65% yield (α/β = 
1/5.4) or 2.6 and 2.12 in 91% yield (α/β = 1/3.4). Analytical data for 2.16a were 
essentially the same as reported previously.41 
 
Methyl 6-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α-D-
glucopyranoside (17a). 
The title compound was obtained by Method A from glycosyl donors 2.2a, 2.3a, 2.5a, 
2.8, 2.9 or 2.11 and glycosyl acceptor 2.1342 in 92% (α/β 2.4:1), 89% (α/β 1.2:1), 95% 
(α/β 1.3:1), 97% (α/β 1.6:1), 81% (α/β 2:1) and 80% (α/β 1.5:1) yield, respectively. (see 
Table 2.1). In addition, the title compound was obtained by Method B from 2.2 and 2.13 
in 91% yield (α/β = 1.4/1), by Method C - from 2.1 and 2.13 in 95% yield (α/β = 2/1), by 
Method D obtained from 2.6 or 2.7 and 2.13 in 91% (α/β 1.2:1) and 89% (α/β 1:1) and 
by Method E obtained from 2.6 or 2.7 and 2.13 in 92% (α/β 1.2:1) and 76% (α/β 1.2:1).  
Analytical data for 2.17a were essentially the same as reported previously.43 
 
Methyl 6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-3,4,6-tri-O-benzyl-α-D-
glucopyranoside (2.17b): This compound was obtained by Method A from glycosyl 
donors 2.2b, 2.3b, 2.4b or 2.5b and glycosyl acceptor 2.13 in 96%, 91%, 90% and 90% 
yield, respectively. Analytical data for 17b were essentially the same as reported 
previously.44 
 
Methyl 6-O-(3,4,6-tri-O-acetyl-2-O-benzyl-D-glucopyranosyl)-2,3,4-tri-O-benzyl-α -
D-glucopyranoside (17c)  
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This compound was obtained by Method A from glycosyl donors 2.3c or 2.5c and 
glycosyl acceptor 2.13 in n 91% (α/β 1.6:1) and 75% (α/β 1.2:1), respectively. Analytical 
data for 2.17c were essentially the same as reported previously.10 
 
Methyl 2-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-3,4,6-tri-O-benzyl-α -D-
glucopyranoside (2.18a) 
The title compound was obtained by Method A from glycosyl donor 2.5a and glycosyl 
acceptor 2.14 in 92% yield (α/β = 1.4/1). Analytical data for 2.18a were essentially the 
same as reported previously.10 
 
Methyl 2-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-3,4,6-tri-O-benzyl-α -D-
glucopyranoside (2.18b) 
This compound was obtained by Method A from glycosyl donor 2.2b and glycosyl 
acceptor 2.14 in 82% yield. Analytical data for 2.18b were essentially the same as 
reported previously.10 
 
Methyl 2-O-benzyl-3-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-4,6-O -
benzylidene-α-D-glucopyranoside (2.19a). This compound was obtained by Method A 
from glycosyl donors 2.4a or 2.9 and glycosyl acceptor 2.1545 in 87 % (α/β 7.4:1) and 
81% (α/β 2.3:1), respectively. Analytical data for 2.19a were essentially the same as 
reported previously.46 
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Pent-4-en-1-yl 3-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-4,6-O-benzylidene-2- 
deoxy-2-(2,2,2-trichloroethoxycarbamoyl)−β−D-galactopyranoside (2.21) 
This compound was obtained by Method A from glycosyl donors  2.2a, 2.4, 2.5 or 2.9 and 
glycosyl acceptor 2047 in 86% (α/β 1.1:1), 85% (α/β 1.3:1), 83% (α/β 1.2:1) and 65% 
(α/β 1.6:1) yield, respectively. Analytical data for 2.21 were essentially the same as 
reported previously.10 
 
Ethyl 6-O-(2,3,4,6-tetra-O-benzyl-D-glycopyranosyl)-2,3,4-tri-O-benzyl-1-thio−β-D-
glucopyranoside (23) 
This compound was obtained by Method A from glycosyl donors 2.2a, 2.4a, 2.5a, 2.8 or 
2.9 and glycosyl acceptor 2.2248 in 84% (α/β 1.6:1), 87% (α/β 2:1), 89% (α/β 2.4:1), 
84% (α/β 2.2:1) and 83 (α/β 2.4:1) yield, respectively. (see Table 2.2). Analytical data 
for 2.23 were essentially the same as reported previously.17 
 
Methyl 2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl-(1→6)-2,3,4-tri-O-benzoyl-β-D-
galactopyranosyl-(1→6)-2,3,4-tri-Ο-benzyl-α-D-glucopyranoside (2.25) 
This compound was obtained by one-pot glycosylation procedure in 55-70% overall yield 
(22.b 62%, 2.3b 70%, 2.4b 55%, and 2.5b 72%). [α]D24.8 = + 56.74  (c = 1, CHCl3); Rf = 
0.47 (ethyl acetate/hexane, 4.5/5.5, v/v); 1H NMR: δ =  3.24 (s, 3H; OCH3), 3.33 (m, 2H, 
H-2, 4), 3.51 (m, 2H, H-6a,5), 3.85 (dd, 1H, J3,4 =  9.0 Hz, H-3), 3.87 (m, 1H, H-6a”), 
3.93 (dd, 1H, H-6a), 4.01-4.10 (m, 3H, H-5’,5”,6b”), 4.32 (s, 1H; CH2Ph), 4.33 (dd, 1H, 
H-6a’), 4.47 (d, 1H; CH2Ph),  4.50 (d, 1H, J1’,2’ = 8.0 Hz, H-1’), 4.51 (d, 1H, J1,2 = 3.4 
Hz, H-1), 4.55 (d, 1H; CH2Ph), 4.55 (dd, 1H, H-6b’), 4.69 (dd, 2H; CH2Ph), 4.88 (d, 1H, 
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CH2Ph), 4.91 (d, 1H, J1”,2” = 7.8 Hz, H-1”), 5.52 (dd, 1H, J2”,3” = 3.5 Hz, H-2”), 5.54 (dd, 
1H, J3’,4’ = 7.8 Hz, H-3’), 5.65 (dd, 1H, J4”,5” = 9.8 Hz, H-4”), 5.75 (dd, 1H, J2’,3’ = 8.0 
Hz, H-2’), 5.84 (d, 1H, J4’,5’ = 2.5 Hz, H-4’), 5.86 (dd, 1H, J3”,4” = 10.4 Hz, H-3”), 7.09-
8.05 (m, 50H, aromatic); 13C NMR: δ = 55.4, 63.0, 68.0, 68.4, 68.9, 69.6, 69.7, 70.0, 
71.8, 72.1, 72.5, 73.0, 73.6, 74.7, 75.6, 77.4, 80.0, 80.1, 98.2, 101.3, 101.8, 127.7 (×2), 
127.8, 128.0 (×2), 128.1, 128.2, 128.3, 128.3, 128.4 (×3), 128.5 (×2), 128.6 (×5), 128.6 
(×6), 128.7 (×2), 128.7 (×2), 128.9, 129.0, 129.0, 129.3, 129.4, 129.5, 129.7, 129.9 (×2), 
129.9 (×6), 130.0 (×3), 130.1 (×2), 133.3 (×2), 133.4, 133.5 (×2), 133.6, 133.6 (×2), 
138.4,.138.6, 139.1, 165.1, 165.3, 165.6, 165.7, 166.0, 166.2. HR-FAB MS: calcd for 
C90H80O23 [M+H]+: 1559.4547 ; found: 1559.4550. (See Appendix; Figure A-1, A-2, and 
A-3) 
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3.1  Introduction 
Traditional linear approaches to oligosaccharide assembly are often cumbersome 
and consequently the availability of complex glycostructures remains insufficient to 
address the challenges of modern glycosciences.P1-3 Recent improvements in strategies 
for oligosaccharide assembly, have significantly shortened the number of synthetic steps 
required by minimizing protecting group manipulations between glycosylation steps.4-9 
One of the most flexible assembly strategies is the orthogonal concept.10,11 Unlike the 
armed-disarmed approach,12 the orthogonal activation is not reliant on the nature of the 
protecting groups, which can interfere with stereoselectivity. The only requirement for 
the orthogonal approach is a set of two orthogonal leaving groups and a pair of suitable 
activators. Unfortunately, this simple concept is still limited to the following two 
examples: Ogawa’s S-ethyl and fluoride,10,11 and the thioimidate S-thiazolinyl (STaz) and 
S-alkyl/aryl.13,14 In addition, a related, albeit less flexible, semi-orthogonal approach with 
the use of S-ethyl and O-pentenyl glycosides was reported,15 and was recently extended 
to fluoride/pentenyl leaving groups. Overall, the orthogonal strategy is an excellent 
concept for flexible sequencing of oligosaccharides that remains under explored, with too 
few examples to become universal. The excellent glycosyl donor properties of glycosyl 
thioimidates and their unique activation conditions have led to a number of useful 
developments for oligosaccharide synthesis, including the orthogonal approach.13,14 From 
our previous studies we had determined the S-benzoxazolyl (SBox) glycosyl donors16,17 
to be significantly more reactive than their STaz counterparts,13,14 and, although direct 
selective activations of the SBox donors over STaz acceptors were reported in the 
presence of Cu(OTf) ,2 13,14 no comprehensive side-by-side comparisons had been 
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performed.  
 
3.2 Results and Discussion 
With the main purpose of determining relative reactivity patterns of thioimidates, 
we set-up a series of glycosidations including STaz,13,14 SBox,16,17 and structurally related 
Mukaiyama’s S-benzothiazolyl (SBaz) derivatives.18 All reactions of benzylated glycosyl 
donors 3.1-3.3 with glycosyl acceptor 3.4 promoted with MeOTf were very effective, and 
disaccharide 3.5 was obtained in high yields (Table 3.1). Although the disparity amongst 
the reaction times was unremarkable, it was evident that glycosidation of the STaz 
glycoside 3.1 (entry 1) was about two times slower than that of its SBox counterpart 3.2 
(entry 2), with the reactivity of the SBaz glycoside 3 (entry 3) somewhere in the middle.  
To gain better control of the glycosylations and to achieve a more precise 
differentiation of reactivity between the different thioimidates, we turned to investigating 
other activators. Amongst these, results obtained with common alkylating (and acylating) 
reagents were particularly attractive. For example, MeI was only effective for 
glycosidation of per-benzylated STaz glycoside 3.1 (entry 4). Surprisingly, when these 
reaction conditions were applied to the glycosidation of expectedly more reactive SBox 
and SBaz glycosides, no glycosylation took place (entry 5). Also BnBr was only effective 
for glycosidation STaz derivative 3.1, whereas glycosyl donors 3.2 or 3.3 gave only trace 
amounts of products (entries 6-8). 
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Table 3.1  Alkylation-initiated glycosidation of benzylated thioimidates 3.1-3.3 
 
 
Entry Donor Promoter             
(equiv, temp) 
Time Product 3.5   
 Yield (%), α/β ratio 
3.1 1 MeOTf (3, rt) 0.75 h 87%, 1.4/1 
2 3.2 MeOTf (3, rt) 0.33 h 88%,1.6/1 
3 3.3 MeOTf (3, rt) 0.58 h 89%, 1.6/1 
4 3.1 MeI (9, rt) 120 h 89%, 8.0/1 
5 3.2 or 3.3 MeI (9-15, rt) 120 h no reaction 
6 3.1 BnBr (3, 55 oC) 24 h 90%, 3.5/1 
7 3.2 BnBr (3-9, 55oC) 120 h traces 
8 
 
 
3.3 BnBr (3-9, 55oC) 120 h no reaction 
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Subsequently, similar observations have been made with less reactive per-
benzoylated glycosyl donors. Thus, all reactions of benzoylated glycosyl donors 3.6-3.8 
with glycosyl acceptor 3.4 promoted with MeOTf were very effective, and disaccharide 
3.9 was obtained in high yields (Table 3.2, entries 1-3). With MeI though, no 
glycosidation of benzoylated glycosyl donors 3.6-3.8 took place (entry 4). BnBr was only 
effective for the STaz derivative 3.6, (entry 5), whereas glycosidation of glycosyl donors 
3.7 or 3.8 gave no products (entry 6). It should be noted that all reactions with benzylated 
glycosyl donors (Table 3.1) were significantly faster than those with their benzoylated 
counterparts (Table 3.2).  
 
Table 3.2  Alkylation-initiated glycosidation of benzoylated thioimidates 3.6-3.8 
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 This discovery signified the gap in our understanding of the thioimidate activation 
and created a basis for the development of the STaz-SBox orthogonal strategy. The 
uniqueness of this approach would be that both leaving groups employed are of 
essentially the same class. Although certain pathways for the activation of thioimidates 
were postulated (Scheme 3.1),19-21 little proof had been available until our recent 
mechanistic study,16,17 wherein we showed that MeOTf-promoted activation of the SBox 
glycosyl donor 3.10 proceeds via the anomeric sulfur atom (direct activation). This was 
confirmed by isolating the departed S-methylated aglycone MeSBox (3.11, Scheme 3.1).  
 
Entry Donor Promoter          
(equiv, temp) 
Time Product 3.9  
Yield (%), α/β ratio 
1 3.6 MeOTf (3, rt) 2 h 97%, β only 
2 3.7 MeOTf (3, rt) 1 h 95%, β only 
3 3.8 MeOTf (3, rt) 2 h 84%, β only 
4 3.6-3.8 MeI (9-15, rt) 120 h No reaction 
5 3.6 BnBr (3, 55 oC) 72 h 79%, β only 
6 3.7 or 3.8 BnBr (3-9, 55oC) 120 h no reaction 
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 Scheme 3.1  Activation of thioimidates: a study with SBox glycoside 3.10.  
 
Since the exact nature of the STaz activation was not known, our working 
hypothesis for this study was based on our previous findings with the SBox moiety, 
taking into consideration the structural differences between the two moieties. We 
anticipated that the activation of the STaz moiety proceeds via the nitrogen (remote 
activation), as opposed to the direct activation of the SBox moiety. This remote activation 
of STaz would lead to a marginally slower reaction with a powerful promoter, such as 
MeOTf (refer to Tables 3.1 and 3.2). When weak alkylating reagents are used (MeI, 
BnBr), a powerful nucleophile is needed to replace the iodine or bromine, respectively. 
Evidently, this can be predominantly achieved with STaz glycosides that bear the reactive 
nitrogen atom, but not with the SBox glycosides, which can only be activated via the 
exocyclic sulfur16,17 (Figure 3.1). For comparison, previous reports suggest that SPh 
glycosides do not react with MeI (direct activation), while S-pyridyl derivatives do 
(remote activation is postulated).21  
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 Figure 3.1  Working hypothesis for thioimidate activation.  
 
The credibility of this working hypothesis was verified by a series of experiments 
in which glycosyl donor 3.1 was reacted with the standard acceptor 3.4 in the presence of 
BnBr (Scheme 3.2). Upon disappearance of 3.1, the reaction mixture was concentrated in 
vacuo and the fastest moving UV-active spot, corresponding to the benzylated aglycone, 
was separated from the disaccharide product 3.5 by column chromatography on silica gel. 
The structure of the isolated alkylated aglycone was assigned as thioamide 3.13 
(BnNTaz) by X-ray (Figure 3.2) and UV (λmax = 277 nm, C=S).  
 
 
Scheme 3.2  Mechanism of thioimidate activation with BnBr. 
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A similar reaction between 3.2 and 3.4 was significantly slower, nevertheless, we 
succeeded in isolating the departed aglycone, which was assigned as thioimide 3.14 
(BnSBox) by X-Ray (Figure 3.2) and UV (λmax = 280, 287 nm, C=N), as anticipated. To 
exclude the impact of tautomerization of the products both reactions were monitored by 
HPLC (Figure 3.3).  
 
 
 
Figure 3.2  X-ray structure of compound 3.14 and 3.15 
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Figure 3.3  HPLC chromatograms of reaction mixture at 1h, 2h, 3h, 5h, 9h and 16h 
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With a better understanding of the mechanistic pathway, we were well positioned 
to undertake further studies of expeditious oligosaccharide assembly. First, the activation 
of STaz donors 3.1 and 3.6 over SBaz/SBox acceptors 3.15a-c was investigated in the 
presence of BnBr or MeI. As a result, disaccharides 3.16a-c were obtained in good yields 
(70-82%, Table 3.3). Conversely, SBox donor 3.7 was also activated over the STaz 
acceptor 3.15d. This activation could be accomplished in the presence of a variety of 
activators, amongst which Bi(OTf)3 was the most promising; disaccharide 3.16d was 
obtained in 69% yield. The terminal SBox moieties of 3.16b or 3.16c could be 
glycosidated either with model acceptor 3.4 or with STaz acceptor (3.15d). Conversely, 
the STaz moiety of 3.16d could be glycosidated with 3.4 or activated over the SBox 
acceptor (3.15c). The resulting trisaccharides 3.17a-d were isolated in 62-92% yields 
(Table 3.3), with 1,6-anydro and hemiacetal being the major by-products identified. 
Among trisaccharides generated, 3.17c and 3.17d can be used in subsequent sequencing.  
 
Table 3.3  Orthogonal activations for oligosaccharide synthesis 
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Entry Donor Acceptor A Promo- 
ter A a
Disaccharide 
(yield, α/β) 
Acceptor B Promoter 
B a
Trisaccharide  
(yield, α/β) 
  
 
 
BnBr 
 
(70%, β only) 
 
 
 
1 
 
 
 
 
3.4 
 
 
 
AgBF4
(75%, β only)  
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
(82%, 6/1) 
 
 
 
3.4 
 
 
 
 
AgOTf 
       
 
(92%, 1.6/1) 
 MeI 
 
 
3 
 
 
3.6 
 
 
BnBr 
(76%, β only) 
 
 
 
 
3.4 
 
 
 
 
AgOTf 
 
 
 
3.17a 
(72%, β only)  
 
 
 
 
      
(62%, β only) 
   
   
   
4 Bi(OTf)33.16c 3.15d 
 
 
 
5 
 
 
  
 
(69%, β only) 
 
 
3.4 
 
 
 
Bi(OTf)3 AgBF4
 
 
 
3.17a 
(81%, β only)  
 
 
 
 
 
6 
    
 
3.16d 
 
 
 
 
3.15c 
 
 
 
 
BnBr 
 
(67%, β only) 
 
a – Conditions:  All glycosylations were performed in 1,2-dichloromethane in the 
presence of molecular sieves (3 Å). Promoters:  BnBr (3 equiv, 55 oC); AgBF4 (3 equiv, 
rt); MeI (9 equiv, 55 oC); AgOTf (2 equiv, rt); Bi(OTf)3 (3 equiv, 0 oC ? rt). Reaction 
time: 3.16a - 24 h, 3.16b – 16 h, 3.16c – 24 h, 3.16d – 1h, 3.17a – 30, 30, and 40 min 
(entries 1, 3, and 5, respectively), 3.17b – 15 min, 3.17c – 2 h, 3.17d – 36 h.  
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The further study of this methodology was applied to the synthesis of a β-(1→6)-
linked hexasaccharide via the five-step selective activation sequence which was 
employing six different leaving groups as depicted in Scheme 3.33. The synthesis began 
with the selective activation of thiocyanate donor 3.18 over STaz glycosyl acceptor 3.15d 
using Cu(OTf)2 as a promoter. The STaz leaving group of disaccharide 3.16d was then 
directly activated over SBox acceptor 3.15c with benzyl bromide to give trisaccharide 
3.17d. The SBox moiety of 3.17d was then selectively activated over fluoride acceptor 
3.19 in the in presence of MeOTf. The resulting tetrasaccharide 3.20 was glycosidated 
with thioglycoside acceptor 3.21 in presence of AgClO4/Cp2ZrCl2 to provide 
pentasaccharides 3.22. Finally, the S-ethyl leaving group of 3.22 was selectively activated 
over n-pentenyl acceptor 3.23 in the presence of MeOTf as a promoter to furnish the 
hexasaccharide 3.24 in 72% yield.22  
 
 3.3 Conclusions 
In conclusion, a mechanistic study of the alkylation pathway for the activation of 
glycosyl thioimidates has led to the development of the “thioimidate-only orthogonal 
strategy”. The synthesis of trisaccharides 3.17a-d clearly illustrates the entirely 
orthogonal character of the SBox and STaz derivatives.  
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Scheme 3.3  Selective activation utilizing six different leaving groups employing SBox 
and STaz glycosides in the synthesis of 1,2-trans hexasaccharide. 
 
3.4  Experimental part 
 
3.4.1 General 
Column chromatography was performed on silica gel 60 (70-230 mesh), reactions 
were monitored by TLC on Kieselgel 60 F254. The compounds were detected by 
examination under UV light and by charring with 10% sulfuric acid in methanol. 
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Solvents were removed under reduced pressure at <40 oC. CH2Cl2, ClCH2CH2Cl, and 
MeCN were distilled from CaH2 directly prior to application. Methanol was dried by 
refluxing with magnesium methoxide, distilled and stored under argon. Pyridine was 
dried by refluxing with CaH2 and then distilled and stored over molecular sieves (3Å). 
Molecular sieves (3Å or 4Å), used for reactions, were crushed and activated in vacuo at 
390 °C during 8 h in the first instance and then for 2-3 h at 390 °C directly prior to 
application. AgOTf (Acros) was co-evaporated with toluene (3 x 10 mL) and dried in 
vacuo for 2-3 h directly prior to application. Optical rotations were measured at ‘Jasco P-
1020’ polarimeter. 1H-NMR spectra were recorded at 300 or 500 MHz, 13C-NMR spectra 
were recorded at 75 or 125 MHz. HRMS determinations were made with the use of JEOL 
MStation (JMS-700) Mass Spectrometer. 
 
3.4.2 Synthesis of glycosyl acceptor 
 
Benzothiazol-2-yl 2,3,4-tri-O-benzoyl-1-thio-β-D-glucopyranoside (3.15a)  
Benzothiazol-2-yl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside23 (550 mg, 1.1 
mmol) was dissolved in methanol (5 mL) and the pH 8-9 was adjusted by careful addition 
of 1M solution of NaOCH3 in MeOH (~0.1 mL). The reaction mixture was kept for 1 h at 
rt, then Dowex (H+) was added until a neutral pH was reached. The resin was filtered off 
and washed with methanol (3 x 5 mL).  The combined filtrate was concentrated in vacuo 
and dried.  The residue was dissolved in dry pyridine (5.0 mL) and triphenylmethyl 
chloride (439 mg, 1.57 mmol) was added.  The reaction mixture was left stirring for 16 h 
at rt. After that, the reaction mixture was cooled to 0 °C and benzoyl chloride (0.49 mL, 
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4.21 mmol) was added dropwise. The reaction mixture was allowed to gradually warm 
up. Upon stirring for 3 h at rt, the reaction was quenched with methanol (5 mL), co-
evaporated with toluene (3 x 10 mL), then diluted with dichloromethane (20 mL) and 
washed with 1N HCl (10 mL), water (10 mL), sat. NaHCO3 (10 mL), and water (3 x 10 
mL). The organic layer was separated, dried with MgSO4, and concentrated in vacuo. The 
residue was purified by silica gel column chromatography (ethyl acetate-toluene gradient 
elution). After that, the product was dissolved in dichloromethane (10 mL) containing 
one drop of water and trifluoroacetic acid (0.2 mL) was added dropwise. Upon 
completion, the reaction was then diluted with dichloromethane (10 mL), washed with 
saturated NaHCO3 (10 mL) and water (3 x 15 mL). The organic layer was separated, 
dried with MgSO4 and concentrated in vacuo. The residue was purified by silica gel 
column chromatography (ethyl acetate-toluene gradient elution) to obtain 3.15a as yellow 
amorphous solid in 64% yield. Rf = 0.35 (ethyl acetate/toluene, 1.5/8.5, v/v); [α]D23 = 0.48 
(c = 1.0, CHCl3); 1H NMR: δ, 2.75 (broad s, 1H, OH), 3.86 (m, 2H, H-6a, 6b), 4.06 (m, 
1H, H-5), 5.62 (dd, 1H, J4,5 = 4.7 Hz, H-4), 5.74 (dd, 1H, J2,3 = 4.5 Hz, H-2), 5.97 (d, 1H, 
J1.2 = 10.2 Hz, H-1), 6.11 (dd, 1H, J3,4 = 9.6 Hz, H-3), 7.2- 8.10 (m, 19H, aromatic) ppm; 
13C NMR: δ, 60.6, 61,7, 69.4, 70.8, 74.0, 79.7, 84.4, 121.3, 122.5, 125.2, 126.6, 128.6 
(×4), 128.7, 128.7 (×2), 128.8, 128.9, 129.9 (×2), 130.1 (×3), 133.6, 133.7, 134.0, 135.8, 
152.9, 162.4, 165.4, 165.9, 166.1 ppm; HR FAB MS [M+Na]+ calcd for C34H27NO8S2Na 
664.1076, found 664.1085. 
 
3.4.3  General glycosylation procedures 
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Method A.  A typical MeOTf - promoted glycosylation procedure: A mixture of the 
glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated 
molecular sieves (3Å, 200 mg) in (ClCH2)2 (2 mL) was stirred under argon for 1 h. 
MeOTf (0.33 mmol) was added and the reaction mixture was stirred for 20 min – 2 h. 
Upon completion, the reaction mixture was diluted with CH2Cl2 (30 mL) and washed 
with water (10 mL), saturated NaHCO3 (10 mL) and water (3 x 10 mL). The organic 
phase was separated, dried and concentrated in vacuo. The residue was purified by 
column chromatography on silica gel (acetone/toluene gradient elution) to allow the 
corresponding disaccharide. Anomeric ratios (if applicable) were determined by 
comparison of the integral intensities of relevant signals in 1H NMR spectra. 
 
Method B.  A typical MeI - promoted glycosylation procedure.  A mixture of the glycosyl 
donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular 
sieves (3Å, 200 mg) in (ClCH2)2 (2 mL) was stirred under argon for 1 h, then MeI (1.0-
1.5 mmol) was added. The reaction mixture was stirred for 60 h at rt. Upon completion, 
the reaction mixture was diluted with CH2Cl2, the solid was filtered-off and the residue 
was washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq. 
NaHCO3 (10 mL) and water (3 x 10 mL), the organic phase was separated, dried with 
MgSO4 and concentrated in vacuo. The residue was purified by column chromatography 
on silica gel (ethyl acetate/hexane gradient elution) to allow the corresponding di- or 
oligosaccharide. Anomeric ratios (if applicable) were determined by comparison of the 
integral intensities of relevant signals in 1H NMR spectra. 
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Method C – A typical BnBr- promoted glycosylation procedure:  A mixture of the 
glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated 
molecular sieves (3Å, 200 mg) in (ClCH2)2 (2 mL) was stirred under argon for 1 h, then 
BnBr (0.33-0.99 mmol) was added. The reaction mixture was stirred for 24-36 h at 55 °C. 
Upon completion, the reaction mixture was diluted with CH2Cl2,  the solid was filtered-
off and the residue was washed with CH2Cl2. The combined filtrate (30 mL) was washed 
with 20% aq. NaHCO3 (10 mL) and water (3 x 10 mL), the organic phase was separated, 
dried with MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford the 
corresponding di- or oligosaccharide. Anomeric ratios (if applicable) were determined by 
comparison of the integral intensities of relevant signals in 1H NMR spectra. 
 
Method D – A typical Bi(OTf)3- promoted glycosylation procedure: A mixture the 
glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated 
molecular sieves (3 Å, 200 mg) in (ClCH2)2 (2mL) was stirred under argon for 1 h.  The 
reaction mixture was cooled down at 0°C and then Bi(OTf)3 (0.22 mmol) was added into 
the solution.  After that the reaction mixture was stirred for 1-2 h at rt.  Upon completion, 
the reaction mixture was diluted with CH2Cl2, the solid was filtered-off, and the residue 
was washed with CH2Cl2.  The combined filtrate (30 mL) was washed with 20% aq. 
NaHCO3 (15 mL) and water (3 × 10 mL), and the organic phase was separated, dried 
over MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford a di- or 
oligosaccharide derivative. 
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Method E – A typical AgOTf- promoted glycosylation procedure: A mixture the glycosyl 
donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular 
sieves (3 Å, 200 mg) in (ClCH2)2 (2mL) was stirred under argon for 1 h. Freshly 
conditioned AgOTf (0.22 mmol) was added and the reaction mixture was stirred for 1–2 
h at rt and then diluted with CH2Cl2, the solid was filtered-off, and the residue was 
washed with CH2Cl2. The combined filtrate (30 mL) was washed with 20% aq. NaHCO3 
(15 mL) and water (3 × 10 mL), and the organic phase was separated, dried over MgSO4, 
and concentrated in vacuo. The residue was purified by column chromatography on silica 
gel (ethyl acetate/hexane gradient elution) to afford an oligosaccharide derivative. 
 
Method F – A typical AgBF4- promoted glycosylation procedure: A mixture the glycosyl 
donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular 
sieves (3 Å, 200 mg) in (ClCH2)2 (2mL) was stirred under argon for 1 h. AgBF4 (0.22 
mmol) was added and the reaction mixture was stirred for 2 h at rt and then diluted with 
CH2Cl2, the solid was filtered-off, and the residue was washed with CH2Cl2. The 
combined filtrate (30 mL) was washed with 20% aq. NaHCO3 (15 mL) and water (3 × 10 
mL), and the organic phase was separated, dried over MgSO4, and concentrated in vacuo. 
The residue was purified by column chromatography on silica gel (ethyl acetate/hexane 
gradient elution) to afford an oligosaccharide derivative. 
 
Method G-MeOTf  promoted glycosylation procedure: A mixture the glycosyl donor (0.11 
mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular sieves (3 Å, 200 
mg) in (ClCH2)2 (2mL) was stirred under argon for 1 h. MeOTf (0.33 mmol) was then 
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added into the solution. After that the reaction mixture was stirred for 3-5 h at rt. Upon 
completion, the reaction mixture was diluted with CH2Cl2, the solid was filtered-off, and 
the residue was washed with CH2Cl2.  The combined filtrate (30 mL) was washed with 
20% aq. NaHCO3 (15 mL) and water (3 × 10 mL), and the organic phase was separated, 
dried over MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate/hexane gradient elution) to afford a di- or 
oligosaccharide derivative. Anomeric ratios (if applicable) were determined by 
comparison of the integral intensities of relevant signals in 1H-NMR spectra. 
 
Method H-AgClO4/Cp2ZrCl promoted glycosylation procedure: A mixture the glycosyl 
donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular 
sieves (4 Å, 200 mg) in (ClCH2)2 (2mL) was stirred under argon for 1 h. AgBF4 (0.22 
mmol) and Cp2ZrCl (0.22 mmol) were then added into the solution. After that the 
reaction mixture was stirred for 3-5 h at rt. Upon completion, the reaction mixture was 
diluted with CH2Cl2, the solid was filtered-off, and the residue was washed with CH2Cl2.  
The combined filtrate (30 mL) was washed with 20% aq. NaHCO3 (15 mL) and water (3 
× 10 mL), and the organic phase was separated, dried over MgSO4, and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel (ethyl 
acetate/hexane gradient elution) to afford a di- or oligosaccharide derivative. Anomeric 
ratios (if applicable) were determined by comparison of the integral intensities of relevant 
signals in 1H-NMR spectra. 
 
 
 124
Methyl 2,3,4-tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-D-glucopyranosyl)-α-D-
glucopyranoside (3.5). The title compound was obtained as a colorless syrup by a range 
of methods in 87-90% yield (see Table 3.1 of the manuscript). Analytical data for 3.8 was 
in good agreement with those reported previously.24  
 
Methyl 2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-D-glucopyranosyl)-α-D-
glucopyranoside (3.9). The title compound was obtained as a white foam by a variety of 
methods shown in Table 3.2 in the manuscript in 79-97% yield.  Analytical data for 3.9 
was in good agreement with those reported previously.25 
  
Benzothiazol-2-yl 2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)-1-thio-β-D-glucopyranoside (3.16a). The title compound was obtained 
by Method C from 2-thiazolinyl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside 
(3.6)14 and 3.15a in 70% yield as a white foam. Analytical data for 3.16a: Rf = 0.6 (ethyl 
acetate/toluene, 1/4, v/v ); [α]D24  +49.9 (c = 1, CHCl3); 1H NMR; δ, 3.58 (m, 2H, H-
6a,6b), 4.12 (m, 2H, H-5,5’), 4.36 (dd, 1H, J5’,6b’ = 7.4 Hz, H-6b’), 4.48 (dd, 1H, J5’,6a’ = 
2.8 Hz, J6a’,6b’ = 12.1 Hz, H-6a’), 4.60 (m, 1H, H-4), 5.44 (d, 1H, J4’,5’ = 8.7 Hz, H-4’), 
5.72 (m, 2H, H-3,3’), 5.85 (d, 1H, J1,2 = 10.1 Hz, H-1), 5.93 (dd, 1H, J2’,3’ = 9.4 Hz, H-
2’), 5.95 (dd, 1H, J2,3 = 5.0 Hz, H-2), 7.1-8.10 (m, 39H, aromatic); 13C NMR: δ, 63.1, 
64.2, 67.7, 68.6, 69.3, 69.3, 70.8, 72.1, 74.3, 77.4, 84.6, 98.0, 121.2 (×2), 122. 5, 125.1, 
125.5, 126.5, 126.7 (×2), 128.4 (×2), 128.4 (×2), 128.5 (×3), 128.6 (×2), 128.6 (×3), 
128.7 (×2), 128.7 (×2), 128.9, 128.9, 129.0, 129.2 (×2), 129.4, 129.9 (×2), 129.9 (×5), 
130.1 (×2), 130.1 (×3), 130.3 (×2), 133.1, 133.7 (×2), 133.7, 134.5, 135.9, 152. 9, 162.5, 
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164.5, 165.3 (×2), 165.9, 166.2 ppm; HR FAB MS [M+Na]+ calcd for C68H53NO17S2Na 
1242.2653, found 1242.2683.    
 
Benzoxazol-2-yl 2,3,4-tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-α/β-D-
glucopyranosyl)-1-thio-β-D-glucopyranoside (3.16b). The title compound was obtained 
from 2-thiazolinyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-glucopyranoside (3.1)14 and 
benzoxazolyl 2,3,4-tetra-O-benzyl-1-thio-β-D-glucopyranoside (3.15b)26 by Method B in 
82% yield and Method C in 85% yield, as  a colorless syrup. Analytical data for 3.16b: Rf 
= 0.52 (ethyl acetate/hexane, 3/7, v/v); 1H NMR; δ, 3.28 (dd, 1H, J2,3 = 9.8 Hz, H-2), 3.82 
(dd, J3’,4’ = 9.2 Hz, H-3’), 3.42-3.82 (m, 10H, H-3, 4, 5, 6a, 6b, 2’, 4’, 5’, 6a’, 6b’), 4.43-
4.95 (m, 14H, CH2Ph), 4.98 (d, 1H, J1,2 = 3.4 Hz, H-1), 5.09 (d, 1H, J1’,2’ = 3.5 Hz, H-1’), 
5.38 (d, 1H, J1,2 = 10.1 Hz, H-1), 7.10-7.65 (m, 39H, aromatic); 13C NMR: δ, 65.5, 68.7, 
70.4, 72.3, 73.5, 75.0, 75.3, 75.7, 75.8, 77.4, 79.8, 80.3, 80.8, 81.8, 85.0, 86.7, 97.3, 
119.2, 124.4, 124.6, 127.6 (×2), 127.6 (×2), 127.7 (×2), 127.8 (×2), 127.8 (×3), 128.0 
(×3), 128.0 (×3), 128.1 (×3), 128.3 (×3), 128.5 (×3), 128.5 (×3), 128.6 (×3), 128.6 (×3), 
128.7 (×2), 137.7, 138.2, 138.4, 138.5, 138.7, 138.7, 138.8, 139.0, 142.0, 152.0, 161.7 
ppm; HR FAB MS [M+Na]+ calcd for C68H67NO11SNa  1128.4333, found 1128.4368. 
 
Benzoxazol-2-yl 2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)-1-thio-β-D-glucopyranoside (3.16c). The title compound was obtained 
by Method C from 2-thiazolinyl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside 
(3.6)14 and benzoxazolyl 2,3,4-tetra-O-benzoyl-1-thio-β-D-glucopyranoside (3.15c)27 in 
76% yield as a colorless syrup. Analytical data for 3.16c: Rf = 0.45 (ethyl acetate/hexane, 
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7/3, v/v); [α]D24= 48.5 (c = 1, CHCl3]; 1H NMR; δ, 3.53 (dd, 1H, J5,6b = 8.3 Hz, H-6b), 
3.86 (dd, 1H, J6a,6b = 4.8 Hz, H-6a), 4.12 (m, 1H, H-5’), 4.15 (m, 1H, H-5), 4.34 (dd, 1H, 
J5,6b’ = 7.9 Hz, H-6b), 4.47 (dd, 1H, J6a’,6b’ = 2.6 Hz), 4.74 (m, 1H, H-2), 5.43 (d, 1H, J4’,5’ 
= 8.4 Hz, H-4’), 5.68 (dd, 1H, J4,5 = 9.8 Hz, H-4), 5.72 (dd, 1H, J3’,4’ = 9.6 Hz, H-3’), 
5.90-5.99 (m, 3H, H-1, 1’, 2’), 7.09-8.10 (m, 39H, aromatic); 13C NMR: δ, 63.3, 64.4, 
67.8, 68.8, 79.4, 71.0, 72.3, 74.5, 77.6, 84.3, 110.5, 119.2, 121.4, 124.9, 124.9, 126.9 
(×2), 128.7 (×5), 128.8 (×5), 128.9 (×2), 129.0, 129.1, 129.2, 129.5, 129.5, 130.5 (×3), 
130.1 (×5), 130.3 (×5), 130.5 (×2), 133.3, 133.7, 133.8 (×3), 133.9, 134.7, 141.9, 152.2, 
164.7, 165.5, 165.5, 165.6, 166.1, 166.4 ppm; HR FAB MS [M+Na]+ calcd for 
C68H53NO18SNa 1226.2281, found 1226.2283.  
 
2-Thiazolinyl 2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-
1-thio-β-D-glucopyranoside (3.16d).  The title compound was obtained by Method D 
from benzoxazolyl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside (3.7)17 and 2-
thiazolinyl 2,3,4,6-tetra-O-benzoyl-1-thio-β-D-glucopyranoside (3.15d)14 in 69% yield as 
a white foam. Analytical data for 3.16d was in a good agreement with those reported 
previously.28  
 
Methyl 2,3,4-tri-O-benzyl-6-O-[2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-
D-glucopyranosyl)-b-D-glucopyranosyl]-β-D-glucopyranoside (3.17a).  The title 
compound was obtained as a colorless syrup by Method E from methyl 2,3,4-tri-O-
benzyl-α-D-glucopyranoside (3.4)29 and 3.16c in 72% yield and Method F from 3.4 and 
3.16a in 75% yield and from 3.4 and 3.16d in 81% yield.  Analytical data for 3.17a was 
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in a good agreement with those reported previously.30  
 
Methyl 2,3,4-tri-O-benzyl-6-O-[2,3,4-tri-O-benzyl-6-O-(2,3,4,6-tetra-O-benzyl-D-
glucopyranosyl)-D-glucopyranosyl]-α-D-glucopyranoside (3.17b). The title compound 
was obtained by Method E from 3.4 and 3.16b in 92% yield as a white amorphous solid. 
Analytical data for α/β−3.17b; Rf = 0.48 (ethyl acetate/hexane, 3:7, v/v ); 13C NMR: δ, 
55.4, 70.7, 70.8, 72.4, 72.5., 72,6, 73.5, 73.6, 73.6, 75.1, 75,1, 75.2, 75.6, 75.7, 75.7, 75.7, 
75.8, 75.9, 77.4, 78.0, 80.0, 80.3, 80.3, 80.4, 80.5, 81.9, 82.1, 82.3, 82.4, 84.9, 97.3, 97.4, 
97.5, 98.1, 98.2, 98.2, 103.7, 127.7, 127.7, 127.8, 127.9, 127.9, 127.9, 128.0, 128.0, 
128.1, 128.2, 128.3, 128.5, 128.5, 128.6, 128.6, 138.2, 138.3, 138.4, 138.5, 138.6, 138.6, 
138.7, 138.8, 138.9, 139.0,  HR FAB MS [M+Na]+ calcd for C89H94O16Na 1441.6440, 
found 1441.6437.  
 
2-Thiazolinyl  2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-
benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-thio-β−D-glucopyranoside 
(3.17c). The title compound was obtained by Method D from 16c and 15d in 62 % yield 
as a white foam. Analytical data for 17c: Rf = 0.46 (ethyl acetate/toluene, 1/4, v/v ); 
[α]D21 = 5.84 (c = 1, CHCl3); 1H NMR; δ, 3.29-3.39 (m, 2H, CH2S), 3.59 (m, 1H, H-6a’), 
3.85 (m, 2H, H-5’,6b”), 4.00 (m, 1H, 6a”), 4.13-4.29 (m, 2H, CH2N), 4.44 (m, 2H, H-5, 
6a’), 4.66 (m, 1H, H-6b), 4.67 (d, 1H, J1”,2” = 7.8 Hz, H-1”), 5.04 (dd, 1H, J4”,5” = 9.5 Hz, 
H-4”), 5.11 (dd, 1H, J2”.3” = 7.8 Hz, H-2”), 5.21 (d, 1H, J1’,2’ = 7.9, H-1’), 5.27 (dd, 1H, 
J2’,3’ = 4.0 Hz, H-2’), 5.59-5.62 (m, 2H, H-3”, 4’), 5.65 (dd, 1H, J4,5 = 8.3 Hz, H-4), 5.77 
(dd, 1H, J2,3 = 7.1 Hz, H-2), 5.78 (d, 1H, J1,2 = 7.9 Hz, H-1), 5.91 (dd, 1H, J3,4 = 9.6 Hz, 
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H-3), 6.15 (dd, 1H, J3’,4’ = 9.7 Hz, H-3’), 7.15-8.10 (m, 50H, aromatic); 13C NMR: δ, 
58.8, 63.5, 64.4, 68.2, 68.4, 69.8, 69.9, 70.6, 70.8, 72.0, 72.3, 72.5, 72.9, 73.0, 74.2, 74.3, 
83.5, 100.2, 101.5, 125.5 (×2), 127.2, 127.9, 128.4 (×2), 128.4 (×2), 128.5 (×2), 128.5 
(×2), 128.5 (×3), 128.6 (×2), 128.6 (×4), 128.8 (×2), 128.8, 128.9 (×2), 129.0, 129.1, 
129.1 (×3), 129.2 129.3, 129.4 (×2), 129.5, 129.8, 129.9 (×2), 130.0 (×3), 130.0 (×5), 
130.1(×3), 130.1 (×2), 130.2 (×2), 130.3 (×2), 130.3 (×2), 133.3, 133.3, 133.4 (×2), 133.5 
(×2), 133.6, 133.6, 165.2, 165.3, 165.4, 165.6 (×2), 166.0, 166.0, 166.4 ppm; HR FAB 
MS [M+Na]+ calcd for C91H75NO25S2Na 1668.3967, found 1668.4023. (See Appendix; 
Figure A-4, A-5, and A-6) 
 
Benzoxazol-2-yl  2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-
benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-thio-β−D-glucopyranoside 
(3.17d). The title compound was obtained by Method B from 16d and 15c in 67% yield 
as a colorless syrup. Analytical data for 3.17d:  Rf = 0.48 (ethyl acetate/toluene, 1.5/8.5, 
v/v ); [α]D28= 47.4 (c = 1, CHCl3); 1H-n.m.r.: δ, 3.43-3.45 (m, 2H, H-6a, 6b), 3.66 (dd, 
1H, J5’,6a’ = 5.5 Hz,  J6a’,6b’ = 11.5 Hz, H-6a’), 3.84 (m, 1H, H-5’), 4.06-4.16 (m, 3H, H-5, 
5’’, 6b’), 4.30 (dd, 1H, J5”,6a” = 5.1 Hz, J6a”,6b” = 12.1 Hz, H-6a”), 4.54-4.58 (m, 2H, H-4, 
6b”), 4.95 (d, 1H, J1’,2’ = 11.0 Hz, H-1’), 5.22 (dd, 1H, H-4’), 5.50-5.55 (m, 2H, H-2’, 
3’), 5.60-5.69 (m, 2H, H-3”, 4”), 5.71 (dd, 1H, J3,4 = 9.6 Hz, H-3), 5.77 (d, 1H, J1”,2” = 
5.3 Hz, H-1”), 5.86 (dd, 1H, J2,3 = 9.7 Hz, H-2), 5.95 (d, 1H, J2”,3” = 9.5 Hz), 5.96 (d, 1H, 
J1,2 = 10.3 Hz, H-1), 7.15-8.10 (m, 54H, aromatic); 13C NMR: δ, 60.6, 63.0, 63.3, 68.1, 
68.6, 69.3, 69.5, 69.98, 70.8, 71.7, 72.4, 72.4, 73.2, 74.3, 76.7, 77.6, 77.7, 84.1, 97.8, 
102.0, 110.3, 119.1, 121.1, 124.6, 124.8, 126.6, 128.2 (×2), 128.4 (×2), 128.4 (×2), 128.5 
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(×4), 128.6 (×4), 128.8, 128.9, 129.0, 129.1, 129.1, 129.2, 129.4 (×3), 129.7, 129.8 (×2), 
129.9 (×4), 130.0 (×4), 130.0 (×4), 130.0 (×4), 130.10 (×2), 130.3, 133.1, 133.2, 133.3 
(×2), 133.4, 133.5, 133.6 (×2), 133.6, 134.4, 141.7, 152.0, 161.4, 164.5, 165.1, 165.2, 
165.2, 165.4, 165.9, 166.0, 166.3 ppm; HR FAB MS [M+Na]+ calcd for C95H75NO26SNa 
1700.4196, found 1700.4182. (See Appendix; Figure A-7, A-8, and A-9) 
 
2,3,4-Tri-O-benzoyl-β-D-glucopyranosyl-(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-
O-benzoyl-β-D-glucopyranosyl fluoride (3.20). This compound was obtained by 
Method G from 3.17d and 2,3,4-tri-O-benzoyl-α-D-glucopyranosyl fluoride (3.19)31 in 
87% yield. Rf = 0.42 (ethyl acetate/toluene, 1/9, v/v); [α]D25 = -2.02 (c = 1, CHCl3]; 1H 
NMR: δ, 3.54 (m, 1H), 3.59 (m, 1H), 3.86 (m, 3H), 4.00 – 4.08 (m, 3H), 4.14 (dd, 1H, J 
= 12.1 Hz), 4.34 (m, 1H), 4.46 (dd, 1H, J = 4.9, 11.4 Hz), 4.60 (dd, 1H, J = 11.8 Hz), 
4.76 (d, 1H, J =7.7 Hz), 4.82 (d, 1H, J = 7.9 Hz), 5.11 (d, 1H, J = 7.8 Hz), 5.21 (dd, 1H, J 
= 9.8), 5.28 (dd, 1H, J = 9.3 Hz), 5.34 (d, ½ H, J = 6.2 Hz), 5.40 (dd, 1H, J = 9.7 Hz), 
5.46 (m, 1.5 H), 5.53 (dd, 1H, J = 9.5 Hz), 5.62 – 5.70 (m, 3H), 5.75 (dd, 1H, J = 9.6 Hz), 
5.79 – 5.85 (m, 2H), 6.16 (dd, 1H, J = 9.6 Hz), 7.22 – 8.10 (m, 65H, aromatic) ppm; 13C 
NMR: δ, 63.45, 68.14, 68.66, 68.91, 69.14, 69.67, 69.79, 70.24, 71.76, 71.98, 72.03, 
72.40, 72.46, 72.78, 72.93, 73.03, 73.77, 74.24, 74.76, 100.87, 101.51, 101.71, 106.23, 
128.36, 128.38, 128.46, 128.50, 128.52, 128.62, 128.67, 128.70, 128.73, 128.77, 128.83, 
128.89, 128.92, 129.05, 129.07, 120.10, 129.16, 129.21, 129.57, 129.72, 129.80, 129.89, 
129.96, 129.99, 130.02, 130.09, 130.18, 133.21, 133.25, 133.29, 133.35, 133.40, 133.44, 
133.52, 133.65, 133.70, 133.77, 133.82, 134.05, 165.01, 165.11, 165.23, 165.26, 165.39, 
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165.43, 165.46, 165.73, 165.80, 165.89, 165.91, 166.00, 166.10, 166.32 ppm; 
HRFABMS [M+Na]+ calcd for C115H93FO33Na 2043.5481, found 2043.5452. (See 
Appendix; Figure A-10, A-11, and A-12) 
 
Ethyl O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-benzoyl-
β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-
(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-thio-D-
glucopyranoside (3.22). This compound was obtained by Method H from glycosyl 
fluoride 3.20 and ethyl 2,3,4-tri-O-benzoyl-thio-β-D-glucopyranoside (3.21)32 in 84% 
yield. Rf = 0.46 (ethyl acetate/toluene, 1.5/8.5, v/v); [α]D26 = -9.32 (c = 1, CHCl3]; 1H 
NMR: δ, 1.14 (t, 3H, SCH2CH3), 2.68 (m, 2H, SCH2CH3), 3.58 (m, 1H, J = 5.5, 6.2 Hz), 
3.67 – 3.75 (m, 3H), 3.85 – 3.92 (m, 6H), 4.02 (dd, 1H, J = 10.8 Hz), 4.12 (m, 1H), 4.35 
(m, 1H), 4.48 (dd, 1H, J = 5.5, 12.1 Hz), 4.57 (dd, 1H, J = 11.0 Hz), 4.70 (d, 1H, J = 10.0 
Hz), 4.76 (d, 1H, J = 7.7 Hz), 4.86 (m, 2H), 5.16 (d, 1H, J = 7.9 Hz), 5.25 (dd, 1H, J =9.6 
Hz), 5.33 (dd, 1H, J = 9.3 Hz), 5.39 (dd, 1H, J = 9.6 Hz), 5.43 – 5.56 (m, 7H), 5.70 (dd, 
1H, J = 9.7 Hz), 5.76 – 5.87 (m, 2H), 5.90 – 5.95 (m, 2H), 6.23 (dd, 1H, J =9.7 Hz), 6.95 
– 8.90 (m, 80H, aromatic) ppm; 13C NMR: δ, 14.88, 31.14, 63.48, 67.95, 68.03, 69.00, 
69.29, 60.74, 69.91, 70.12, 70.19, 70.74, 70.95, 72.18, 72.28, 72.42, 72.47, 72.77, 72.87, 
72.98, 73.05, 73.76, 74.16, 74.66, 83.73, 101.20, 101.27, 101.39, 101.80, 128.19, 128.28, 
128.35, 128.45, 128.49, 128.60, 128.67, 128.74, 128.82, 128.92, 128.94, 129.01, 129.05, 
129.11, 129.18, 129.24, 129.28, 129.52, 129.69, 129.74, 129.77, 129.79, 129.82, 129.90, 
129.96, 129.99, 130.05, 130.08, 130.12, 133.08, 133.19, 133.27, 133.35, 133.49, 133.65, 
133.82, 165.20, 165.27, 165.30, 165.34, 165.38, 165.43, 165.58, 165.61, 165.76, 165.89, 
 131
165.91, 165.97, 166.29 ppm;  HRFABMS [M+Na]+ calcd for C144H120O41SNa 
2559.6923, found 2559.6938. (See Appendix; Figure A-13, A-14, and A-15) 
 
4-Pentenyl O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-
benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl) 
(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-
D-glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-D-glucopyranoside (3.24). This 
compound was obtained by Method E from thio pentasaccharide (3.22) and 4-pentenyl 
2,3,4-tri-O-benzoyl-β-D-glucopyranoside (3.23)33 in 72% yield. Rf = 0.50 (ethyl 
acetate/toluene, 2/8, v/v); [α]D22 = -10.54 (c = 1, CHCl3), 1H NMR; δ, = 1.41 – 1.58 (m, 
4H), 1.89 (m, 2H), 3.28 (m, 1H), 3.55 (m, 2H), 3.71 (dd, 1H, J = 11.5 Hz), 3.75 – 3.81 
(m, 5H), 3.90 - 4.07 (m, 7H), 4.12 (m, 1H), 4.31 (m, 1H), 4.47 (dd, 1H, J = 5.4, 12.1 Hz), 
4.56 (dd, 1H, J = 2.6, 9.3 Hz), 4.64 (d, 1H, J = 7.9 Hz), 4.75 (d, 1H, J = 1.6 Hz), 4.79 - 
4.87 (m, 6H), 5.12 (d, 1H, J = 7.8 Hz), 5.24 (dd, 1H, J = 9.7 Hz), 5.31 (dd, 1H, J = 1.8, 
9.6 Hz), 5.38 - 5.55 (m, 9H), 5.58 – 5.63 (m, 1H), 5.68 (dd, 1H, J = 9.7 Hz), 5.67 (dd, 
1H, J = 9.7 Hz), 5.86 (dd, 1H, J = 9.6 Hz), 5.90 -5.97 (m, 2H, J = 9.6 Hz), 6.06 (dd, 1H, J 
= 9.6 Hz), 6.16 (dd, 1H, J = 9.7 Hz), 6.90 – 8.00 (m, 95H, aromatic) ppm; 13C NMR: δ, 
28.71, 29.92, 30.01, 31.15, 63.04, 63.43, 67.64, 68.19, 69.80, 69.94, 70.09, 70.47, 70.51, 
70.93, 72.12, 72.31, 72.26, 72.42, 72.85, 72.89, 72.99, 74.54, 89.86, 101.28, 101.30, 
102.35, 101.44, 101.57, 115.02, 128.24, 128.34, 128.36, 128.41, 128.47, 128.50, 128.52, 
128.65, 128.69, 128.75, 128.79, 128.98, 129.00, 129.02, 129.05, 129.08, 129.15, 129.18, 
129.22, 129.28, 129.44, 129.72, 129.80, 129.82, 129.84, 129.86, 129.95, 129.99, 130.04, 
130.08, 130.13, 130.16, 130.17, 165.23, 165,25, 165.27, 165.30, 165.37, 165.42, 165.46, 
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165.49, 165.62, 165.65, 165.74, 165.90, 165.91, 165.95, 166.31 ppm; HRFABMS 
[M+Na]+ calcd for C174H146O50Na 3057.8780, found 3057.8748. (See Appendix; Figure 
A-16, A-17, and A-18) 
 
3.4.3 Aglycone isolation 
 
3-Benzyl-thiazolidine-2-thione (3.13).  The title compound was isolated by column 
chromatography from the reaction mixture resulted from glycosylation between 3.1 and 
3.7.  Analytical data for 3.13 was reported previously.34 The structure of 3.13 was 
confirmed by UV spectrometry with absorption maximum at 277 nm.   
 
2-(Benzylthio)-benzoxazole (3.14).  The title compound was isolated by column 
chromatography from the reaction mixture resulted from glycosylation between 3.3 and 
3.7.  Analytical data for 3.14 was reported previously.35 The structure of 3.14 was 
confirmed by UV spectrometry with two absorption maxima at 280 and 290 nm.36  
 
3.4.5 HPLC Monitoring 
The analyses were carried out on a Supelcosil LC-SI Semi Prep (250mm×10mm 
i.d., 5μm) (Supelco, Bellefonte, PA, USA). The mobile phase was ethyl acetate/hexane 
(30/70, v/v), under isocratic conditions. The sample analysis (injection volume 20 μL) 
was performed for 60 min at rt with the flow rate 1.0 mL/min and UV detection at 254 
nm.  
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On the stereoselectivity of glycosidation of thiocyanates, thioimidates and 
thioglycosides 
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4.1  Introduction 
The stereocontrolled introduction of glycosidic linkages1,2 is arguably the most 
challenging aspect in the synthesis of oligosaccharides3-9 and glycoconjugates.10-12 While 
a 1,2-trans glycosidic linkage can be usually stereoselectively obtained by using the 
anchimeric assistance from the participatory neighboring substituent at C-2 (most 
commonly an ester13 or recently introduced picolinyl),14,15 the stereoselective formation 
of a 1,2-cis linkage still remains a notable challenge,16 despite significant recent 
improvements.17-19 In addition to the effect of protecting groups on the glycosyl donor, a 
myriad of other factors is known to have effect on the stereoselectivity of the chemical 
glycosylation;20 and the effect of conformation,21 solvent,22-24 temperature,25 metal 
coordination,26 steric hindrance,27,28 and remote participation29-31 are only a few to 
mention. It is commonly believed that a typical glycosylation follows the unimolecular 
mechanism with the rate-determining step being the glycosyl acceptor attack on the 
intermediate formed as a result of the leaving group departure.32 Nevertheless, 
occasionally the effect of a leaving group itself may also have an influence on the 
anomeric stereoselectivity. However, it is often unclear whether this effect is a result of a 
bimolecular or close-ion pair rather than the unimolecular displacement mechanism, or 
other factors affecting this complex process.  
As part of a program to develop new protocols for stereocontrolled glycosylation, 
we have been investigating various classes of sulfur-based leaving groups ranging from 
conventional alkyl/aryl thioglycosides to relatively novel S-benzoxazolyl (SBox) or S-
thiazolinyl (STaz) thioimidates. In particular, we were interested in a possible influence 
that different leaving groups may have on the outcome of glycosylations. While on a 
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number of occasions we managed to achieve very good to excellent stereoselectivities, 
particularly with the SBox glycosides, these results have been occasionally outshadowed 
by other classes of glycosyl donors. For example, glycosyl thiocyanates, introduced two 
decades ago, have proven to be very effective glycosyl donors for what then appeared to 
be “stereospecific 1,2-cis glycosylations”.33  
Indeed, in a series of publications, Kochetkov et al., provided a convincing case 
of the power of this class of glycosyl donors.33-37 Various hexose and pentose 1,2-trans 
thiocyanate glycosyl donors were found to provide 1,2-cis glycosides completely 
stereoselectively (or stereospecifically, as quoted in the original literature) with the only 
failure reported when the method was applied to the synthesis of β-mannosides.38 
Another attractive feature of this glycosylation approach is that the activation could be 
performed in the presence of a catalytic amount of promoter and at ambient temperature. 
While tritylated acceptors were used in most of the reported transformations, a 
complementary procedure involving an unprotected hydroxyl group was also 
developed.35 The major drawback of this technique was modest yields obtained during 
both the synthesis of glycosyl thiocyanates and glycosidations thereof. This drawback 
was arguably related to the propensity of thiocyanates to isomerize into the corresponding 
isothiocyanates. The latter would remain inert under the glycosylation conditions leading 
to average to modest yields, which could be further diminished by the migration of acetyl 
substituents that have been used as protecting groups throughout the original reports.  
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4.2  Results and Discussion 
When 3,4,6-tri-O-acetyl-2-O-benzyl-β-D-glucopyranosyl-thiocyanate 4.137 was 
allowed to react with glycosyl acceptor 4.239 in the presence of catalytic amount (0.2 
equiv.) of triphenylmethyl perchlorate40 (TrClO4) in 1,2-dichloroethane (DCE) at ambient 
temperature, the corresponding 1,2-cis linked disaccharide 4.537 was obtained with 
complete stereoselectivity (conservative estimation α/β > 25:1, although no evidence of 
the corresponding 1,2-trans anomer could be detected by 1H NMR) yet only in a modest 
yield of 65% (Scheme 4.1).  
 
O
AcO
OAc
BnO
AcO
SCN
1 2: P = Ac
3: P = Bz
4: P = Bn
5: P = Ac, 65%, α/β > 25/1
6: P = Bz, 78%, α/β > 25/1
7: P = Bn, 72%, α/β = 8.3/1
O
OAc
AcO
AcO
BnO
O
O
PO
PO
PO
OMe
O
OTr
PO
PO
PO
OMe
+ TrClO4
1,2-DCE
 
Scheme 4.1  Reaction of thiocyanate 4.1 with differently protected 6-O-trityl glycosyl 
acceptors 4.2-4.4. 
 
This result was in line with previously reported results for similar systems.37 We 
assumed that the application of more stable benzoyl or benzyl protecting groups would 
enhance the overall stability of the glycosyl acceptor by reducing the acyl migration. 
Indeed, the disaccharide 4.6,41 derived from benzoylated glycosyl acceptor 4.3,42 was 
isolated in a significantly improved yield of 78% and with complete 1,2-cis 
stereoselectivity. However, when the structurally similar benzylated glycosyl acceptor 443 
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was employed, the corresponding disaccharide 4.744 was obtained in a yield of 72%, but 
as a mixture of diastereomers (α/β = 8.3:1). This notable decrease in the stereoselectivity 
of glycosyl thiocyanates, which were previously described as glycosyl donors capable of 
the concerted stereospecific displacement, was intriguing. To the best of our knowledge, 
this was the first example wherein thiocyanate 4.1 of the D-gluco series gave the 
anomeric mixture, although prior to this study the stereoselectivity of glycosyl 
thiocyanates was only investigated with partially acetylated acceptors.37 Hence, this a 
typical observation led us to a decision to reinvestigate glycosidations of thiocyanates in 
a greater detail. In principle, the effect of protecting groups on the reactivity of glycosyl 
acceptor has been noted.16,45-47 It has been observed that strongly electron withdrawing 
ester protecting groups decrease electron density at the hydroxyl group (or 
triphenylmethoxy as in the examples depicted in Scheme 1) thus lowering its 
nucleophilicity and hence reactivity in glycosylation. However, still very little is 
understood about the actual effect that the glycosyl acceptor protection may have on 
stereoselectivity of glycosylation.48 Basic knowledge in this area implies that an 
enhanced stereocontrol could be achieved with the less nucleophilic acceptors (such as 
4.2 or 4.3). Occasionally, a mismatch between donor-acceptor pair may result in the 
unexpected stereoselectivity outcome and/or reduced yields.49-53 Hence, at first, we 
attributed the result obtained for disaccharide 4.7 to the increased reactivity of the 
glycosyl acceptor 4.4, which implies that the glycosidation of glycosyl thiocyanate 
donors follows unimolecular rather than the earlier proposed concerted push-pool 
mechanism.33,37
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In order to extend this finding, we employed common benzoylated (4.10)42 and 
benzylated (4.11)54 6-OH glycosyl acceptors that were subjected to systematic 
investigation with the thiocyanate donor 4.1 along with a variety of other thioderivatives. 
As previously reported,35 glycosyl thiocyanate 4.1 could be activated for reactions with 
non-tritylated acceptors in the presence of catalytic amount of TMSOTf. However, these 
rather sluggish reactions were commonly accompanied by the competing isomerization of 
glycosyl donor 4.1 into the corresponding isocyanate, which was reflected in low 
efficiency.35 Although excellent stereoselectivity (α/β = 10.2:1) was observed with the 
benzoylated glycosyl acceptor 4.10, the disaccharide 4.6 was obtained in only 45% yield 
(Entry 1, Table 1). The reaction with the more reactive glycosyl acceptor 4.11 was more 
rapid (36 vs. 48 h), which was also reflected in the improved yield of disaccharide (69%) 
yet displayed two-fold reduced stereoselectivity (Entry 2).  
Since our key task was to compare glycosyl thiocyanates with other classes of 
thioglycosyl donors, such as thioimidates, we decided to search for the universal 
promoters of glycosylation that would activate both classes of glycosyl donors. If such 
promoters were available, one could standardize the reaction conditions across the 
spectrum of different classes of glycosyl donors to obtain comparable results by 
excluding the possibility of the promoter effect. Based on our previous reports, the most 
prominent results for glycosidation of S –benzoxazolyl (SBox, 4.8)41,55 and S-thiazolinyl 
(STaz, 4.9)44,56 glycosides have been obtained in the presence of AgOTf as the promoter. 
Hence, thiocyanate 4.1 was also investigated in the presence of stoichiometric amount of 
AgOTf. Relatively clean and fast activations (5–15 min) resulted in good yields for the 
coupling products 4.6 and 4.7 (78–84%, Entries 3 and 4). This result could serve as a 
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promising new beginning of comparative glycosylation studies with thiocyanates and 
thioimidates.  
 
Table 4.1 Glycosylation of various glycosyl donors 4.1 (thiocyanate), 4.2 (S-
benzoxazolyl) and 4.9 (S-thiazolinyl) with glycosyl acceptor 4.10 and 4.11 
 
O
OH
PO
PO
PO
OMe
10: P = Bz
11: P = Bn
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OAc
AcO
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BnO
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PO
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6: P = Bz
7: P = Bn
O
OAc
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AcO
OBn
R
1: R = SCN
8: R = SBox
9: R = STaz
+
 
Entry Donor Acceptor Cond’s Time 
Product,  
Yield (%) Ratio α/β
1 1 10 A 48 h 6, 45% 10.2/1 
2 1 11 A 36 h 7, 69% 5.0/1 
3 1 10 B 5 min 6, 84% 7.5/1 
4 1 11 B 15 min 7, 78% 2.2/1 
5 8 10 B 1 h 6, 92% 9.5/1 
6 8 11 B 30 min 7, 84% 3.8/1 
7 9 10 B 2 h 6, 89% 7.4/1 
8 9 11 B 1.5 h 7, 81% 2.7/1 
Reagents and conditions: All glycosylations were performed in 1,2-dichloroethane under 
argon at rt:  A - TMSOTf (0.2 equiv);  B - AgOTf (1.0 equiv for 1, 2.0 equiv for 8 and 9), 
3Å molec. sieves 
 
However, somewhat lower overall stereoselectivity was observed in comparison 
to that seen in TMSOTf-promoted glycosidations (Entries 1 and 2). Nevertheless, the 
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trend remained the same, and the disaccharide 4.6 derived from the benzoylated glycosyl 
acceptor 4.10 was obtained in a notably higher α stereoselectivity than its benzylated 
counterpart 4.7 from 4.11 (7.5:1 and 2.2:1, respectively). The latter result was particularly 
surprising considering the sturdy common knowledge that thiocyanates are amongst the 
most stereoselective glycosyl donors developed to date. Indeed, this example clearly 
illustrated that the effect of glycosyl acceptor and promoter of glycosylation cannot be 
underestimated and may have a prevailing effect on the reaction outcome.  
When SBox or STaz glycosides (4.8 and 4.9, respectively) have been 
investigated, a very similar trend has been observed, although these activations were 
slower than those of glycosyl thiocyanate 4.1, and required at least 2.0 equivalents of 
AgOTf. Again, disaccharide 4.6 derived from the benzoylated glycosyl acceptor 10 was 
obtained with a much higher (approximately three-fold) α stereoselectivity (Entries 5 and 
7) than its benzylated counterpart 4.7 from acceptor 4.11 (Entries 6 and 8). It should be 
noted that the rate of the reaction did not clearly correlate with the stereoselectivity 
observed: for example, slower glycosidations of the STaz derivative 4.9 provided lower 
stereoselectivity than that of the SBox glycoside 4.8.  
To gain a broader insight, a similar set of experiments have been performed using 
a variety of standard secondary glycosyl acceptors with the uniform benzoyl and benzyl 
protecting group pattern (4.12,57 4.14,58 4.16,57 4.18,59 4.20,60 and 4.2261). STaz glycosyl 
donor 4.9 was used in this comparative evaluation. As evident from the results presented 
in Table 4.2, the glycosylations of secondary glycosyl acceptors were in accordance with 
the observation made for primary glycosyl acceptors 4.10 and 4.11. Thus, benzoylated 
glycosyl acceptors (4.12, 4.16 and 4.20) gave consistently higher stereoselectivity (α/β~ 
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12:1, Entries 1, 3, and 5) for the formation of disaccharides (4.13, 4.17, and 4.21, 
respectively) than their benzylated counterparts (4.14, 4.18, and 4.22) provided for 
disaccharides 4.15,44 4.19, and 4.2344 (α/β ~ 6.5 - 9.3:1, Entries 2, 4, and 6).  
 
Table 4.2 The glycosylation of secondary acceptor 4.12, 4.14, 4.16, 4.18, 4.20, and 4.22 
with the STaz donor 4.9 
 
Entry Acceptor Time Product, yield Ratio α/β 
1 12 16 h 13, 89% 11.7/1 
2 14 14 h 15, 90% 6.8/1 
3 16 12 h 17, 87% 12.1/1 
4 18 8 h 19, 85% 6.5/1 
5 20 12 h 21, 72% 12.0/1 
6 22 6 h 23, 87% 9.3/1 
 
O
OP
RO
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OMe
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OAc
AcO
AcO
BnO
4.12: P=Bz, R=H
4.13: P=Bz, R=Sug
4.14: P=Bn, R=H
4.15: P=Bn, R=Sug
Sug =
O
OP
PO
RO
PO
OMe
4.16: P=Bz, R=H
4.17: P=Bz, R=Sug
4.18: P=Bn, R=H
4.19: P=Bn, R=Sug
O
OP
PO
PO
RO
OMe
4.20: P=Bz, R=H
4.21: P=Bz, R=Sug
4.23: P=Bn, R=H
4.23: P=Bn, R=Sug
 
 
Since ethyl thioglycosides are inert in the presence of either TMSOTf or AgOTf, 
direct comparison of them with thiocyanates and thioimidates was not possible. 
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Nevertheless, we supposed that this general study may benefit from the indirect 
comparison with a common ethyl thioglycosides, even though its activation required 
entirely different activation protocol. Indeed, a very similar trend was achieved when 
ethyl 3,4,6-tri-O-acetyl-2-O-benzyl-1-thio-β-D-glucopyranoside62 was glycosidated in 
the presence of NIS–TfOH (or other common promoters for thioglycoside activation).63-66 
For example, disaccharide 4.6 derived from the benzoylated glycosyl acceptor 4.10 was 
obtained in a significantly higher α-stereoselectivity than its benzylated counterpart 4.7 
(6.8:1 vs. 1.7:1, respectively). In addition, a very similar trend has been observed with 
per-benzylated STaz and SEt glycosyl donors (these results are not shown herein and will 
be reported elsewhere).  
 
4.3 Conclusions 
In conclusion, we observed that protecting groups on glycosyl acceptor have a 
profound effect on stereoselectivity of glycosylation. The effect of protecting groups of 
glycosyl acceptor on the stereoselectivity of glycosylation seemed very directly 
correlated to their electron-withdrawal power. Thus, we demonstrated that much higher 
α-stereoselectivity can be obtained with glycosyl acceptors bearing more 
electronwithdrawing benzoyl substituents in comparison to that of their benzylated 
conterparts. This improvement was consistently achieved with all classes of glycosyl 
donors investigated (thiocyanates, thioimidates, and thioglycosides) and was practically 
independent on the leaving group used. Both primary and secondary glycosyl acceptors 
showed the same trend; and these results were in line with generally accepted principles 
of the effect of protecting groups on glycosyl acceptor. The actual effect remains unclear, 
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but it is possible that a variety of factors may have to be considered: dipole moments of 
the entire molecule, dipole-dipole interactions, polarizability, donor-acceptor match-
mismatch, the role of the promoter (and the activation mode), solvent, etc. Further 
investigation of the protecting and leaving group effects on stereoselectivity of 
glycosylation is currently underway in our laboratory. 
 
4.4     Experimental part 
4.4.1    General 
   Column chromatography was performed on silica gel 60 (EM Science, 70-230 
mesh), reactions were monitored by TLC on Kieselgel 60 F254 (EM Science). The 
compounds were detected by examination under UV light and by charring with 10% 
sulfuric acid in methanol.  Solvents were removed under reduced pressure at <40 oC. 1, 2-
Dichloroethane was distilled from CaH2 directly prior to application in glycosylations.  
Molecular sieves (3Å or 4 Å), used for reactions, were crushed and activated in vacuo at 
390 °C during 8 h in the first instance and then for 2-3 h at 390 °C directly prior to each 
application.  AgOTf (Acros) was co-evaporated with toluene (3 x 10 mL) and dried in 
vacuo for 2-3 h directly prior to each application.  1H-NMR spectra were recorded in 
CDCl3 at 300 MHz, 13C-NMR spectra were recorded at 75 MHz (Bruker Avance).  
HRMS determinations were made with the use of JEOL MStation (JMS-700) Mass 
Spectrometer. 
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4.4.2 Typical glycosylation procedures 
Method A.  Typical AgOTf promoted glycosylation procedure: A mixture the glycosyl 
donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated molecular 
sieves (3 Å, 200 mg) in (ClCH2)2 (2mL) was stirred under argon for 1.5 h.  Freshly 
conditioned AgOTf (0.11-0.22 mmol) was added and the reaction mixture was monitored 
by TLC.  Upon completion (see Table), the reaction mixture was diluted with CH2Cl2 (20 
mL), the solid was filtered-off and the residue was washed with CH2Cl2.  The combined 
filtrate (30 mL) was washed with 20% aq. NaHCO3 (15 mL), water (3 × 10 mL), and the 
organic phase was separated, dried over MgSO4, and concentrated in vacuo.  The residue 
was purified by column chromatography on silica gel (ethyl acetate/toluene gradient 
elution) to afford the corresponding disaccharide derivative. 
 
Method B.  TMSOTf promoted glycosylation procedure: A mixture the glycosyl donor 
(0.11 mmol) and glycosyl acceptor (0.10 mmol) and freshly activated molecular sieves (4 
Å, 200 mg) in (ClCH2)2 (2 mL) was stirred for 1.5 h under argon.  TMSOTf (0.022 
mmol) was added and the reaction mixture was monitored by TLC.  Upon completion, 
the reaction was quenched with a drop of pyridine.  The reaction mixture was diluted 
with CH2Cl2 (20 mL) and washed with 20% aq. NaHCO3 (15 mL) and water (3 × 10 mL).  
The organic phase was separated, dried over MgSO4, and concentrated in vacuo.  The 
residue was purified by column chromatography on silica gel (ethyl acetate/toluene 
gradient elution) to afford the corresponding disaccharide derivative. 
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Method C.  NIS-TfOH promoted glycosidation of S-ethyl glycosides. A mixture of the 
glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly activated 
molecular sieves (4 Å, 200 mg) in (ClCH2)2 (2 mL) was stirred for 1.5 h under argon.  
NIS (0.22 mmol) and TfOH (0.022 mmol) were added and the reaction mixture was 
monitored by TLC.  Upon completion, the reaction mixture was diluted with CH2Cl2 (20 
mL), the solid was filtered off and the residue was washed with CH2Cl2.  The combined 
filtrate (30 mL) was washed with 20% aq. Na2S2O3 (15 mL) and water (3 × 10 mL).  The 
organic phase was separated, dried over MgSO4, and concentrated in vacuo.  The residue 
was purified by column chromatography on silica gel (ethyl acetate–toluene gradient 
elution) afford a disaccharide derivative. 
 
Methyl 3-O-(3,4,6-tri-O-acetyl-2-O-benzyl-α/β-D-glycopyranosyl)-2,4,6-tri-O-
benzoyl-α-D-glucopyranoside (4.17) was obtained from 9 and 16 in 89% yield (α/β = 
11.7/1).  Analytical data for 17: Rf = 0.48 (ethyl acetate/toluene, 3/7, v/v); 1H NMR: δ, 
1.76, 1.78, 2.02 (3s, 9H, 3 × COCH3), 3.27 (dd, 1H, J2’,3’ = 10.0 Hz, H-2’), 6.46 (s, 3H; 
OCH3), 3.76-3.87 (m, 3H, H-6a’, 6b’, ½ CH2Ph), 4.06 (dd, 1H, J5’,6a’ = 10.4 Hz, J5’,6a’ = 
5.3 Hz, H-5’), 4.17 (d, 1H, J2 = 12.7 Hz, ½ CH2Ph), 4.33 (m, 1H, H-5), 4.45 (dd, 1H, 
J6a’,6b’ = 14.4 Hz, H-6a’), 4.56-4.62 (m, 2H; H-3, 6b’), 4.74 (dd, 1H, J4’,5’ = 9.8 Hz, H-4’), 
5.06 (d, 1H, J1’,2’ = 3.7 Hz, H-1’), 5.10 (d, 1H, J1,2 = 3.4 Hz, H-1), 5.22 (dd, 1H, J3’,4’ = 9.6 
Hz, H-3’), 5.36 (dd, 1H, J2,3 = 9.9 Hz, H-2), 5.68 (dd, 1H, J4,5 = 9.5 Hz, H-4), 6.91-8.06 
(m, 20H, aromatic) ppm; 13C NMR: δ, 20.7, 20.8, 20.9, 55.8, 61.8, 63.3, 67.8 (x2), 68.3, 
71.4, 71.7, 72.5, 72.6, 76.3, 77.4, 97.3, 98.0, 127.9 (×2), 128.5 (×2), 128.6 (×2), 128.7 
(×3), 129.9, 130.0 (×2), 130.7 (×2), 130.2 (×2), 133.3, 133.5, 133.6, 164.9, 165.8, 166.5, 
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169.7, 169.9, 170.8 ppm; HR-FAB MS: calcd for C47HB48O17Na [M+Na] : 907.2789 
found: 907.2790. 
+
 
Methyl 3-O-(3,4,6-tri-O-acetyl-2-O-benzyl-α/β-D-glycopyranosyl)-2,4,6-tri-O-benzyl-
α-D-glucopyranoside (4.19) was obtained from 9 and 18 in 90% yield (α/β = 6.8/1).  
Analytical data for 19: Rf = 0.50 (ethyl acetate/toluene, 3/7, v/v); 1H NMR: δ, 1.91, 1.94, 
2.06 (3s, 9H, 3 × COCH3), 3.35 (s, 3H, OCH3), 3.52-3.79 (m, 3H, H-2, 2’, 4), 3.76 (m, 
1H, H-5), 3.89-3.93 (m, 2H, H-6a, 6b), 4.24 (dd, 1H, J3,4 = 9.3 Hz, H-3), 4.34-4.53 (m, 
4H, H-6a’, 6b’, CH2Ph), 4.59-4.68 (m, 4H, H-5’, CH2Ph), 4.73 (d, 1H, J1,2 = 3.5 Hz, H-1), 
4.84 (d, 1H, J2 = 12.0 Hz, ½ CH2Ph), 4.91 (dd, 1H, J4’,5’ = 10.3 Hz, H-4’), 5.49 (dd, 1H, 
J3’,4’ = 9.8 Hz, H-3’), 5.60 (d, 1H, J1’,2’ = 3.5 Hz, H-1’), 6.90-7.35 (m, 20H, aromatic) 
ppm; 13C NMR: δ, 20.9, 21.0, 21.1, 55.3, 62.0, 67.3, 68.6, 68.8, 70.0, 72.4, 72.8, 73.5, 
73.7 (x2), 76.4, 77.4, 78.3, 78.9, 97.1, 97.7, 126.6 (×2), 127.4, 127.8 (×2), 127.9 (×2), 
128.1 (×2), 128.8, 128.5 (×4), 128.6 (×2), 128.6 (×2), 128.8 (×2), 137.7, 137.9, 138.0, 
138.6, 170.1, 170.3, 171.0 ppm; HR-FAB MS: calcd for C47H48O17Na [M+Na]+: 907.2789 
found: 907.2785. 
 
Methyl 4-O-(3,4,6-tri-O-acetyl-2-O-benzyl-α/β-D-glycopyranosyl)-2,3,6-tri-O-
benzoyl-α-D-glucopyranoside (4.13) was obtained from 9 and 12 in 87% yield (α/β = 
12.1/1).  Analytical data for 13: Rf = 0.46 (ethyl acetate/toluene, 3/7, v/v); 1H NMR: δ, 
1.97, 2.01, 2.02 (3s, 9H, 3 × COCH3), 3.37 (dd, 1H, J2’,3’ = 5.8 Hz, H-2’), 3.45 (s, 3H, 
OCH3), 4.09 (m, 1H, H-5’), 4.16-4.26 (m, 3H, H-4, 6a’, 6b’), 4.08 (m, 1H, J5,6b = 2.7 Hz, 
H-5), 4.66 (dd, 1H, H-6a), 4.78 (dd, 1H, J6a,6b = 12.0 Hz, H-6b), 4.85 (dd, 1H, J4’,5’ = 9.4 
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Hz, H-4’), 5.14 (d, 1H, J1,2 = 2.1 Hz, H-1), 5.14-5.22 (m, 3H, H-1’, CH2Ph), 5.36 (dd, 1H, 
J3’,4’ = 9.8 Hz, H-3’), 6.20 (dd, 1H, J3,4 = 8.5 Hz, H-3), 7.03-8.10 (m, 20H, aromatic) ppm; 
13C NMR: δ, 20.8 (×3), 55.7, 62.1, 63.6, 68.5, 68.6, 68.7, 71.7, 72.2, 72.4, 73.1, 75.7, 
76.4, 77.4, 97.0, 98.0, 127.8 (×2), 128.0, 128.5 (×2), 128.6 (×3), 128.8 (×3), 129.2, 129.9 
(×4), 130.1, 130.2 (×2), 133.3, 133.6 (×2), 137.7, 165.4, 166.3 (x2), 169.9, 170.0, 170.7 
ppm; HR-FAB MS: calcd for C47H55O14 [M+H]+: 843.3592 found: 843.3594. 
 
Methyl 2-O-(3,4,6-tri-O-acetyl-2-O-benzyl-α/β-D-glycopyranosyl)-3,4,6-tri-O-
benzoyl-α-D-glucopyranoside (4.21) was obtained from 9 and 20 in 72% yield (α/β = 
12/1).  Analytical data for 21: Rf = 0.40 (ethyl acetate/toluene, 3/7, v/v); 1H NMR: δ, 1.83 
(s, 3H; COCH3), 1.99 (s, 6H; 2 × COCH3), 3.51 (s, 3H; OCH3), 3.53-3.60 (m, 2H, H-2’, 
5’), 3.87 (dd, 2H, J6a’,6b’ = 9.5 Hz, H-6a’, 6b’), 3.94 (dd, 1H, J2,3 = 10.0 Hz, H-2), 4.39 (m, 
1H, H-5), 4.46 (dd, 1H, J6a,6b = 12.1 Hz, H-6a), 4.57-4.60 (m, 2H, H-6b, ½ CH2Ph), 4.64 
(d, 1H, J2 = 12.1 Hz, ½ CH2Ph), 4.85 (dd, 1H, J4’,5’ = 9.6 Hz, H-4’), 4.88 (d, 1H, J1’,2’ = 
3.5 Hz, H-1’), 5.00 (d, 1H, J1,2 = 3.1 Hz, H-1), 5.33 (dd, 1H, J3’,4’ = 9.6 Hz, H-3’), 5.54 
(dd, 1H, J4,5 = 9.9 Hz, H-4), 6.03 (dd, 1H, J3,4 = 9.7 Hz, H-3), 7.28-8.06 (m, 20H, 
aromatic) ppm; 13C NMR: δ, 20.7, 20.8, 21.0, 56.0, 61.3, 63.3, 67.8, 68.0, 68.1, 69.8, 
71.6, 72.0, 73.4, 77.1, 97.5, 97.6, 128.1 (×3), 128.4, 128.6 (×6), 128.8 (×3), 129.1, 129.7, 
129.9 (×4), 130.1 (×2), 133.3 (×2), 133.6, 137.9, 165.6, 165.7, 166.4, 169.9, 170.0, 170.7 
ppm; HR-FAB MS: calcd for C47H48O17Na [M+Na]+: 907.2789 found: 907.2788 
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CHAPTER V 
 
Glycosidation of thioglycosides in the presence of bromine: mechanism, reactivity, 
and stereoselectivity 
 
 
 
 
 
 
 
 
 
__________________________________________________________________ 
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5.1 Introduction 
Since the first glycosylation reactions were performed in the late 1800s, 
carbohydrate chemistry has evolved into a broad area of research that has persistently 
captured the interest of the scientific community. Nevertheless, the installation of the 
glycosidic linkage remains cumbersome due to the lack of understanding the mechanistic 
detail of glycosylation or the inability to translate such knowledge into practical 
application.1,2  With significant recent advances in the rapidly expanding fields of 
glycosciences, the demand for reliable and stereocontrolled glycosylation technologies 
has increased.  Owing to many recent breakthroughs in the field, the formation of many 
glycosidic bonds can be readily achieved;3,4 however, it is the inability to effectively 
control the stereoselectivity of glycosylation that has proven to be the major synthetic 
hurdle.  
Building upon our earlier discovery of the O-2/O-5 cooperative effect in 
glycosidation of superdisarmed glycosyl donors bearing 2-benzyl-3,4,6-triacyl protecting 
group pattern,5 herein we present our study for the development of a highly 
stereocontrolled glycosylation using glycosyl bromides as glycosyl donors generated in 
situ.  It has been our belief that a carefully controlled reaction pathway helps to ensure 
predictable, rather than serendipitous, outcome of chemical glycosylation, a remarkably 
complex and multi-step reaction of very high scientific and industrial significance as a 
vast majority of all sugars are bound via the glycosidic linkage.  There are many 
complexities to consider when depicting the mechanism of the glycosylation reaction, 
and often a clear delineation between SN1 and SN2 nucleophilic substitution reactions is 
obscured.6,7  Nevertheless, today it is generally presumed that the reaction conditions 
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favor that of a unimolecular SN1 mechanism, and the reaction is thought to proceed 
through a total of four distinct steps: activation, dissociation, nucleophilic attack and 
deprotonation.6   
Glycosyl bromides are arguably the best known and the most studied glycosyl 
donors to date.  Historically being the first glycosyl donors investigated, glycosyl 
bromides are still in frequent use, particularly in glycosylations of simple aglycones.  In 
the recent years, however, their utility for oligosaccharide synthesis has been diminished 
by the development of new classes of glycosyl donors.  A very significant application of 
the accrued mechanistic and kinetic knowledge was the halide-ion catalyzed 
glycosylation developed by Lemieux et al. in 1975.8  Through extensive theoretical 
studies, careful consideration of the reaction intermediates, and conformations thereof, it 
was found that a rapid equilibrium could be established between a relatively stable α-
halide A and its more reactive β-counterpart I, by adding tetraalkylammonium bromide 
(Scheme 5.1).  At first, the expulsion of α-halide A results in the formation of ion-pair B.  
Since no inverted product (E) is formed herein, it was concluded that the ion-pair F 
leading to the anomerized β-linked bromide I is a more energetically favorable pathway.  
The existence of alternate conformations for intermediates G and H en route to/from I 
was deemed necessary to form/activate the equatorial bond.9  At this point, the highly 
unstable β-halide dissociates back into its ion pair (I→G), whereupon it quickly 
undergoes nucleophilic attack (G→K) to form the 1,2-cis product L.  As an end result, 
nucleophilic substitution of the β-bromide I occurs favorably, whereas the α-bromide A 
anomerizes before glycosylation can occur.   
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 Scheme 5.1  Lemieux’s in situ anomerization concept. 
 
 Does this concept offer a practical application to synthesis of glycosides and 
oligosaccharides? Yes, but it lacks generality as it requires very reactive per-benzylated 
bromides (or iodides)10 as glycosyl donors and provides satisfactory results mainly with 
the highly reactive series, L-fucose and D-galactose.   
 
5.2 Results and Discussion 
 In our hands, this procedure was found less effective and thorough investigation 
of differently protected glucosyl bromides 5.1a-5.5a in reactions with glycosyl acceptor 
5.6, showed it is it mainly applicable to glycosidation of per-benzylated glucosyl bromide 
5.1a.  Herein and below, index a or b is used to designate α- or β-anomeric configuration 
in glycosyl donors, if known.  Even then, the reaction was extremely sluggish and 
proceeded only half-way in 120 h (entry 1, Table 1).  The stereoselectivity obtained for 
disaccharide 5.7 was good (α/β = 9/1), but far from being exclusive; and, in principle, the 
application of such uniformly protected building blocks in oligosaccharide synthesis is 
limited to the introduction of terminal units only.  Our consecutive attempt to 
 160
differentiate the protecting group pattern by adding a single benzoyl substituent led to the 
significant decrease in the rate of glycosylation and yields (entries 2 and 3).  
Stereoselectivity and yields observed with 6-O-benzoyl bromide 5.2a and 4-O-benzoyl 
bromide 5.3a differed drastically indicating that the effect of the electron-withdrawal is 
very position dependable.  Not surprisingly, all our attempts to activate the disarmed and 
superdisarmed bromides 5.4a and 5.5a, respectively, under Lemieux’s inversion 
conditions have failed (entries 4 and 5). 
 
Table 5.1  Glycosidation of differently protected glucosyl bromides 5.1a-5.5a in the 
presence of Bu4NBr. 
 
Entry Glycosyl donor Intermediate Product (yield, α/β ratio) 
1 
  
5.7 (50%, 9.0/1) 
2 
  
5.8 (43%, 24/1) 
3 
  
5.9 (15%, 6.2/1) 
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4 
 
5.10 (no reaction) 
5 
 5.5b (not formed)
O
OBz
BzO
BzO
BnO
Br
 
5.11 (no reaction) 
 
 Interestingly, glycosyl bromide 5.5 generated from the corresponding β-
ethylthio glycoside 5.12 in the presence of bromine reacted readily and provided 
disaccharide 5.11 as the α-linked diastereomer only (entry 1, Table 5.2).  We also 
observed that no reaction would take place if the acceptor 5.6 was added at the later 
stage, when all thioglycoside 5.12 has been consumed. Strikingly, we also observed that 
bromide 5.5a cannot be glycosidated directly by the addition of bromine (entry 2).  These 
observations led us to a working hypothesis that thioglycoside 5.12 is first converted into 
a highly reactive β-bromide 5.5b that reacts readily with the glycosyl acceptor 5.6 to give 
the α-linked disaccharide 5.11 exclusively.  The literature precedent for this exists, and 
the formation of β-bromide from thioglycosides or selenium glycosides has been 
observed.  In a majority of studies, however, the reaction of thioglycoside with bromine 
is used to generate the corresponding glycosyl bromide, which is usually seen as the α-
anomer only upon isolation.  Perhaps, in the absence of the glycosyl acceptor, the kinetic 
β-bromide rapidly equilibrates into the thermodynamically more stable α-anomer.  If the 
glycosyl acceptor is present from the beginning, β-bromide 5.5b can undergo direct 
nucleophilic displacement that arguably takes place via concerted bimolecular pathway 
resulting in the formation of α-linked glycoside only.  Since the disaccharide 5.11 was 
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isolated in only 28% yield along with 63% of α-bromide 5.5a, we hypothesized that there 
is a competition between β-bromide glycosidation and anomerization, with both reactions 
being irreversible under these reaction conditions.  The α-bromide 5.5a is stable under 
these reaction conditions and cannot be glycosidated, which is significant as it helps to 
ensure complete stereoselectivity of such transformation.   
 
Table 5.2  Comparative glycosidations of β-thioglycosides and their corresponding α-
glycosyl bromides in the presence of bromine. 
 
Entry Glycosyl donor Intermediate Time Product  
(yield, α/β ratio) 
1 
  
16 h 5.11  
(28%, >25/1) 
2 
 
5b (not formed) 16 h 5.11  
(no reaction) 
3 
  
16 h 5.10  
(45%, β-only) 
4 
 
4b (not formed) 16 h 5.10  
(no reaction) 
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5 
  
10 min 5.7  
(71%, 2.2/1) 
 
5.1b  5.7  6 10 min 
(67%, 1.5/1) 
 
 In a similar fashion, per-benzoylated thioglycoside 5.13b was glycosidated in 
the presence of bromine to afford disaccharide 5.10 as β-linked product only in 45% yield 
(entry 3). Since α-bromide 5.4a did not undergo glycosidation under these reaction 
conditions (entry 4), we conclude that the formation of 5.10 also takes place via the 
intermediacy of β-bromide 5.4b only.  Differently, since bromide 5.4b is equipped with 
the participating group at C-2, it undergoes a two-step displacement via bicyclic 
acyloxonium ion (vide infra, see Scheme 3). Since no α-linked disaccharide formation 
was detected; this appears to be the only feasible route leading to the products of 
glycosylation, which copes well with the well-known effect of the neighboring protecting 
groups.  
 When a similar glycosylation was set up with per-benzylated thioglycoside 
5.14b, disaccharide 5.7 was readily obtained in a good yield of 71%, but as a mixture of 
diastereomers (entry 5). Also the corresponding α-bromide 5.1a reacted readily under 
these reaction conditions (entry 6) providing nearly identical outcome to that obtained 
with thioglycoside 5.14b.  Perhaps, this reaction proceeds via the classic SN1 pathway via 
the intermediacy of the flattened oxacarbenium ion (vide infra) resulting in scrambled 
stereoselectivity.7  
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 In order to improve an outcome of the reaction between the superdisarmed 
thioglycoside 5.12b and acceptor 5.6 in the presence of bromine leading to complete 
stereoselectivity, we attempted to delineate between two plausible reactions pathways, as 
follows.  First, it is possible that the rate of formation of the diastereomeric bromides 
from the thioglycoside precursor are similar, but only the β-bromide then elaborates into 
the glycoside product while the α-counterpart remains intact.  Second, it is also possible 
that the kinetic β-bromide forms exclusively first and then anomerizes into its 
thermodynamically more stable α-counterpart concomitantly with glycosidation.  To 
differentiate between these two anticipated scenarios by which the glycosylation reaction 
may proceed we developed a toolkit for the reaction monitoring by 1H NMR.  First, we 
investigated the reaction of per-benzoylated β-thioglycoside 5.13b with bromine, as 
depicted in Scheme 5.2.  It was determined that α- and β-bromides 5.4a/5.4b form 
rapidly (5 min) with a vast predominance of the latter (α/β = 1/11).  This was followed by 
a relatively slow anomerization of β-bromide 5.4b into its α-linked counterpart 5.4a 
resulting in a nearly equal mixture of anomers with a slight predominance of 5.4a after 16 
h (see also entry 1 in Table 5.3).  
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 Scheme 5.2  In situ NMR monitoring of the reaction of thioglycoside 5.13b with        
bromine. 
 
 Certainly, the predominant formation of β-bromide 5.4b in this case can be 
attributed to the assistance of the neighboring benzoyl substituent at C-2.  Hence, it was 
important to establish how the β-thioglycosides of the armed and superdisarmed series 
5.14b and 5.12b, respectively, both bearing a non-participating 2-O-benzyl substituent, 
react.  The results of this study are summarized in Table 5.3.  The reaction of per-
benzylated thioglycoside 5.14b was very fast and by the time the first 1H NMR was 
acquired, 5 min since the addition of bromine, α-bromide 5.1a was present exclusively 
(entry 2, Table 5.3).  Therefore, we attempted to perform the reaction monitoring at low 
temperature, which was performed as follows. Thioglycoside 5.14b was dissolved in 
CDCl3, placed in the standard 5 mm NMR tube equipped with a septum, which was then 
placed into a dewar containing liquid nitrogen for 5 min.  Bromine (1 equiv.) was added 
via syringe, the external cooling was removed, and the NMR tube was placed 
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immediately into the magnet and the spectrum was recorded (approximately 5 min since 
Br2 addition). This approach allowed us to detect an anomeric mixture of bromides 5.1a 
and 5.1b (α/β = 7.3/1), which then rapidly equilibrated into the pure α-bromide 5.1a 
(entry 3, Table 5.3).   
 Next, the reaction of thioglycoside 5.12b equipped with the superdisarming 
protecting group pattern (2-O-benzyl-3,4,6-tri-O-benzoyl) was investigated. As indicated 
by NMR, room temperature reaction resulted in the formation of a 2.1/1 mixture of 
bromides 5.4a/5.4b with predominance of α-anomer 5.4a.  This mixture then began 
equilibrating slowly, and further accumulation of the α-anomer was monitored (entry 4, 
Table 5.3).  The outcome of this study was that even though β-bromides only can react 
under these reaction conditions, the predominate formation of the α-bromide is a serious 
conceptual drawback of such an approach.  This significantly diminishes the likelihood of 
further improvement of this reaction. For example, if one assumes that the β-anomer in a 
α/β = 2.1/1 mixture were to react entirely to form glycoside, the theoretical yield of such 
transformation based on the starting material cannot exceed 32%.  This maximum yield 
correlates well with the actual observed yield of 28% for the formation of disaccharide 
5.11 (see Table 5.2, entry 1), which corresponds to about 88% of conversion β-bromide 
5.4b into 5.11 leaving about 12% as a tribute to the competing anomerization process.  
This result is significant as it demonstrates that the glycosidation of 5.4b is significantly 
faster than the competing anomerization into 5.4a.  Further evidence was acquired during 
the NMR-monitored glycosidation of 5.4a/5.4b with CD3OD as a glycosyl acceptor 
(Figure 5.1). 
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H-1 α-OCD3
H-1 α-Br 
 
Figure 5.1  In situ NMR monitoring of the reaction of thioglycoside 5.12b with bromine 
in presence of CD3OD. 
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Table 5.3  Reactions of thioglycosides 5.12-5.14 with bromine: NMR monitoring of 
glycosyl bromide formation and anomerization. 
 
Entry Reaction Temperature Time recorded Ratio α/β 
13b?4a/4b rt 
5 min 
15 min 
30 min 1 
3 h 
16 h 
1/10.7 
1/10.3 
1/9.0 
1/4.3 
1/0.8 
2 14b?1a/1b rt 5 min >25/1 
5 min 7.3/1 
10 min 8.9/1 
3 Low (see text) 14b?1a/1b 
20 min 10.2/1 
30 min 12.7/1 
5 min 2.1/1 
4 rt 15 min 2.2/1 12b?5a/5b 
1 h 2.4/1 
5 rt 5 min >25/1 14a?1a/1b 
5 min 1/>25 
10 min 1/2.5 
6 Low (see text) 15 min 1/0.9 14a?1a/1b 
30 min 1/0.3 
1 h >25/1 
5 min 1/20 
15 min 1/17.3 
7 rt 30 min 1/16.3 12a?5a/5b 
3 h 1/11.5 
16 h 1/4.5 
 169
 Since no Lemieux-like equilibrium could be established with the bromides of 
the unreactive series, the only possibility to improve the yield of glycosylation is to make 
sure that β-bromide is generated preferentially.  In case of thioglycosides equipped with 
the neighboring participating group at C-2, such as 5.13, or schematically represented as 
A in Scheme 5.3a, the β-thioglycoside undergoes a multi-step displacement via the 
intermediacy of the bicyclic acyloxonium ion D.  Thus, upon interaction of A with 
bromine, active sulfonium intermediate B is generated. The promoter-assisted leaving 
group departure then results in the formation of oxacarbenium intermediate C. The 
leaving group departs as BrSEt that then disproportionates into ethyl disulfide (easily 
detectable by NMR) and bromine.  Oxacarbenium ion C is then stabilized via the 
anchimeric assistance of the neighboring benzoyl group resulting in the formation of 
cyclic acyloxonium intermediate D.  The formation of the latter can be used to explain 
the preferential formation of β-bromide E as the bottom; α-face of the ring is blocked for 
the bromide ion attack.  In the case of β-thioglycosides 5.12 and 5.14, schematically 
shown as F in Scheme 5.3b, there is no direct route that would lead to the stereoselective 
formation of the corresponding β-bromides. This reaction proceeds via the formation of 
oxacarbenium intermediate G and although β-bromide H is the kinetic product, our 
results show that more thermodynamically stable α-bromide formation predominates, 
with most β-bromide obtained in case of the superdisarmed series 5.5a/5.5b (α/β = 2.1/1, 
see Table 5.3, entry 4).  
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 Scheme 5.3  Mechanistic rationale for the transformation of thioglycosides to bromides. 
 
 We conceptualized that the use of α-thioglycosides, generically shown as I in 
Scheme 5.3, as the starting material may offer a more direct route to obtain β-bromide H.  
Our modified working hypothesis that has been adjusted as more experimental data was 
gathered is depicted in Scheme 5.3c. Thus, promoter-assisted activation of the leaving 
group of α-thioglycode I with bromine will lead to the formation of α-sulfonium ion J. 
Two possible pathways by which J may convert into bromides H can be assumed as 
follows. First, the formation of β-Η takes place directly via the concerted nucleophilic (or 
close ion-pair) displacement of BrSEt leading to the complete inversion. Second, upon 
monomolecular departure of the activated leaving group in J, the reaction would proceed 
via the intermediacy of the oxocarbenium ion G that will result in the formation of the 
anomeric mixture of α/β-H, as it has been proven for reactions with β-thioglycosides F.  
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 To reveal the most likely reaction pathway by which α-ethylthio glycosides 
may elaborate into bromides, we obtained per-benzylated derivative 5.14a.  
Disappointingly, an NMR experiment with 5.14a performed at room temperature led to 
the formation of α-bromide 5.1a exclusively (entry 5, Table 5.3).  Very differently 
though, when this experiment was performed at low temperature (vide supra), β-bromide 
5.1b was formed nearly exclusively (α/β > 1/25, entry 6) with some trace amount of 
unreacted α-thioglycoside still remaining. After that, a rapid anomerization of 5.1b 
resulted in complete anomerization into 5.1a within 1 h of the addition of bromine.  
Assuming that the rate of this transformation would be very difficult to control, we 
obtained thioglycoside 5.12a equipped with the super-disarming 2-benzyl-tri-benzoyl 
protecting group pattern.  We anticipated that 5.12a would provide the bromination and 
anomerization reaction rates that would be easier to comprehend. This in turn, may lead 
to the enhanced control of the subsequent glycosidation process.   
 Figure 5.2 shows a series of NMR spectra that have been acquired at different 
times of reaction (see also the summary in entry 7, Table 5.3). After recording the 
spectrum of the starting material 5.12a (Figure 5.2a), bromine (1 equiv) was injected into 
the NMR tube. Subsequent NMR spectrum recorded at 5 min (Figure 5.2b) since the 
addition of Br2 showed that bromides 5.5a/5.5b formed in a ratio of α/β = 1/20 favoring 
the formation of β-anomer. The ratios were measured by comparison of the integral 
intensity of the signals corresponding to H-1 of α-bromide 5.5a (6.48 ppm) and H-5 of β-
bromide 5.5b (4.20 ppm), which were clearly separable from the rest of the signals.  At 
this time, about 24% of the starting material 5.12a was still remaining, as judged by the 
integral intensity of its H-3 signal (5.96 ppm).  This result indicates that the formation of 
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β-bromide takes place by the direct displacement of the activated leaving group (Figure 
5.2c) rather than via the intermediacy of the oxacarbenium intermediate. Subsequent 
NMR spectra recorded at 15 and 30 min time points since the addition of bromine 
showed that the starting material was completely consumed (by 30 min), and the β-
bromide began slow anomerisation into its more stable α-counterpart (Figure 5.2b and 
5.2c). This result indicates that anomerization of the superdisarmed bromide 5.5b is much 
slower than that observed for its armed, per-benzylated counterpart 5.1b. Moreover, it 
5.5b anomerizes even slower that per-benzoylated disarmed bromide 5.4b.  Thus, the 
super-disarmed 5.5b it is still present as the major anomer after 16 h (α/β = 1/4.5), 
whereas 5.4b has been succeeded by 5.4a by the same time point (α/β = 1/0.8, see entry 
1, Table 5.3). 
     
Figure 5.2  NMR monitoring of the conversion of thioglycoside 5.12a into bromides 
5a/5b at rt. 
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 Having established favorable reaction conditions for the formation of relatively 
stable β-bromide 5.5b at room temperature, we turned our attention to studying its 
glycosidation.  For this purpose we obtained a number of glycosyl acceptors ranging from 
simple aliphatic alcohols to secondary hydroxyls of monosaccharide acceptors.  The 
results summarized in Table 5.4 clearly indicate the correlation between the reactivity of 
glycosyl acceptors and the yield: more reactive primary acceptors providing higher yields 
in glycosylations.  In all cases, α-linked glycosides have been formed exclusively.   
 
Table 5.4  Glycosidation of thioglycoside 5.12a with various glycosyl acceptors 
O
OBz
BzO
BzO
BnOSEt5.12a
+ ROH
Br2 O
OBz
BzO
BzO
BnOOR(see Table)  
%yield, Entry ROH Time Product α/β ratio 
O
OBz
BzO
BzO
BnOOMe5.18  
78%, >25/1Pa1 MeOH 16 h 
 
2 BnOH 16 h 75%, >25/1 
 
 
3 16 h 67%, >25/1 
 
 
4 48 h 35%, >25/1 
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5 48 h 27%, >25/1 
 
 
6 24 h 42%, >25/1 
 
a – conservative estimation, no traces of β-linked glycosides could be detected by NMR. 
 
 Having achieved this promising outcome, we conceptualized that if an efficient 
equilibrium could be established between stable α-anomeric bromide 5.5a and its more 
reactive b-linked counterpart 5.5b, this would lead to the further improvement. Since the 
bromide 5.5a cannot be anomerized in the presence of Bu NBr or Br4 2 at room 
temperature (see Tables 5.1 and 5.2), it might be possible to anomerize it with the 
assistance of a metal-based promoter. As discovered in 1901 by Koenigs and Knorr11 
(and independently by Fischer and Armstrong12), glycosyl halides can be activated in the 
presence of Ag CO or Ag2 3 2O. The silver salt was used with the primary intention to 
scavenge the hydrogen halide by-product, and it was not until the early 1930’s when it 
was realized that it plays an active role by assisting in leaving group departure.13 This 
mild assistance resulted in the Koenigs-Knorr glycosylation reaction being very 
stereoselective and being one of the rare examples wherein a concerted bimolecular 
displacement occurs. Even in case of α-bromide equipped with the neighboring 
participating group, as noticed by Isbell,14 the inversion product was obtained as a result 
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of concerted displacement, not participation due to the lack of the 1,2-orthoester 
formation.  
 
Table 5.5  Attempts to anomerize unreactive α-bromide 5a into its more reactive β-
counterpart 5b. 
O
OBz
BzO
BzO
BnO
Br
5.5a
O
OH
BnO
BnO
BnO
OMe
5.6
O
OBz
BzO
BzO
BnO
O
O
BnO
BnO
BnO
OMe5.7
see
table
+
 
Entry Promoter (equiv.) Time %yield, α/β ratio  
1 TBAB (0.5-5) 72 h No reaction 
2 AgCO /TBAB (1-3/0.5-2) 72 h No reaction 3
3 TBAB, 80 oC (1.0) 16 h 52% 5.6/1 
4 80 oC 72 h 84% 7/1 
5 KBr/18-crown-6 (1/0.5) 72 h No reaction 
6 HgBr2 (1.0) 12 h 77% 9.3/1 
7 HgBr /TBAB (1.0/0.5) 12 h 81% 9.5/1 2
 
 It is possible that the anomerization can be achieved by using other heavy metal 
salt-based systems, although a delicate balance between reactivity and stereoselectivity 
should be kept in place to ensure success of this study. As shown by Helferich et al.,15-17 
mercury(II) salts offer a potent assistance for the leaving group departure. On the other 
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hand, Helferich’s study serves as an important lesson to necessitate caution and find a 
balance between the reactivity and stereoselectivity as it was noted that faster reactions 
often result in a decreased stereoselectivity.  Nevertheless, investigation of mercury-
based reagents, such as mercury (II) bromide, seemed attractive as this reagent is capable 
of both assisting the leaving group departure and providing Br-. In order to prove the 
concept, we performed glycosidation of 5.5a with 5.6 in the presence of HgBr2 (1 equiv.) 
and obtained the expected disaccharide in 73% yield. Importantly, along with the notable 
increase of the yield, stereoselectivity remained high.  
 
5.3 Conclusions   
 
 
  
 The conceptual similarity between this approach and the Lemieux method that 
was introduced in 1975 is undeniable. However, because no equilibrium between 5.5a 
and 5.5b can be established by the addition of tetraalkylammonium bromide, we believe 
that the concept described herein offers a novel complementary approach to glycosidation 
of relatively unreactive alkyl halides. The fact that α-bromide was found to be totally 
unreactive with glycosyl acceptors under these reaction conditions is a very significant 
result as it guarantees that its β-counterpart will be the only species en route to the 
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product. The yields achieved are similar to (or surpass) those achieved using traditional 
Lemieux method (see results in Table 5.1), but the complete stereoselectivity observed 
here is unmatched.  Significantly, both simple aliphatic alcohols and the less reactive 
sugar acceptors provided complete α-stereoselectivity.  
 
5.4       Experimental part 
 
5.4.1 General 
Column chromatography was performed on silica gel 60 (EM Science, 70-230 
mesh), reactions were monitored by TLC on Kieselgel 60 F254 (EM Science). Preparative 
layer chromatography was performed on PLC silica gel 60 glass plates, Kieselgel 60 F254, 
1 mm (Merck). The compounds were detected by examination under UV light and by 
charring with 10% sulfuric acid in methanol. Solvents were removed under reduced 
pressure at < 40 oC. CH Cl  and ClCH CH Cl were distilled from CaH2 2 2 2 2 directly prior to 
application. Pyridine was dried by refluxing with CaH2 and then distilled and stored over 
molecular sieves (3 Å). Molecular sieves (3 Å), used for reactions, were crushed and 
activated in vacuo at 390 °C during 8 h in the first instance and then for 2-3 h at 390 °C 
directly prior to application. Optical rotations were measured at ‘Jasco P-1020’ 
polarimeter. 1 13H-n.m.r. spectra were recorded in CDCl  at 300 and 500 MHz, 3 C-NMR 
spectra were recorded in CDCl3 at 75 and 125 MHz (Bruker Avance). HR FAB-MS 
determinations were made with the use of JEOL MStation (JMS-700) Mass 
Spectrometer, matrix m-nitrobenzyl alcohol, with NaI as necessary. 
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5.4.2 Synthesis of glycosyl donors  
 
6-O-benzoyl-2,3,4-tri-O-benzyl-α-D-glucopyranosyl bromide (5.2a)  
The solution of ethyl 2,3,4-tri-O-benzyl-6-O-benzoyl-1-thio-β-D-galactopyranoside (0.5 
g, 0.83 mmol) and activated molecular sieves (3 Å, 0.40 g) in CH Cl2 2 12.5 mL) was 
stirred under argon for 1 h. Freshly prepared solution of Br  in CH Cl2 2 2 (8 mL, 1/165, v/v) 
was then added and the reaction mixture was kept for 15 min at rt. After that, the solid 
was filtered-off and the filtrate was concentrated in vacuo at rt. The residue was purified 
by silica gel flash column chromatography (ethyl acetate-toluene gradient elution) to 
obtain compound 2a as a white syrup in 59% yield (0.31 g, 0.50 mmol). Rf = 0.43 (ethyl 
acetate - hexane, 2/8, v/v); [α]D24 1+122.56 (c = 1.0, CHCl ); 3 H NMR: δ, 3.56 (ddd, 1H, 
J1,2 = 3.8 Hz, J2,3 = 9.2, H-2), 3.73 (dd, 1H, J4,5 = 9.1 Hz, H-4), 4.11 (dd, 1H, J3,4 = 9.1 
Hz, H-3), 4.27 (m, 1H, J5,6a = 3.02 Hz, H-5), 4.50-5.02 (m, 8H, 3×CH2Ph, H-6a, 6b), 6.41 
(d, 1H, J1,2 = 3.8 Hz, H-1), 7.20-7.60 (m, 18H, aromatic), 7.90 (d, 2H, aromatic) ppm; 13C 
NMR: δ, 62.6, 72.9, 73.9, 75.5, 76.1, 76.2, 77.6, 80.0, 82.2, 91.1, 128.1, 128.2 (×3), 
128.3(×2), 128.4 (×3), 128.6 (×2), 128.7 (×4), 128.8 (×2), 129.8 (×3), 164.1 ppm. HR 
FAB MS [M+Na]+ calcd for C34H33O BrNa 639.1358, found 639.1332. 6
 
4-O-benzoyl-2,3,6-tri-O-benzyl-α-D-glucopyranosyl bromide (5.3a) 
The solution of ethyl 2,3,6-tri-O-benzyl-4-O-benzoyl-1-thio-β-D-galactopyranoside (0.5 
g, 1.59 mmol) and activated molecular sieves (3 Å, 0.40 g) in CH Cl2 2 (12.5 mL) was 
stirred under argon for 1 h. Freshly prepared solution of Br  in CH Cl2 2 2 (8 mL, 1/165, v/v) 
was then added and the reaction mixture was kept for 15 min at rt. After that, the solid 
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was filtered-off and the filtrate was concentrated in vacuo at rt. The residue was purified 
by silica gel flash column chromatography (ethyl acetate-toluene gradient elution) to 
obtain compound 3a as a white syrup in 70% yield (0.36 g, 0.58 mmol).  Rf = 0.42 (ethyl 
acetate - hexane, 2/8, v/v); [α]D24 1+110.56 (c = 1.0, CHCl ); 3 H NMR: δ, 3.55-3.72 (m, 
3H, H-2, 6a, 6b), 4.16 (dd, 1H, J3,4 = 9.3 Hz, H-3), 4.34 (m, 1H, J5,6a = 3.7 Hz, H-5), 4.51 
(dd, 2H, J = 2.5, 12.0 Hz, CH 2Ph), 4.77 (dd, 2H, J = 12.7 Hz, CH Ph), 4.88 (d, 1H, J2 2  = 
11.2 Hz, ½ CH Ph), 5.56 (dd, 1H, J2 4,5 = 12.0 Hz, H-4), 4.47 (d, 1H, J1,2 = 3.7 Hz, H-1), 
7.13-7.50 (m, 17H, aromatic), 7.62 (m, 1H, aromatic), 8.00 (d, 2H, aromatic) ppm; 13C 
NMR: δ, 67.9, 69.4, 73.1, 73.7, 74.1, 75.5, 79.3, 79.5, 91.4, 127.7, 127.8, 128.0 (×2), 
128.2 (×3), 128.3 (×3), 128.3 (×4), 128.4 (×2), 128.5 (×2), 128.7 (×3), 129.6, 129.9 (×2), 
133.4, 137.4, 137.5, 137.9, 165.2 ppm. HR FAB MS [M+Na]+ calcd for C34H29O8BrNa 
639.1358, found 639.1343. 
 
3,4,6-tri-O-benzoyl-2-O-benzyl-α-D-glucopuranosyl bromide (5.5a)  
The solution of ethyl 2-O-benzyl-3,4,6-tri-O-benzoyl-1-thio-β-D-galactopyranoside (1.0 
g, 1.59 mmol) and activated molecular sieves (3 Å, 0.79 g) in CH Cl2 2 (24 mL) was stirred 
under argon for 1 h. Freshly prepared solution of Br  in CH Cl2 2 2 (15 mL, 1/165, v/v) was 
then added and the reaction mixture was kept for 15 min at rt. After that, the solid was 
filtered-off and the filtrate was concentrated in vacuo at rt. The residue was re-dissolved 
in CH Cl2 2 and then washed with distill water. The organic phase was concentrated in 
vacuo at rt and then the residue was purified by silica gel column chromatography (ethyl 
acetate-toluene gradient elution) to obtain compound 1 as a white solid in 71% yield 
(0.76 g, 1.18 mmol). Rf = 0.52 (ethyl acetate - hexane, 4/6, v/v); [α]D23 +65.21 (c = 1.0, 
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1H NMR: δ, 3.78 (ddd, 1H, J = 3.9 Hz, J = 9.6 Hz, H-2), 4.45 (dd, 1H, JCHCl ); 3 1,2 2,3 5,6a = 
4.7 Hz, J  = 12.3 Hz, H-6a), 4.54-4.70 (m, 4H, H-5, 6b, CH Ph), 5.60 (dd, 1H, J6a,6b 2 4,5 = 
9.9 Hz, H-4), 6.03 (dd, 1H, J3,4 = 9.6 Hz, H-3), 6.48 (d, 1H, J1,2 = 3.9 Hz, H-1), 7.22 – 
7.57 (m, 14H, aromatic), 7.93 (dd, 4H, aromatic), 8.03 (dd, 2H, aromatic) ppm; 13C 
NMR: δ, 62.3, 68.3, 72.3, 72.7, 76.7, 89.2, 128.1  (×2), 128.4 , 128.5  (×2), 128.5  (×2), 
128.6  (×3), 128.7  (×3), 128.8, 129.5, 129.7, 129.9  (×4), 130.1  (×2), 133.3, 133.4, 
133.7, 136.8, 165.4, 165.6, 166.3 ppm; HR FAB MS [M+Na]+ calcd for C34H29O8BrNa 
667.0943, found 667.0970. 
 
3,4,6-tri-O-benzoyl-2-O-benzyl-β-D-glucopyranosyl bromide (5.5b)    
The solution of ethyl 2-O-benzyl-3,4,6-tri-O-benzoyl-1-thio-α-D-glucopyranoside (0.03 
mg, 0.04 mmol) in CD3Cl (0.5 mL) in NMR tube was frozen in liquid nitrogen. After 
that, bromine solution 98% (2.4 μL, 0.04mol) was added directly to NMR tube. 1H NMR 
was recorded immediately. Selected analytical data for the β-isomer; 1H NMR: δ, 4.07 
(dd, 1H, J2,3 =7.8 Hz, H-2), 4.20 (m, 1H, H-5), 4.46 (dd, 1H, J5,6a = 5.1 Hz, J6a,6b = 12.4 
Hz, H-6a), 4.57 (dd, 1H, J 25,6b = 3.1 Hz, H-6b), 4.72 (d, 1H, J  = 10.7 Hz, ½ CH2Ph), 4.91 
(d, 1H, J2 = 10.77 Hz, ½ CH2Ph), 5.67-5.81 (m, 3H, H-1, 3, 4), 7.19-8.05 (m, 20H, 
aromatic) ppm; 13C NMR: δ, 63.0, 68.8, 74.8, 75.3, 76.4, 81.7, 82.6, 128.2, 128.4 (×2), 
128.5 (×5), 128.6 (×4), 129.2, 129.6, 129.9 (×2), 130.0 (×3), 130.1 (×2), 136.9, 165.3, 
165.6, 166.2 ppm. 
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5.4.3 General Glycosylation Procedures 
 
Method A: typical TBAB (tetrabutyl ammonium bromide) promoted glycosylation 
procedure 
A mixture of the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly 
activated molecular sieves (3Å, 200 mg) in (ClCH )2 2 (2 mL) was stirred under argon for 1 
h., then TBAB (0.11 mmol) was added. The reaction mixture was stirred at rt and 
monitored with TLC. Upon completion, the reaction mixture was diluted with 
dichloromethane, the solid was filtered-off and the residue was washed with 
dichloromethane. The combined filtrate was washed with 20% aq. NaHCO3 and water, 
the organic phase was separated, dried with MgSO4 and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (ethyl acetate/hexane 
gradient elution) to allow the corresponding disaccharide. Anomeric ratios (if applicable) 
were determined by comparison of the integral intensities of relevant signals in 1H-n.m.r. 
spectra. 
 
Method B: typical Br2 promoted glycosylation procedure 
A mixture of the glycosyl donor (0.11 mmol), glycosyl acceptor (0.10 mmol), and freshly 
activated molecular sieves (3Å, 200 mg) in (ClCH )2 2 (2 mL) was stirred under argon for 1 
h., then bromine solution, 99.8% (0.11 mmol) was added. The reaction mixture was 
stirred at rt and monitored with TLC. Upon completion, the reaction mixture was diluted 
with dichloromethane, the solid was filtered-off and the residue was washed with 
dichloromethane. The combined filtrate was washed with 20% aq. NaHCO  and water, 3
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the organic phase was separated, dried with MgSO4 and concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (ethyl acetate/hexane 
gradient elution) to allow the corresponding disaccharide. Anomeric ratios (if applicable) 
were determined by comparison of the integral intensities of relevant signals in 1H-n.m.r. 
spectra. 
 
Method C: typical Br2 pre-activation glycosylation procedure 
A mixture of the glycosyl donor (0.1 mmol) freshly activated molecular sieves (3Å, 200 
mg) in (ClCH )2 2 (2 mL) was stirred under argon for 1 h.  Bromine solution 98% (0.1 mol) 
was added and the reaction mixture was stirred for 10 min at rt. After that, the solvent 
was removed out under vacuo at rt and dried in vacuo for 1 h. The solution of glycosyl 
acceptor (0.15 mmol of glycosyl in 2 mL (ClCH )2 2 was added into the glycosyl flask and 
the reaction was stirred under argon for 3-5 days at rt. Upon completion, the reaction 
mixture was diluted with dichloromethane, the solid was filtered-off and the residue was 
washed with dichloromethane. The combined filtrate was washed with 20% aq. NaHCO3 
and water, the organic phase was separated, dried with MgSO4 and concentrated in 
vacuo. The residue was purified by column chromatography on silica gel (ethyl 
acetate/hexane gradient elution) to allow the corresponding disaccharide. Anomeric ratios 
(if applicable) were determined by comparison of the integral intensities of relevant 
signals in 1H-n.m.r. spectra. 
 
Methyl 6-O-(6-O-benzoyl-2,3,6,-tetra-O-benzyl-α/β-D-glucopyranosyl)-2,3,4-tri-O-
benzyl-α-D-glucopyranoside (5.8) 
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This compound was obtained by Method B from compound 2a and compound 6 in 45% 
yield as a white syrup (α/β = 24/1), Rf = 0.41 (ethyl acetate/hexane, 3/7, v/v); selected 
analytical data 1H NMR: δ, 3.32 (ddd, 1Η, J1’,2’ = 3.6 Ηz, J2’,3’ = 9.6 Hz, H-2’), 3.46-3.54 
(m, 3H, H-2, 4, 4’), 3.62 (m, 1H, J6a,6b = 10.1 Hz, H-6a), 3.72 (m, 2H, H-5, 6b), 3.90 (m 
3H, J =9.8 Hz, H-3, 3’,5’), 4.31 (dd, 1H, J = 4.4 Hz, J5’,6a’ 6a’,6b’ = 11.9 Ha, H-6a’), 4.43 
(dd, 1H, J5’,6b’ = 2.0 Hz), 4.47-4.64 (m, 7H, J1’,2’ = 3.3 Hz, H-1’, 3×CH2Ph), 4.70-4.75 (m, 
2H, CH 13Ph), 4.81-4.93 (m, 5H, J2 1,2 = 3.56 Hz, H-1, 3×CH Ph)  ppm; δ, 2 C NMR : δ, 
55.4, 63.6, 66.2, 69.1, 70.6.72.6, 73.5, 75,2 (×2), 75.9 (×2), 77.4, 78.0, 80.3, 80.4, 81.9, 
82.3, 97.1, 98.1, 127.8 (×3), 127.9 (×2), 127.9 (×3), 127.9 (×2), 128.0 (×2), 128.1 (×2), 
128.2 (×4), 128.4 (×3), 128.5 (×3), 128.5 (×3), 128.6 (×4), 129.8 (×3), 130.2, 133.2, 
138.2, 138.3, 138.5 (×2), 138.7, 139.0, 166.4 ppm; HRFABMS [M+Na]+ calcd for 
C62H54O12Na  1023.4295, found 1023.4257. 
 
Methyl 6-O-(4-O-benzoyl-2,3,4,-tetra-O-benzyl-α/β-D-glucopyranosyl)-2,3,4-tri-O-
benzyl-α-D-glucopyranoside (5.9) 
This compound was obtained by Method B from compound 3a  and compound 6 in 15% 
yield as white syrup (α/β = 6.2/1), Rf = 0.41 (ethyl acetate/hexane, 3/7, v/v); Selected 
analytical data for the α-isomer 1H NMR: δ, 3.38 (s, OCH3), 3.47 (m, 2H, H-2’, 4), 3.98-
4.11 (m, 3H, H-3, 3’, 5), 4.59 (d, 1H, J1’,2’ = 3.8 Hz, H-1’), 4.96 (d, 1H, J1,2 = 2.5 Hz, H-
1), 5.31 (dd, 1H, J4’,5’ = 9.45 Hz, H-4’) ppm; 13C NMR : δ, 55.3, 69.1, 69.3, 70.6, 71.1, 
72.7, 73.6, 73.7, 75.1, 75.2, 75.9, 77.4, 78.1, 78.4, 79.9, 80.3, 82.4, 127.5 (×2), 127.6 
(×2), 127.8, 127.8 (×3), 127.9 (×3), 128.1 (×2), 128.2 (×2), 128.2 (×2), 128.3 (×2), 128.3, 
128.4, 128.5 (×3), 128.6 (×2), 128.6 (×3), 129.9 (×2), 130.1, 133.2, 138.0, 138.3, 138.5, 
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138.7, 139.0, 165.46  ppm; HRFABMS [M+Na]+ calcd for C62H54O12Na  1023.4295, 
found 1023.4337. 
 
Benzyl 3,4,6-tri-O-benzoyl-2-O-benzyl-α-D-glucopyranoside (5.19) was obtained by 
method B from glycosyl donor  and benzyl alcohol, as a clear film in 75% yield.  
Analytical data for 5.19 : Rf = 0.35 (ethyl acetate-toluene, 0.5/9,.5 v/v); [α]D26 +29.30 (c = 
1.0, CHCl 1 ): δ, 3.78 (ddd, 1H, J3); H NMR (CDCl3 1,2 = 3.6 Hz, J2,3 = 9.9 Hz, H-2), 4.37-
4.51 (m, 6H, CH Ph, H-5, 6a, 6b), 4.62 (d, 1H, J2 = 12.3 Hz, ½ CH Ph), 4.98 (d, 1H, J2 2 1,2 
= 3.5 Hz, H-1), 4.99 (d, 1H, J2 Ph), 5.49 (dd, 1H, J = 15.0 Hz, ½CH2 4,5 = 9.93 Hz, H-4), 
6.03 (dd, 1H J3,4 = 9.7 Hz, H-3), 7.14-7.60 (m, 19H, aromatic), 7.91 (m, 4H, aromatic), 
8.02 (d, 2H, aromatic) ppm; 13C NMR (CDCl3): δ, 31.4, 63.4, 68.1, 69.6, 70.1, 72.2, 77.4, 
72.8, 95.5, 128.0 (×2), 128.1, 128.2, 128.4 (×2), 128.5 (×2), 128.6 (×5), 128.7 (×3), 
128.8, 129.1, 129.9 (×3), 130.0 (×3), 130.1 (×2), 133.2, 133.3, 133.5, 136.9, 137.7, 165.7, 
165.9, 166.4 ppm; HR-FAB MS calcd. for C  41H36O Na 695.2257, found 695.2244. 9
 
Ethyl 6-O-(2-O-benzyl-3,4,6-tri-O-benzoyl-α-D-glucopyranosyl)-2,3,4-tri-O-benzoyl-
thio-β-D-glucopyranoside (5.22) 
This compound was obtained by Method B from ethyl 2-O-benzyl-3,4,6-tri-O-benzoyl-1-
thio-α-D-glucopyranoside and ethyl 2,3,4-tri-O-benzoyl-1-thio-β-D-glucopyranoside in 
42% yield as a white syrup, Analytical data for 5.22 : Rf = 0.62 (ethyl acetate/toluene, 1/9, 
v/v); [α]D25 1+28.06 (c = 1.0, CHCl H NMR: δ, 1.39 (t, 3H, J = 7.4 Hz, CH); CH3 3 2S), 
2.83 (m, 2H, CH CH S), 3.37 (d, 1H, J3 2 6b,6a = 10.7 Hz, H-6b), 3.79 (ddd, 1H, J1’,2’ = 3.3 
Hz, J2’,3’ = 9.9 Hz, H-2’), 4.00 (dd, 1H, J  = 10.4 Hz, H-6a), 4.19 (dd, 1H, J6a,6b 5,6a = 8.3 
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Hz, H-5), 4.36 (dd, 1H, J5’,6a’ = 5.6 Hz, J6a’,6b’ = 12.1 Hz, H-6a’), 4.51–4.53 (m, 2H, H-5’, 
6b’), 4.56 (d, 1H, J2 = 12.53 Hz, ½ CH Ph), 4.64 (d, 1H, J2 = 12.54 Hz, ½ CH2 2Ph), 4.85 
(d, 1H, J  = 3.3 Hz, H-1’), 4.88 (d, 1H, J1’,2’ 1,2 = 10.0 Hz, H-1), 5.39 (dd, 1H, J4’,5’ = 9.6 
Hz, H-4’), 5.48 (dd, 2H, J = 10.0 Hz, H-2, 4), 5.92 (dd, 1H, J3’,4’ = 9.4 Hz, H-3’), 6.0 (dd, 
1H, J 133,4 = 9.8 Hz, H-3), 7.10–7.98 (m, 35H, aromatic) ppm; δ, C NMR : δ, 14.3, 24.9, 
63.1, 67.2, 68.1, 69.7, 69.9, 70.9, 72.1, 73.3, 74.3, 84.1, 89.6, 96.6, 125.5, 128.1 (×3), 
128.4, 128.5 (×3), 128.5 (×4), 128.6 (×3), 128.6 (×2), 128.7 (×3), 128.9, 129.1, 129.2, 
129.4, 129.8, 129.9 (×3), 130.0 (×2), 130.1 (×3), 130.1 (×3), 133.2, 133.3, 133.4, 133.4, 
133.5, 133.7, 137.7 (×2), 165.3, 165.4, 165.6, 165.8, 165.9, 166.2 ppm; HRFABMS 
[M+Na]+ calcd for C63H56NO16SNa  1123.3187, found 1123.3198. 
 
Deuterated methoxy 2-O-benzyl-3,4,6-tri-O-benzoyl-α-D-glucopyranoside  
This compound was obtained by Method A from ethyl 2-O-benzyl-3,4,6-tri-O-benzoyl-1-
thio-α-D-glucopyranoside (1 equiv) and deuturated methanol (2 equiv) in 74 % yield as a 
white syrup, Rf = 0.5 (ethyl acetate/hexane, 4/6, v/v); [α]D25 1+7.7 (c = 1.0, CHCl ); 3 H 
NMR: δ, 3.83 (ddd, 1H, J1,2 = 3.5 Hz, J2,3 = 9.9 Hz, H-2), 4.37 (m, 1H, H-5), 4.47 (dd, 
1H, J  = 12.01 Hz, J6a,6b 5,6a = 5.5 Hz, H-6a), 4.58 (dd, 1H, H-6b), 4.67 (dd, J = 3.09, 12.49 
Hz, CH Ph), 4.90 (d, 1H, J2 1,2 = 3.5 Hz, H-1), 5.48 (dd, 1H, J4,5 = 9.8 Hz, H-4), 6.02 (dd, 
1H, J3,4 = 9.7 Hz, H-3), 7.30 (m, 4H, aromatic), 7.45 (m, 7H, aromatic), 7.55 (m, 3H, 
aromatic), 7.97 (m, 4H, aromatic), 8.05 (d, 2H, aromatic) ppm; 13C NMR.: δ, 63.4, 67.8, 
70.1, 72.1, 73.3, 98.1, 128.1 (×3), 128.2, 128.5 (×2), 128.5 (×4), 128.6 (×2), 129.2, 129.8 
(×3), 129.9 (×2), 130.0 (×2), 130.1 (×2), 133.2, 133.3, 133.5, 165.7, 165.8, 166.3 ppm; 
HR FAB MS [M+Na]+ calcd for C35D H3 29O Na 622.2129, found 622.2132.   9
 186
5. 4 References: 
(1) Mydock, L. K.; Demchenko, A. V. Org. Biomol. Chem. 2010, 8, 497-510  
(2) Crich, D. Acc. Chem. Res. 2010, 43, 1144-1153. 
(3) Handbook of Chemical Glycosylation: Advances in Stereoselectivity and 
Therapeutic Relevance; Demchenko, A. V., Ed.; Wiley-VCH: Weinheim, 
Germany, 2008. 
(4) Zhu, X.; Schmidt, R. R. Angew. Chem. Int. Ed. 2009, 48, 1900-1934. 
(5) Kamat, M. N.; Demchenko, A. V. Org. Lett. 2005, 7, 3215-3218. 
(6) Nukada, T.; Berces, A.; Whitfield, D. M. Carbohydr. Res. 2002, 337, 765-774. 
(7) Whitfield, D. M. Adv. Carbohydr. Chem. Biochem. 2009, 62, 83-159. 
(8) Lemieux, R. U.; Hendriks, K. B.; Stick, R. V.; James, K. J. Am. Chem. Soc. 1975, 
97, 4056-4062 and references therein. 
(9) Andrews, C. W.; Fraser-Reid, B.; Bowen, J. P. J. Am. Chem. Soc. 1991, 113, 
8293-8298. 
(10) Kulkarni, S. S.; Gervay-Hague, J. In Handbook of Chemical Glycosylation; 
Demchenko, A. V., Ed.; Wiley-VCH: Weinheim, Germany, 2008, p 59-93. 
(11) Koenigs, W.; Knorr, E. Ber. 1901, 34, 957-981. 
(12) Fischer, E.; Armstrong, E. F. Ber. 1901, 34, 2885-2900. 
(13) Igarashi, K. Adv. Carbohydr. Chem. Biochem. 1977, 34, 243-283. 
(14) Isbell, H. S. Ann. Rev. Biochem. 1940, 9, 65-92. 
(15) Helferich, B.; Bohn, E.; Winkler, S. Ber. 1930, 63B, 989-998. 
(16) Helferich, B.; Gootz, R. Ber. 1931, 64B, 109-114. 
(17) Helferich, B.; Wedemeyer, K. F. Ann. 1949, 563, 139-145. 
 187
  
 
 
 
 
 
CHAPTER VI 
 
Development of CD14-targeting therapeutics: synthesis and evaluation of 
glucopyranoside-spacer-amino acid motifs 
 
 
 
 
 
 
 
 
__________________________________________________________________ 
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6.1 Introduction 
Septicemia is a serious world-wide health problem associated with mortality rates 
of 40-60%.1 It has been estimated that 1% of hospital patients and 20-30% of ICU 
patients develop sepsis. The cardiovascular consequences of septic shock resulting from 
bacterial infections include myocardial dysfunction that develops in nearly all patients,2 
vascular tone and permeability abnormalities, as well as abnormal oxygen delivery and 
metabolism. As a result, vital organs, such as the brain, heart, kidneys, and liver may be 
affected or may fail, and this is reflected in over 100,000 deaths annually in the US.1 It is 
well established that septic shock is initiated by movement of bacterial endotoxin (or 
lipopolysaccharide, LPS) into the blood stream. LPS, a vital component of the outer 
leaflet of the gram-negative outer membrane, has been shown to be a principle mediator 
of the depression of left ventricular function and myocardial contractility.3 LPS is 
comprised of three structural regions (O-antigen, core-oligosaccharide, and Lipid A), the 
Lipid-A region of which consists of a polyacylated glucosamine disaccharide and is 
largely responsible for the toxic activity.4 The results of recent studies suggest that 
concurrent evidence of a proinflammatory response to LPS is by far more important than 
detection of LPS in circulation.5,6 The effects of LPS are initiated after it interacts with a 
plasma LPS-binding protein (LBP), which has strong affinity for both the Lipid-A region 
of endotoxin and glycosylphosphatidyl inositol-anchored LPS receptor CD14 on 
mononuclear phagocytes. When LPS-LBP complex interacts with CD14 (and then TLR-
4), the cells produce proinflammatory factors, such as tumor necrosis factor α (TNFα) 
(Figure 6.1). 
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Due to recent advances in the understanding of structure-function relationships for 
LPS, some generalizations regarding the most important structural determinants that 
result in the endotoxic activity of Lipid-A were made.7 These determinants include the 
number and chain length of fatty acids (lipids). Typically, 1,4’-diphosphate disaccharides 
of the E. coli type are used (6.1, Figure 6.1), but their fair stability (chemical or in vitro) 
has been a major drawback in their synthesis and application. Although the exact role of 
the phosphate moieties is still unknown, the findings that showed 1-hydroxyl-4’-O-
phosphate derivative as inactive gave rise to a belief that omitting at least one phosphate 
results in the entire loss of activity.7,8 
In an effort to explore molecules that will bind with high affinity to CD14 without 
activating the inflammatory cascade, our laboratories have been designing simplified 
Lipid A analogs that lack the complexity of the highly lipidated diphosphorylated 
disaccharide core yet still maintain potent antagonistic activity against LPS. Herein we 
present the synthesis and unprecedented LPS-antagonistic activity of the methyl 
glucopyranoside-amino acid conjugates.  This project was inspired by observations that 
structurally modified or totally unrelated to Lipid A can still exhibit potent antagonistic 
activity.  Amongst a myriad of research articles that have been disseminated in the past 
years, the following three groundbreaking discoveries appeared to us to be of a particular 
inspiration and relevance to our own attempts.   
First, as reported by Boons et al. strong binding and antagonistic effect was 
achieved even with ‘phosphateless’ Rhizobium syn-1 disaccharide 6.2, which bears a 
lactone moiety at the reducing end (Figure 6.1).9,10 This finding shows that one could 
avoid hurdles associated with labile phosphate group installation, handling, and storage.  
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Second, Shiozaki et al. showed that strong anti-LPS antagonistic response can be 
achieved even with disaccharide 6.3, in which the non-reducing glucosamine is replaced 
with glucose. In addition, instead of chiral β-hydroxy/acyl esters, relatively simple alkyl 
chains were used at C-3 and 3’ positions, whereas a β-ketoamide moiety is used at C-2.8   
 
 
Figure 6.1  Structure of monsaccharide and disaccaharide Lipid A analogs   
 
Third, Peri et al. demonstrated that even simple methyl glycoside-heterocycle 
conjugates 6.4 and 6.5 bearing alkyl chains instead of traditional lipids provide 
antagonistic activity.11 To this end, we found it attractive to develop molecules that 
contain the following: a methyl glucoside core to simplify the synthesis, hydrophobic 
chains to facilitate membrane intercalation, and amino acids to provide an ionic character. 
Here we report a highly efficient synthesis of molecules of this type and biological 
studies of their endotoxic activity in vitro.  
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6.2 Results and Discussion 
The synthesis began with the conversion of commercially available methyl α-D-
glucopyranoside 6.6 into methyl 2,3-di-O-benzyl-α-D-glucopyranoside 6.7 via sequential 
4,6-benzylidene acetal formation, 2,3-dibenzylation, and acetal cleavage accomplished in 
67% overall yield (Scheme 6.1).  4,6-Diol 6.7 was then succinoylated at the primary 
position with succinic anhydride in the presence of 4-dimethylaminopyridine (DMAP) in 
pyridine to afford derivative 6.8 in 71 % yield.  The carboxyl moiety of the linker was 
then coupled with 3-hydroxyl of protected L-serine derivative 6.9. This was 
accomplished using N,N'-diisopropylcarbodiimide (DIC) as the coupling reagent in the 
presence of DMAP in pyridine to afford conjugate 6.10 in 80% yield.  Having obtained 
the key construct 6.10, we decided to pursue further protecting group transformations. 
The main driving force for these synthetic manipulations was to obtain a series of simple 
analogs that would allow us to investigate the effect of cationic and anionic character on 
LPS-antagonistic activity in vitro.  With this objective in mind, carboxylated compound 
6.11 was obtained from 6.10 by cleavage of tert-butyl ester in presence of TFA/DCM in 
81% yield.  Alternatively, the Fmoc protecting group could also be removed from 
compound 6.10 with piperidine in DMF to afford free amine 6.12.  Subsequently, we also 
obtained compound 6.13 having both carboxyl and amine groups unprotected. This was 
accomplished by the treatment of compound 6.12 with TFA/CH2Cl2 to give derivative 
6.13 in 75% yield.   
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 Scheme 6.1  Synthesis of monosaccharide Lipid analog 6.10-6.13 
 
The inhibitory activity of compounds 6.10-6.13 on LPS-induced 
TNFα production was investigated in vitro using THP-1 macrophages.  Compounds 6.10, 
6.12, and 6.13 exhibited no inhibitory activity against LPS-induced TNFα production in 
the concentration range of 0.1 nM to 10 µM (Figure 6.2A-C). These compounds were 
also tested in the absence of LPS and demonstrated no agonist activity (data not shown). 
Compound 6.11 which has a free carboxylic group was able to significantly inhibit LPS-
induced TNFα production at concentrations greater than 10 μM (Figure 6.3).  
Unfortunately, cell viability measurements using an XTT reduction assay indicated that 
compound 6.11 was toxic to the cells in the 30-100 µM range. Although there was a gap 
between inhibition and toxicity at 30 and 50 µM, the similarities between the inhibition 
and toxicity curves suggested that much of the antagonistic activity by 6.11 was related to 
toxicity.   
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compound 6.10 compound 6.12
 
compound 6.13
 
Figure 6.2  Antagonistic activity of compound 6.10, 6.12 and 6.13 (Experimental work 
and data analysis done by Maria Udan in the laboratory of Dr. MR  Nichols) 
 
 
 
 
 
 
 
 
Figure 6.3  Antagonistic activity and toxicity of compound 6.11(Experimental work and 
data analysis done by Geeta Paranajape in the laboratory of Dr. MR  Nichols) 
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With the purpose of gaining further insight into the effect of various substituents 
on endotoxic activity of monosaccharide-amino acid conjugates we obtained an analog of 
compound 6.11 in which benzyl groups have been replaced with acyl (myristoyl, C14) 
fatty acid chains.  The synthesis of lipidated analog 6.19 was accomplished as depicted in 
Scheme 6.2.   
 
 
Scheme 6.2  Synthesis of monosaccharide Lipid A analog 6.19    
 
Methyl glycoside 6.6 was protected as 4,6-O-(p-methoxybenzylidene) acetal 6.14 
by treatment with anisaldehyde dimethylacetal in presence of camphorsulfonic acid in 
89% yield. The acylation of 6.14 with myristoyl chloride in the presence of pyridine 
furnished compound 6.15 in 85% yield. The benzylidene ring in 6.15 was reductively 
opened by treatment with BH3-THF catalyzed with Cu(OTf)2 to obtain unexpected 
product 6.16 lacking the C-2 acyl chain in 67% yield.  The loss of the acyl chain was 
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rather unexpected, but this glitch was overcome by regioselective succinoylation with 
succinic anhydride in pyridine at the primary C-6 position followed by C-2 acylation with 
miristoyl chloride. This two-step one-pot procedure allowed us to obtain compound 6.17 
in 79% yield. L-serine derivative 6.9 was linked to the carboxyl group of 6.17 of via 
DIC-mediated coupling in the presence of DMAP. The target monosaccharide-amino 
acid conjugate 6.18 was obtained in 83% yield. Acid treatment of the fully protected 
compound 6.18 led to concomitant cleavage of the p-methoxybenzyl (PMB) group at C-4 
and tert-butyl ester. As a result, compound 6.19 was isolated in 75% yield.  
The synthesis of alkylated analog 6.24 was accomplished as depicted in Scheme 
6.3.  Intermediate 6.14 was di-alkylated at C-2 and C-3 with myristyl bromide in 
presence of NaH to afford compound 6.20 in 72% yield. The benzylidene ring in 6.20 
was reductively opened by treatment with BH3-THF catalyzed with Cu(OTf)2 to obtain 
product 6.22 in 87%. Acylation of 6.22 with succinic anhydride led to compound 6.22 in 
89% yield.  L-serine derivative 6.9 was then linked to the carboxyl group of 6.22 via 
DIC-mediated coupling in the presence of DMAP. The resulting monosaccharide-amino 
acid conjugate 6.23 was obtained in 79% yield. Acid treatment of the fully protected 
compound 6.23 led to concomitant cleavage of the p-methoxybenzyl (PMB) group at C-4 
and tert-butyl ester. As a result, target compound 6.24 was isolated in 81% yield. 
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 Scheme 6.3  Synthesis of monosaccharide Lipid A analog 6.24   
 
Having obtained compounds 6.19 and 6.24, a lipidated and alkylated analogs of 
compound 6.11, respectively, we were well positioned to perform comparative studies. In 
addition, as the comparison point, we obtained the standard positive control compound 
6.4 as described by Peri et al.11  A marked improvement in LPS-antagonistic ability was 
observed with the lipidated compound 6.19.  Inhibition of LPS-induced TNFα was found 
to begin at 550 nM. A reproducible biphasic response was consistently observed in the 
activity of 6.19. This may indicate multiple binding sites on the macrophages, both higher 
and lower affinity for the antagonist compound. Eighty percent of the LPS response was 
blocked at 5 µM compound 6.19 with no observable toxicity. Cell viability began to be 
compromised at 10 µM and some agonist activity was found in the 10-30 µM range 
(Figure 6.4).  
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Figure 6.4  Biological activity test of compound 6.19 (Experimental work and data 
analysis done by Geeta Paranajape and Shana E. Terrill,in the laboratory of Dr. MR  
Nichols) 
 
Compound 6.24 with alkyl chains rather than lipid chains as in 6.19 was found to 
be a very effective inhibitor of LPS-induced TNFα production in human macrophages. 
Seventy percent inhibition was observed at 1 µM and overall inhibition reached 90% at 
40 µM. Compound 6.24 exhibited no toxicity or agonist activity in the tested 0.2 to 40 
µM range. Curve fitting of the inhibition data in Figure 6.5 produced an IC50 value of 470 
nM.  These results were superior to those obtained with compound 6.4 11 which had an 
inhibition range from 3-10 µM and began to show agonist activity at concentrations >10 
µM (Figure 6.6). Compound 6.4 was only toxic at high concentrations.  
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Figure 6.5  Biological activity test of compound 6.24 (Experimental work and data 
analysis done by Geeta Paranajape and Shana E. Terrill,in the laboratory of Dr. MR  
Nichols 
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Figure 6.6  Biological activity test of compound 6.4 (Experimental work and data 
analysis done by Geeta Paranajape and Shana E. Terrill,in the laboratory of Dr. MR  
Nichols 
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6.3 Conclusions 
 In summary, studies described herein provide new information regarding 
structure-activity relationship of novel class of compounds mimicking classic Lipid-A 
analogs, and the scientific basis for future studies to prevent the deleterious effects of 
endotoxemia. We believe that the results of these studies will have far reaching impacts 
on the treatment of patients diagnosed with endotoxemia. As a consequence, we can 
foresee additional efforts to investigate the molecular mechanisms responsible for the 
antagonistic actions of the synthetic Lipid A analogs. 
 
6.4 Experimental Section 
 
6.3.1. General.  Column chromatography was performed on silica gel 60 (EM Science, 
70-230 mesh) and reactions were monitored by TLC on Kieselgel 60 F254 (EM Science). 
The compounds were detected by examination under UV light and by charring with 10% 
sulfuric acid in methanol. Solvents were removed under reduced pressure at < 40 oC. 
CH2Cl2 was freshly distilled from CaH2 prior to application.  The solvent was kept in 
contact with the alloy until distilled for use. N,N'-Diisopropylcarbodiimide, 4-
dimethylaminopyridine, trifluoroacetic acid, anhydrous N,N-dimethylformamide were 
purchased from Sigma-Aldrich and used as is. Pyridine was dried by refluxing with CaH2 
and then distilled and stored over.  Optical rotations were measured using ‘Jasco P-1020’ 
polarimeter. Unless noted otherwise, 1H-NMR spectra were recorded in CDCl3 at 300 
MHz (Bruker Avance) or at 500 MHz (Bruker ARX-500), 13C-NMR spectra and two-
dimensional experiments were recorded in CDCl3 at 75 MHz (Bruker Avance) or at 125 
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MHz (Bruker ARX-500). HRMS determinations were made with the use of JEOL 
MStation (JMS-700) Mass Spectrometer.  
 
Methyl 2,3-di-O-benzyl-6-O-(3-carboxypropanoyl)-α-D-glycopyranoside (6.8).  
DMAP (32 mg, 0.26 mmol) and succinic anhydride (0.16 g, 1.56 mmol) were added to a 
stirred solution of methyl 2,3-di-O-benzyl-α-D-glucopyranoside 6.7 (0.5 g, 1.3 mmol) in 
dry pyridine (5 mL) at room temperature under argon. The reaction mixture was stirred 
for 16 h at room temperature under argon. After that, the reaction mixture was 
concentrated under the reduced pressure, the residue was dissolved in CH2Cl2 (30 mL) 
and washed successively with water (3 × 15 mL).  The organic phase was dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate-hexane gradient elution) to give compound 
6.8 (0.45 g, 0.95 mmol) as a colorless syrup in 71% yield.  Analytical data for 6.8: Rf = 
0.43 (ethyl acetate); [α]D22 +7.19 (c = 1.0, CHCl3); 1H NMR (300 MHz, CDCl3): δ, 2.60 
(m, 4H, 2×CH2), 3.38 (s, 3H, OCH3), 3.44 (dd, 1H, J2,3 = 9.5 Hz, H-2), 3,51 (ddd, 1H, J = 
3.5, 9.5 Hz, H-4), 3.73 (m, 1H, J5,6b = 4.8 Hz, H-5), 3.80 (dd, 1H, J2,3 = 9.2 Hz, H-3), 
4.26 (dd, 1H, J6a,6b = 10.0 Hz, H-6a), 4.42 (dd, 1H, H-6b), 4.61 (d, 1H, J1,2 = 3.5 Hz, H-
1), 4.65 (d, 1H, J2 = 12.1 Hz, ½ CH2Ph), 4.74-4.79 (m, 2H, CH2Ph), 4.99(d, 1H, J = 
11.31 Hz, ½ CH2Ph), 7.26-7.36 (m, 10H, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ, 
55.39, 3.73, 69.37, 69.99, 73.34, 75.34, 79.65, 81.34, 98.26, 128.02, 128.12, 128.24, 
128.49, 128.62, 128.68, 138.08, 138.63, 172.64, 177.19 ppm; HR FAB MS [M+Na]+ 
calcd for C25H30O9Na 497.1788, found 497.1770.  
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Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-3-(tert-
butoxy)-3-oxopropyl)oxy-4-oxobutanoyl)-α-D-glycopyranoside (6.10).   
DMAP (12.7 mg, 0.01 mmol) and DIC (0.16 mL, 1.04 mmol) were added to a stirred 
solution of the O-tert-butyl-N-fluorenylmethoxycarbonyl-L-serine 6.9 (0.19 g, 0.52 
mmol) in CH2Cl2 (4 mL). After 1 h, the carboxylic acid derivative 6.8 (0.29 g, 0.62 
mmol) was added and the reaction was stirred for 5-9 h when TLC indicated no further 
conversion of starting material. The reaction was diluted with CH2Cl2 (20 mL), washed 
with distill water (2 × 15 mL) and brine (15 mL). The organic phase was dried over 
MgSO4, filtered and concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (ethyl acetate-hexane gradient elution) to obtain compound 
6.10 (0.34g, 0.41 mmol) as a white powder in 80 % yield. Rf = 0.34 (ethyl acetate-hexane 
1/1, v/v); [α]D27 +12.05 (c = 1.0, CHCl3); 1H NMR (300 MHz, CDCl3) : δ = 1.48 (s, 9H, t-
Bu), 2.53 (broad s, OH), 2.66 (m, 4H, 2×CH2), 3.37 (s, 3H, OCH3), 3.42 (d, 1H, J2,3 = 
9.0, H-2), 3.73 (m, 1H, H-5), 3.78 (dd, 1H, J3,4 = 9.1 Hz, H-3), 4.25 (m, 2H, H-6b, SerCβ-
H), 4.38 (m, 2H, H-6ª, SerCβ-H), 4.44 (m, 2H, CH2Fmoc), 4.52 (m, 1H, SerCα-H), 4.61 
(d, 1H, J1,2 = 3.2 Hz, H-1), 4.64 (d, 1H, J2 = 12.1 Hz, ½ CH2Ph), 4.75 (dd, 2H, J = 12.0 
Hz, CH2Ph), 4.98 (d, 1H, J2 = 11.33 Hz, ½ CH2Ph), 4.75 (d, 1H, JNH,CH = 8.00 Hz, Ser-
NH), 7.27-7.42 (m, 14H, aromatic), 7.62 (d, 2H, J = 7.4 Hz, aromatic), 7.77 (d, 2H, J = 
7.5 Hz, aromatic)  ppm; 13C NMR (125 MHz, CDCl3): δ = 28.12, 29.09, 29.11, 47.30, 
54.07, 55.48, 63.85, 64.81, 67.41, 69.38, 70.11, 73.40, 75.71, 79.74, 81.31, 83.29, 98.39, 
120.17, 125.35, 125.40, 127.28, 127.91, 128.06, 128.16, 128.27, 128.68, 128.76, 138.18, 
138.86, 141.48, 144.01, 144.05, 156.00, 168.51, 171.80, 172.60 ppm; HR FAB MS 
[M+Na]+ calcd for C47H53NO13Na 862.3415, found 862.3432.   
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Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-2-
carboxyethyl)oxy-4-oxobutanoyl)-α-D-glycopyranoside (6.11).  
Methyl glucoside derivative 6.10 (0.25g, 0.29 mmol) was dissolved in TFA/CH2Cl2 (1/5 
v/v, 2mL) and stirred for 2 h. Upon completion as assessed by TLC analysis, solvents 
were evaporated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) and neutralized 
with triethylamine (TEA). The solvent was removed under the reduced the pressure. The 
residue was subjected to column chromatography on silica gel (ethyl acetate-hexane 1/1, 
v/v) to afford carboxylic derivative 6.11 (0.18g, 0.24 mmol) as white foam in 81% yield. 
Rf = 0.5 (methanol-ethyl acetate 2/8, v/v) ); [α]D26 +22.48 (c = 1.0, CHCl3); 1H NMR (500 
MHz, CDCl3:(CD3)2SO 4:2 ) : δ = 2.49 - 2.54 (m, 4H), 3.26 (s, 3H, OCH3), 3.39 (m,2H), 
3.57 (m,2H), 4.01 (broad s, 1H), 4.12 (m, 2H), 4.22 (m, 2H), 4.32 (dd, 2H, J = 6.6 Hz), 
4.43 (d, 1H, J = 5.1 Hz), 4.60 (s, 2H), 4.76 (m, 2H), 7.24 – 7.43 (m, 10H, aromatic), 7.68 
(d, 2H, J = 4.38 Hz, aromatic), 7.93 (d, 2H, J = 4.89 Hz, aromatic) ppm; 13C NMR (75 
MHz, CDCl3:(CD3)2SO 4:2): δ = 28.84, 28.99, 31.06, 47.03, 54.71, 54.83, 63.42, 63.90, 
65.31, 65.92, 69.85, 70.20, 71.85, 74.50, 79.36, 81.46, 97.29, 120.47, 125.56, 127.44, 
127.49, 127.87, 127.83, 127.90, 127.98, 128.33, 128.52, 138.94, 139.62, 141.06, 144.23, 
156.05, 172.16, 172.23 ppm; HR FAB MS [M+Na]+ calcd for C43H45NO13Na 806.2789, 
found 806.2780. (See Appendix; Figure A-22, and A-23) 
 
Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-amino-3-(tert-butoxy)-3-oxopropyl)oxy-4-
oxobutanoyl)-α-D-glycopyranoside (6.12). 
Piperidine (0.5 mL) was added dropwise to stirred solution of monosaccharide 6.10 (0.1 
g, 0.12 mmol) in DMF (2.0 mL). After stirred for 20 min, TLC indicated complete 
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conversion of starting material. The solvents were removed in vacuo (co-evaporation 
with toluene). The residue was purified by flash column chromatography (ethyl acetate-
hexane 1/1) to give the amine derivative 6.12 (67 mg, 0.1 mmol) as yellow syrup in 92% 
yield. Rf = 0.62 (methanol-ethyl acetate 1/9, v/v) ); [α]D26 +17.33 (c = 1.0, CHCl3); 1H 
NMR (500 MHz, CDCl3) : δ = 1.49 (s, 9H, t-Bu), 2.52 – 2.66 (m, 3H), 2.73 – 2.78 (m, 
1H), 3.02 (broad s, 1H, OH), 3.38 (s, 3H, OCH3), 3.46  (d, 1H, J2,3 = 9.4 Hz, H-2), 3.50 
(ddd, 1H, J4,5 = 9.5 Hz, H-4), 3.75 (m, 2H, H-5, Ser-CβH), 3.80 (m, 2H, H-3, Ser-CβH), 
4.18 (dd, 1H, J6a,6b = 10.19 Hz, H-6a), 4.46 (m, 1H, Ser-CαH), 4.52 (dd, 1H, J5,6b = 4.19 
Hz, H-6b), 4.61 (d, 1H, J1,2 = 3.53 Hz, H-1), 4.65 (d, 1H, J2 = 12.5 Hz, ½ CH2Ph), 4.77 
(dd, 2H, J = 11.5 Hz, CH2Ph), 4.99 (d, 1H, J2 = 9.0 Hz, ½ CH2Ph,) 6.49 (d, 1H, JNH,CH = 
6.95 Hz, Ser-NH), 7.27 - 7.31 (m, 10H, aromatic) ppm; 13C NMR (125 MHz, CDCl3): δ = 
28.18, 29.76, 31.05, 31.11, 55.51, 55.68, 63.35, 63.63, 69.46, 69.88, 73.49, 75.98, 79.83, 
81.50, 83.01, 98.47, 128.09, 128.17, 128.30, 128.41, 128.68, 128.72, 138, 22, 128.73, 
169.60, 172.05, 173.06 ppm; HR FAB MS [M+Na]+ calcd for C32H43NO11Na 640.2734, 
found 640.2841.   
 
Methyl 2,3-di-O-benzyl-6-O-(4-((S)-2-amino-2-carboxyethyl)oxy-4-oxobutanoyl)-α-
D-glycopyranoside (6.13) 
Methyl glucoside derivative 6.12 (0.1 g, 0.12 mmol) was dissolved in TFA/CH2Cl2 (1/5 
v/v, 2 mL) and stirred for 2 h. Upon completion as assessed by TLC analysis, solvents 
were evaporated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) and neutralized 
with triethylamine (TEA). Solvents were removed under the reduced the pressure. The 
residue was subjected to column chromatography on silica gel (methanol-ethyl acetate 
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gradient elution) to obtain product 6.13 (50 mg, 0.09 mmol) as white foam in 75% yield. 
Rf = 0.5 (methanol-ethyl acetate 2/8, v/v) ); 1H NMR (500 MHz, D2O ) : δ = 1.68 (m, 
2H), 1.82 (m, 3H), 2.73 (m, 4H), 3.19 (dd, 3H, J = 5.7 Hz), 3.4 (s, 3H, OCH3), 3.58 (ddd, 
2H, J = 9.5, 10.0 Hz), 3.80 (dd, 1H, J = 9.2 Hz), 3.87 (d, 3H, J =  4.7 Hz), 4.33 - 4 .37 
(m, 2H, J = 4.7 Hz), 4.54 (d, 1H, J = 10.9 Hz), 7.44 (s, 10H, aromatic) ppm; 13C NMR 
(125 MHz, D2O): δ = 21.87, 22.608, 29.54, 30.46, 44.94, 55.38, 62.43, 69.78, 73.36, 
75.74, 79.13, 81.08, 97.82, 128.69, 128.78, 129.02, 129.11, 137.73, 137.96, 174.53, 
175.12, 176.23 ppm; HR FAB MS [M+Na]+ calcd for C28H35NO11Na 584.2108, found 
584.2104. 
 
Methyl 4,6-O-(p-methoxybenzylidene)-2,3-di-O-tetradecanoyl-α-D-glucopyranoside 
(6.15). 
Myristoyl chloride (2.34 mL, 8.67 mmol) and DMAP (70 mg, 0.57 mmol) were added to 
a stirred solution of methyl 4,6-O-p-anisylidene-α-D-glucoside 6.141 (1 g, 2.89 mmol) in 
pyridine (15 mL) at 0°C. The mixture was stirred under an atmosphere of argon for 16 h. 
Upon completion, the reaction mixture was concentrated in vacuo. The residue was 
dissolved in CH2Cl2 (30 mL), and washed with 1N HCl (2 × 15 mL), distill water (2 × 
15 mL) and brine (15 mL). The organic phase was dried over MgSO4, filtered and 
concentrated in vacuo. The residue was purified by column chromatography on silica gel 
(ethyl acetate-hexane gradient elution) to afford derivative 6.15 (1.81 g, 2.48 mmol) as a 
white foam in 86% yield. Rf = 0.47 (ethyl acetate-hexane 3/7, v/v) ); [α]D23 +23.56 (c = 
1.0, CHCl3); 1H NMR (300 MHz, CDCl3) : δ = 0.88 (t, 6H, J = 7.02 Hz, 2×CH3), 1,26 
(broad s, 40H, 20×CH2), 1.59 (m, 4H, 2×CH2), 2.29 (m, 4H, 2×CH2), 3.40 (s, 3H, OCH3), 
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3.62 (dd, 1H, J4,5 = 9.7 Hz, H-4), 3.75 (dd, 1H, J6a,6b = 10.2 Hz, H-6a), 3.78 (s, 3H, 
OCH3), 3.92 (m, 1H, H-5), 4.28 (dd, 1H, J5,6b = 4.7 Hz, H-6b), 4.82 – 2.94 (m, 2H, H-1, 
2), 5.46 (s, 1H, >CHPh), 5.60 (dd, 1H, J3,4 = 9.7 Hz, H-3), 6.86 (d, 2H, J = 8.8 Hz, 
aromatic), 7.25 (d, 2H, J = 8.7 Hz, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ = 
14.28, 22.86, 25.09, 25.28, 29.18, 29.22, 29.44, 29.47, 29.53, 29.63, 29.66, 29.83, 29.86, 
32.09, 34.26, 34.46, 55.37, 55.49, 62.53, 68.76, 68.95, 71.58, 76.80, 77.23, 77.65, 79.46, 
97.84, 101.62, 113.67, 127.59, 129.62, 160.22, 172.64, 173.39 ppm; HR FAB MS 
[M+Na]+ calcd for C43H72O9Na 755.5074, found 755.5090.   
 
Methyl 4-O-p-methoxybenzyl-3-O-tetradecanoyl-α-D-glucopyranoside (6.16).   
A 1 M solution of borane/tetrahydrofuran complex in tetrahydrofuran (5 mL, 5 mmol) 
was added to a benzylidene acetal 6.15 (0.75 g, 1.02 mmol) at room temperature under 
nitrogen. The mixture was stirred for 10 min, and freshly dried copper (II) 
trifluoromethanesulfonate (18 mg, 0.05 mmol) was added to the solution.  After stirring 
for 2 hours the mixture was cooled down to 0 °C, and the reaction was quenched by 
sequential additions of triethylamine (TEA) (0.14 mL, 1 mmol) and methanol (1.8 mL). 
The resulting mixture was concentrated at reduced pressure followed by co evaporation 
with methanol. The residue was purified by flash column chromatography on silica gel to 
give compound 6.16 (0.35g, 0.67 mmol) as white solid in 67% yield. Rf = 0.40 (ethyl 
acetate-hexane 7/3, v/v) ); [α]D21 +78.50 (c = 1.0, CHCl3); 1H NMR (300 MHz, CDCl3) : 
δ = 0.88 (t, 3H,  J= 7.02 Hz, CH3), 1.24 (broad s, 20H, 10×CH2), 1.63 (m, 2H, CH2), 1.97 
(broad s, 1H, OH), 2.23 – 3.82 (m, 3H, CH2, OH), 3.41 (s, 3H, OCH3), 3.52 -3.82 (m, 5H, 
H-2, 4, 5, 6a, 6b), 3.79 (s, 3H, OCH3), 4.57 (dd, 2H, J = 12.4 Hz, CH2Ph), 4.75 (d, 1H, 
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J1,2 = 3.7 Hz, H-1), 5.30 (dd, 1H, J = 9.1 Hz, H-3), 6.85 (d, 2H, J = 8.6 Hz, aromatic), 
7.20 (d, 2H, J = 8.6 Hz, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ = 14.30, 22.86, 
25.07, 29.31, 29.48, 29.52, 29.64, 29.79, 29.82, 29.85, 32.09, 34.68, 55.41, 55.53, 61.67, 
71.04, 71.87, 74.33, 74.96, 99.65, 114.02, 129.63, 130.10, 159.54, 174.29 ppm; HR FAB 
MS [M+Na]+ calcd for C29H48O8Na 547.3247, found 547.3254.   
 
Methyl 6-O-(3-carboxypropanoyl)-4-O-p-methoxybenzyl-2,3-di-O-tetradecanoyl-α-
D-glucopyranoside (6.17).   
DMAP (8.1 mg, 0.06 mmol) and succinic anhydride (67 mg, 0.67 mmol) were added to a 
stirred solution of partially protected derivative 6.16 (0.35g, 0.67 mmol) in dry pyridine 
(5 mL) at room temperature under argon.  The reaction mixture was stirred for 16 h at 
room temperature under argon.  After 16 h, TLC indicated no further conversion of the 
starting material. Myristoyl chloride (0.21 ml, 0.80 mmol) was added dropwise to the 
reaction mixture. The reaction mixture was stirred for 2 h. Upon completion, the reaction 
mixture was concentrated under reduced pressure, then the residue was dissolved in 
CH2Cl2 (30 mL) and washed with 1N HCl (2 × 15 mL), distill water (2 × 15 mL) and 
brine (15 mL). The organic phase was dried over MgSO4, filtered and concentrated in 
vacuo. The residue was purified by silica gel column chromatography (ethyl acetate-
hexane gradient elution) to give compound 6.17 (0.43 g, 0.52 mmol) as white syrup in 
79% yield. Rf = 0.55 (ethyl acetate-hexane 1/1, v/v); [α]D24 +42.45 (c = 1.0, CHCl3); 1H 
NMR (300 MHz, CDCl3) : δ = 0.87 (t, 6H, 2×CH3), 1.25 (broad s, 40H, 20×CH2), 1.59 
(m, 4H, 2×CH2), 2.26 (m,2H, CH2), 2.33 (m, 2H, CH2), 2.61 (m, 4H, 2×CH2), 3.36 (s, 
3H, OCH3), 3.59 (dd, 1H, J4,5 = 9.5 Hz, H-4), 3.90 (m, 1H, H-5), 4.25 – 4.31 (dd, 2H, 
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J5,6b = 4.4 Hz, J6a,6b = 11.5 Hz, H-6a, 6b), 4.44 (d, 1H, J2 = 10.65 Hz, ½ CH2Ph), 4.54 (d, 
1H, J2 = 10.65, ½ CH2Ph), 4.87 (m, 2H, H-1, 2), 5.55 (dd, 1H, J3,4 = 9.5 Hz, H-3), 6.84 
(d, 2H, J = 8.7 Hz, aromatic), 7.16 (d, 2H, J = 8.6 Hz, aromatic) ppm; 13C NMR (75 
MHz, CDCl3): δ = 14.28, 22.85, 25.07, 28.82, 29.22, 29.35, 29.41, 29.45, 29.52, 29.60, 
29.65, 29.81, 32.08, 34.20, 34.49, 34.30, 34.49, 55.37, 62.56, 68.56, 71.78, 71.89, 74.28, 
75.72, 96.87, 114.04, 129.53, 129.76, 159.62, 171.67, 172.82, 173.68 ppm; HR FAB MS 
[M+Na]+ calcd for C47H78O12Na 857.5391, found 857.5410.   
 
Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-3-(tert-butoxy)-3-
oxopropyl)oxy-4-oxobutanoyl)-2,3-di-O-tetradecanoyl-α-D-glucopyranoside (6.18).  
DMAP (9.5 mg, 0.07 mmol) and DIC (0.12 mL, 0.78 mmol) were added to a stirred 
solution of the O-tert-butyl-N-fluorenylmethoxycarbonyl-L-serine 6.9 (0.15 g, 0.39 
mmol) in CH2Cl2 (3 ml). After 1 h, the carboxylic acid derivative 6.17 (0.39 g, 0.46 
mmol) was added and the reaction was stirred for 5-9 h when TLC indicated no further 
conversion of starting material to the major product. The reaction was diluted with 
CH2Cl2 (20 mL), washed with distill water (2 × 10 mL) and brine (10 mL). The organic 
phase was dried over MgSO4, filtered and concentrated in vacuo. The residue was 
purified by silica gel flash column chromatography (ethyl acetate-hexane gradient 
elution) to obtain compound 6.18 (0.38 g, 0.32 mmol) as white solid in 83 % yield. Rf = 
0.5 (ethyl acetate-hexane 3/7, v/v) ); [α]D24 +25.72 (c = 1.0, CHCl3); 1H NMR (300 MHz, 
CDCl3) : δ = 0.88 (t, 6H, J = 6.4 Hz, 2×CH3), 1.25 (broad s, 40H, 20×CH2), 1.49 (s, 9H, 
t-Bu), 1.59 (m, 4H, 2×CH2), 1.59 (m, 4H, 2×CH2), 2.30 (m, 4H, 2×CH2), 3.37 (s, 3H, 
OCH3), 3.48 (dd, 1H, J4,5 = 9.5 Hz, H-4), 3.76 (s, 3H, OCH3), 3.90 (m, 1H, H-5), 4.16-
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4.26 (m ,3H, H-6a, 6b, Ser-CβH), 4.35 – 4.55 (m, 6H, CH2Ph, Ser-CαH, Ser-CβH, 
CH2Fmoc), 4.90 (m, 2H, H-1, 2), 5.58 (dd, 1H, J3,4 = 9.7 Hz, H-3), 5.82 (d, 1H, JNH,CH = 
8.3 Hz, Ser-NH), 6.18 (d, 2H, J = 8.5 Hz, aromatic), 7.12 (d, 2H, J = 8.5 Hz, aromatic), 
7.32 – 7.43 (m, 5H, aromatic), 7.63 (m, 2H, aromatic), 7.77 (d, 2H, J = 8.5 Hz, aromatic)  
ppm; 13C NMR (75 MHz, CDCl3): δ = 14.25, 22.81, 25.00, 28.03, 28.76, 28.97, 29.27, 
29.35, 29.43, 29.47, 29.62, 29.77, 32.04, 34.19, 34.44, 47.22, 54.02, 55.30, 62.58, 67.37, 
68.53, 71.68, 71.88, 74.27, 83.04, 96.83, 113.95, 120.09, 25.40, 127.23, 127.84, 129.28, 
129.62, 141.39, 143.98, 155.98,159.54, 168.44, 171.50, 172.72, 173.53 ppm; HR FAB 
MS [M+Na]+ calcd for C69H101NO16Na 1222.7018, found 1222.7023.   
 
Methyl 6-O-(4-((S)-2-(9-fluorenylmethoxycarbonyl)amino-2-carboxyethyl)oxy-4-
oxobutanoyl)-2,3-di-O-tetradecanoyl-α-D-glucopyranoside (6.19).   
Methyl glucoside derivative 6.18 (0.2 g, 0.16 mmol) was dissolved in TFA/CH2Cl2 (1/5 
v/v, 4 mL) and stirred for 2 h. Upon completion as assessed by TLC analysis, solvents 
were evaporated in vacuo. The residue was dissolved in CH2Cl2 (5 mL) and neutralized 
with triethylamine (TEA). Solvent were removed under the reduced the pressure. The 
residue was subjected to column chromatography on silica gel (ethyl acetate-hexane 1/1, 
v/v) to obtain product 6.19 (0.13 g, 0.12 mmol) as white foam in 75% yield. Rf = 0.5 
(methanol-ethyl acetate 1/9, v/v) ); 1H NMR (300 MHz, CDCl3 ) : δ = 0.88 (t, 6H, J = 
5.70 Hz, 2×CH3), 1.25 (broad s, 40H, 20×CH2), 1.58 (m, 4H, 2×CH2), 2.33 (m, 4H, 
2×CH2), 3.27 (broad s, 4H, 2×CH2), 3.27 (broad s, 1H, OH), 3.38 (s, 3H, OCH3), 3.47 
(dd, 1H, J4,5 = 9.4 Hz, H-4), 3.83 (m, 1H, H-5), 4.21 – 4.51 (m, 7H, H-6a, 6b, Ser-CβH2, 
Ser-CαH, CH2Fmoc), 4.86 (m, 1H, H-2), 4.90 (broad s, 1H, H-1), 5.31 (dd, 1H, J3,4 = 9.1 
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Hz, H-3), 5.96 (broad s, 1H, Ser-NH), 7.27 – 7.42 (m, 4H, aromatic), 7,61 (d, 2H, J = 6.9 
Hz, aromatic), 7.76 (d, 2H, J = 7.5 Hz, aromatic) ppm; 13C NMR (75 MHz, CDCl3): δ = 
25.03, 25.08, 28.93, 29.26, 29.30, 29.44, 29.54, 29.66, 29.83, 29.86, 32.10, 34.24, 34.47, 
47.20, 55.46, 62.91, 64.33, 67.64, 69.36, 69.57, 69.89, 71.16, 72.73, 77.42, 96.84, 114.10, 
120.18, 124.95, 125.29, 127.28, 127.95, 141.44, 143.83, 143.89, 171.67, 171.78, 174.31, 
174.58, 175.10 ppm; HR FAB MS [M+Na]+ calcd for C57H85NO15Na 1046.5817, found 
1045.5822. (See Appendix; Figure A-24, and A-25) 
 
6.3.2 Biological assays 
The biological activity testings of Lipid A analogues were performed by Geeta 
Paranajape, Shana E. Terrill, and Maria L. D. Udan in the laboratory of Dr. MR Nichols 
with the standard experiments. 
 
Preparation of compounds for cellular treatment.  Synthetic compounds in solid form 
were dissolved in tetrahydrofuran (THF), aliquotted in small volumes, vacuum-
centrifuged for 1 hour and stored at −80°C as dry compounds. For cellular treatment, an 
aliquot was dissolved in an appropriate volume of dimethylsulfoxide (DMSO) (Fisher 
Sci) to give a concentrated working stock solution. This stock solution was further diluted 
in DMSO to give the desired concentration range. The final concentration of DMSO was 
always maintained at 0.6%. 
 
Cell culture.  THP-1 cells were obtained from ATCC (Manassas, VA) and maintained in 
RPMI-1640 culture medium (HyClone, Logan, UT) containing 2 mM L-glutamine, 25 
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mM HEPES, 1.5 g/L sodium bicarbonate, 10% fetal bovine serum (FBS) (HyClone), 50 
units/mL penicillin, 50 μg/mL streptomycin (HyClone), and 50 μM β-mercaptoethanol at 
37°C in 5% CO2. For cellular assay, THP-1 monocytes were centrifuged and resuspended 
in a fresh growth medium to a cell density of 5 x 105 cells/ml. Cell were then seeded in a 
48-well plate and differentiated into adherent macrophages by treatment with 10 ng/ml 
phorbol 12-myristate 13-acetate (PMA) (Sigma) for 24 hours at 37°C in5% CO2. The non 
adherent cells were removed and the adherent cells were washed and replenished with 
reduced FBS growth medium. For the two wells set aside for calculating percent 
differentiation, the cells were washed with PBS (Hyclone) prior to removal by 0.25% 
trypsin-EDTA. The adherent cells were counted under the microscope using 
hemocytometer. Percentage of adherent cells was determined by dividing the number of 
adherent cells by the number of plated cells. For the remaining wells, the cells were pre-
incubated with LPS antagonist at different concentrations for 30 minutes followed by by 
addition of 10 nM ultra pure LPS for 6 h at 37°C in 5% CO2. DMSO was used as a 
negative control. The medium was collected and stores at -20°C until analyzed by ELISA 
for TNFα production 
 
XTT cell toxicity assay.  Cellular toxicity was monitored using an XTT [2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] cell assay.  Estimate of 
cellular metabolic activity was obtained by probing mitochondrial reduction of XTT 
(Sigma) which in turn reflected the toxicity in response to LPS-antagonists. The cells 
treated with LPS antagonists and ultrapure LPS were washed with PBS (Hyclone) and 
then further incubated with XTT and phenazine methosulfate (PMS) (Acros, Morris 
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Plains, NJ) to a final concentration of 0.33 mg/mL and 8.3 μM respectively for 2 h at 37C 
in 5% CO2. The cellular toxicity was then assessed based on the absorbance 
measurement of the reduced XTT at 467 nm. 
 
6.4 References: 
(1) Gram-negative septicemia and septic shock; Young, L.; Glauser, M., Eds.; WB 
Saunders: Philadelphia, 1991. 
(2) Tabbutt, S. Crit. Care Med. 2001, 29, S231-S236. 
(3) Suffredini, A. F.; Fromm, R. E.; Parker, M. M.; Brenner, M.; Kovacs, J. A.; 
Wesley, R. A.; Parrillo, J. E. N. Engl. J. Med. 1989, 321, 280-287. 
(4) Zahringer, U.; Lindner, B.; Rietschel, E. T. Adv. Carbohydr. Chem. Biochem. 
1994, 50, 211-276. 
(5) Raetz, C. R. H.; Ulevitch, R. J.; Wright, S. D.; Sibley, C. H.; Ding, A.; Nathan, C. 
F. FASEB  J. 1991, 5, 2652-2660. 
(6) Garrett, T. A.; Raetz, C. R. H. In Carbohydrates in Chemistry and Biology; Ernst, 
B., Hart, G. W., Sinay, P., Eds.; Wiley-VCH: Weinheim, New York, 2000; Vol. 
2, p 435-447. 
(7) Rossignol, D. P.; Hawkins, L. D.; Christ, W. J.; Kobayashi, S.; Kawata, T.; Lynn, 
M.; Yamatsu, I.; Kishi, Y. In Endotoxin in Health and Disease; Brade, H., Opal, 
S. M., Vogel, S. N., Morrison, D. C., Eds. 1999, p 699-717. 
(8) Christ, W. J.; McGuinness, P. D.; Asano, O.; Wang, Y.; Mullarkey, M. A.; Perez, 
M.; Hawkins, L. D.; Blythe, T. A.; Dubuc, G. R.; Robidoux, A. L. J. Am. Chem. 
Soc. 1999, 11, 3637-3638. 
 
 
212
(9) Price, N. P. J.; Jeyaretnam, B.; Carlson, R. W.; Kadrmas, J. L.; Raetz, C. R. H.; 
Brozek, K. A. Proc. Natl. Acad. Sci., USA 1995, 92, 7352-7356. 
(10) Demchenko, A. V.; Wolfert, M. A.; Santhanam, B.; Moore, J. N.; Boons, G. J. J. 
Am. Chem. Soc. 2003, 125, 6103-6112. 
(11) Peri, F.; Granucci, F.; Costa, B.; Zanoni, I.; Marinzi, C.; Nicotra, F. Angew. 
Chem. Int. Ed. 2007, 46, 3308-3312. 
 
 
 
 
213
  
 
 
 
 
 
APPENDIX   
 
Selected NMR spectral data 
 
 
 
 
 
 
 
 
 
 
__________________________________________________________________ 
 
 
 214
  
O
OBz
BzO
BzO
BzO
O
BzO
O
BzO
BzO
O
BnO
O
BnO
BnO
OMe
2.25
Figure A-1: 1H NMR spectrum of Methyl O-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-galactopyranosyl)-(1→6)-2,3,4-tri-
Ο-benzyl-α-D-glucopyranoside (2.25) 
 
 
CDCl3 125 MHz 
CDCl3 75 MHz 
 
 
Figure A-2: 13C NMR spectrum of Methyl O-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-galactopyranosyl)-(1→6)-2,3,4-tri-
Ο-benzyl-α-D-glucopyranoside (2.25) 
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Figure A-3: 2-D NMR COSY spectrum of Methyl O-(2,3,4,6-tetra-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-galactopyranosyl)-(1→6)-2,3,4-tri-
Ο-benzyl-α-D-glucopyranoside (2.25) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 216
 
 
 
O
BzO
OBz
BzO
BzO O
BzO
O
BzO
BzO O
BzO S
O
BzO
BzO
S
N
3.17c
Figure A-4: 1H NMR spectrum of 2-Thiazolinyl  2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-O-
benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-thio-
β−D-glucopyranoside (3.17c). 
 
 
CDCl3 500 MHz 
CDCl3 125 MHz  
Figure A-5: 13C NMR spectrum of 2-Thiazolinyl  2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-O-
benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-thio-
β−D-glucopyranoside (3.17c). 
 217
 
 
 
 
 
 
 
 
 
ppm
3.54.04.55.05.56.0 ppm
3.5
4.0
4.5
5.0
5.5
6.0
6.5
 
O
BzO
OBz
BzO
BzO O
BzO
O
BzO
BzO O
BzO S
O
BzO
BzO
S
N
3.17c
 CDCl3 300 MHz 
 
Figure A-6: 2-D NMR COSY spectrum 2-Thiazolinyl  2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-
O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-
thio-β−D-glucopyranoside (3.17c). 
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Figure A-7: 1H NMR spectrum of Benzoxazol-2-yl  2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-O-
benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-thio-
β−D-glucopyranoside (3.17d). 
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Figure A-8: 13C NMR spectrum of Benzoxazol-2-yl  2,3,4-tri-O-benzoyl-6-O-(2,3,4-tri-
O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-glucopyranosyl)-1-
thio-β−D-glucopyranoside (3.17d). 
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Figure A-9: 2-D NMR COSY spectrum of Benzoxazol-2-yl  2,3,4-tri-O-benzoyl-6-O-
(2,3,4-tri-O-benzoyl-6-O-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-β-D-
glucopyranosyl)-1-thio-β−D-glucopyranoside (3.17d). 
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Figure A-10: 1H NMR spectrum of 2,3,4-Tri-O-benzoyl-β-D-glucopyranosyl-(1→6)-O-
2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-D-glucopyranosyl fluoride (3.20). 
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Figure A-11: 13C NMR spectrum of 2,3,4-Tri-O-benzoyl-β-D-glucopyranosyl-(1→6)-O-
2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-D-glucopyranosyl fluoride (3.20). 
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Figure A-12: 2-D NMR COSY spectrum of 2,3,4-Tri-O-benzoyl-β-D-glucopyranosyl-
(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-
D-glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-D-glucopyranosyl fluoride (3.20). 
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Figure A-13: 1H NMR spectrum of Ethyl O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-
(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-
D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-
O-benzoyl-β-thio-D-glucopyranoside (3.22). 
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Figure A-14: 13C NMR spectrum of Ethyl O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-
(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-
D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-
O-benzoyl-β-thio-D-glucopyranoside (3.22). 
 223
 
 
 
 
 
 
 
 
 
 
 
O
BzO
OBz
BzO
BzO O
BzO
O
BzO
BzO
O
BzO
O
BzO
BzO O
BzO
O
BzO
BzO O
BzO SEt
O
BzO
BzO
3.22
CDCl3 500 MHz 
 
 
Figure A-15: 2-D NMR COSY spectrum of Ethyl O-(2,3,4-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-
(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-2,3,4-tri-O-benzoyl-β-thio-D-glucopyranoside (3.22). 
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Figure A-16: 1H NMR spectrum of 4-Pentenyl O-(2,3,4-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-
(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl) (1→6)-O-(2,3,4-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-O-
benzoyl-β-D-glucopyranoside (3.24). 
 
 
 
Figure A-17: 13C NMR spectrum of 4-Pentenyl O-(2,3,4-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-
(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl) (1→6)-O-(2,3,4-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-O-
benzoyl-β-D-glucopyranoside (3.24). 
CDCl3 500 MHz
CDCl3 125 MHz
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Figure A-18: 2-D NMR COSY spectrum of 4-Pentenyl O-(2,3,4-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)-(1→6)-O-
(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl) (1→6)-O-(2,3,4-tri-O-benzoyl-β-D-
glucopyranosyl)-(1→6)-O-(2,3,4-tri-O-benzoyl-β-D-glucopyranosyl)-(1→6)-2,3,4-tri-O-
benzoyl-β-D-glucopyranoside (3.24). 
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Figure A-19: 1H NMR monitoring of the conversion of thioglycoside 5.12b into 
5.5a/5.5b. 
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Figure A-20: 1H NMR monitoring of the conversion of thioglycoside 5.14a into 
5.1a/5.1b.  
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Figure A-21: 1H NMR monitoring of the conversion of thioglycoside 5.14b into 
5.1a/5.1b. 
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Figure A-22: 1H NMR spectrum of Lipid A analog 6.11. 
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Figure A-23: 13C NMR spectrum of Lipid A analog 6.11. 
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Figure A-24: 1H NMR spectrum of Lipid A analog 6.19. 
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Figure A-25: 13C NMR spectrum of Lipid A analog 6.19. 
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